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ABSTRACT 
 Cachexia is a devastating a life-threatening condition that occurs secondary to 
underlying disease including cancer, AIDS, COPD and comprises severe loss of muscle 
and fat mass.  Muscle mass atrophy and wasting with cachexia is especially dire, as 
skeletal muscle mass is associated with quality of life, functionality, and ability to 
respond to chemotherapeutics.  While much investigation has been done in the male 
animal to elucidate the inflammatory pathways and muscle signaling underlying 
cachexia, very little work has occurred in the female.  The overall purpose of this study is 
to determine if ovarian function can alter cachexia progression in the female Apc
Min/+
 
mouse through IL-6 signaling and the regulation of skeletal muscle metabolism.  Specific 
aim #1 sought to determine the relationship between circulating IL-6 and cancer cachexia 
progression in the female Apc
Min/+ 
mouse.  We found that the canonical IL-6 signaling 
pathway that is a key point of regulation in the male Apc
Min/+ 
is dysregulated in the 
female, and that IL-6 levels do not correlate with body weight loss and severity as they 
do in the male.  Specific aim #2 sought to determine whether ovarian function loss or 
dysfunction could influence IL-6 regulation of cancer cachexia progression in the female 
Apc
Min/+ 
mouse.  The loss of ovarian function due to disease did cause an increase in Il-6-
related and other inflammation, while ovariectomy (OVX) alleviated much of the 
cachexia-related inflammation.  Specific aim #3 sought to determine whether cachexia-
induced skeletal muscle metabolic dysfunction is regulated by ovarian function in the 
female Apc
Min/+ 
mouse.  As expected, measures of protein degradation and mitochondrial 
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dysregulation increased with increasing cachexia severity; however, OVX brought these 
measures back towards baseline.  These findings provide insight into the intricate 
regulation of cachectic pathways by ovarian endocrine function, and will provide 
potential targets for therapeutics interventions for cancer cachexia.  
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CHAPTER 1 
INTRODUCTION 
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 Cachexia is a devastating condition that occurs secondary to several chronic 
diseases, including AIDS, COPD, chronic renal failure, and many forms of cancer [1].  
There is no cure or FDA-approved treatment for cachexia, though it occurs in 30-50% of 
cancers [1-3] and has an annual mortality rate of 80% [1], underlining the necessity of  
investigation into its etiology and progression.  The most recent definition of cachexia 
includes an unintentional weight loss of 5% or more secondary to a chronic condition in 
addition to other symptoms including anemia, fatigue, muscle weakness, increased 
inflammatory markers and plasma triglycerides, and insulin resistance [1].  Cachexia 
comprises a severe loss of adipose and skeletal muscle mass, the latter of which has 
serious implications for quality of life, function, wound healing, and ability to respond to 
chemotherapeutic treatments. The loss of both lean and fat mass is largely mediated by 
inflammatory cytokines, including IL-1β, IL-6, and TNFα [2]. The ApcMin/+ mouse is an 
established model of colon cancer and cachexia [4-6] that has been widely used by our 
lab and others.  The mouse has a nonsense mutation in the adenomatous polyposis coli 
(Apc) gene, a tumor suppressor gene [7] which is also mutated in the majority of human 
colon cancer cases [8] as well as familial adenomatous polyposis (FAP), a congenital 
disease leading to about 15% of human colorectal cancer cases [9]. Apc encodes the APC 
protein, which regulates cell proliferation via a direct interaction with, and leading to 
ubiquitin-mediated destruction of, β-catenin, a protein regulating multiple proto-
oncogenes [9].  The Apc
Min/+
 mouse develops a large number of intestinal neoplasms 
beginning at 4 weeks of age and plateauing by 12 weeks, after which cachexia develops 
over the next several weeks [4, 10].   
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 IL-6 is a pro-inflammatory cytokines closely involved with cancer cachexia 
progression in many animal models, as well as the human condition [11, 12], including 
the Apc
Min/+ 
mouse.  Our laboratory has previously shown that overexpression of IL-6 in a 
male Apc
Min/+ 
mouse can induce [13] and aggravate [14] cachexia progression; inversely, 
global IL-6 knockout (KO) in a male Apc
Min/+ 
alleviates tumor burden and severity of 
cachexia symptoms [13, 14]. The role of IL-6 during cachexia progression is less clear in 
the female, however.  While our lab has begun to elucidate the differences in IL-6-related 
signaling that occur during cachexia in the female [15], many gaps remain in our 
knowledge of the true etiology of cachexia in the female, as well as the exact role of IL-6 
in the female.  Plasma levels of IL-6 do not correlate with weight loss in the female [15] 
as they do in the male [13], and overexpression experiments in the female ([15], 
unpublished data) have shown no abrogation of cachexia severity. 
Dysregulation of muscle metabolism leading to muscle wasting with cachexia is 
regulated by a number of pro-inflammatory and pro-apoptotic factors.  Four major 
pathways exist that are involved in proteolysis due to various wasting conditions [3]; the 
major pathway at work during cancer cachexia is the ubiquitin-proteasome system (UPS), 
which is an ATP-dependent mechanism that involves tagging (ubiquitinating) proteins for 
breakdown by the 26s proteasome [16].    This process is regulated upstream by 
inflammatory factors including IL-6, STAT3, ERK, and p38 MAPK [17].  Many of the 
pathways are redundant. 
Though cachexia has been well-characterized in the male by our lab and others 
[4-6, 10, 18-24], almost no research into the condition has taken place in the female.  It 
had long been assumed that the male and female underwent the same pathophysiology 
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leading to cachexia; however, data from our laboratory has shown differences in the 
response of the male and female [15].  Though both sexes undergo cachexia, data from 
our lab has shown that the female loses less body weight than the male, and seems to 
have a differential response to IL-6 from the male [20].  Cachectic male and female 
Apc
Min/+ 
mice have similar plasma IL-6 levels [15]; however, induced overexpression of 
IL-6 in the male abrogates the cachectic response [5, 6, 20], but has no effect in the 
female.  There is no increase in STAT3 signaling in the female Apc
Min/+ 
mouse with 
overexpression of IL-6 [15], indicating a differential regulation of this pathway. 
Importantly, it has been shown that estrogen, specifically 17β-estradiol, can block 
transcription of IL-6 [25, 26] and signaling downstream of STAT3 [27].  IL-6 is a major 
putative regulatory point in the pathophysiology of cancer cachexia as it is increased in 
most cachexia models [11] and activates several pathways leading to eventual muscle 
wasting [11, 28]. 
 Ovarian function plays a major role in the health and disease outcomes of 
females.  The role of estrogen, in particular, in the health of both males and females has 
come into focus in the past decade.   Body composition is regulated in part by estrogen 
signaling, and it has been shown that the ablation of such has a significant deleterious 
impact on regulation of muscle and fat mass [29-32]; this dysregulation has potentially 
dire consequences when coupled with the innate dysregulation of cachexia.  Estrogen has 
well-documented benefits against inflammation [33-35], particularly IL-6 [36, 37], that 
may provide some benefit to the female during the onset and progression of cancer 
cachexia.  In addition, the relatively recent discovery of estrogen receptors α and β in 
skeletal muscle has led to new insight into estrogen’s benefits to skeletal muscle mass 
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and strength [30, 38, 39].  Specifically, estrogen is necessary for recovery from atrophy 
[29, 40].  Preliminary data from our lab shows that estrous cycling, which normally 
occurs in the C57BL/6 mouse until around 14 months of age [41], ceases during the 
progression of cancer cachexia in the female Apc
Min/+ 
mouse, which indicates interplay 
between the ovary and cachexia.  Apart from estrogen, the other major ovarian hormone 
progesterone and its analogs show potential for cachexia therapeutics; progestins 
including megestrol acetate (MA) and medroxyprogesterone acetate (MPA) have been 
shown to improve caloric intake and and anorexia symptoms in cachexia patients [3].   
IL-6 plays a role in the normal cyclic signaling of the ovary [42], but its dysregulation is 
also linked to ovarian pathology [42, 43].  This supports the hypothesis that there is 
interplay between ovarian function and IL-6.  This, together with the gaps in 
understanding of the mechanisms underlying cachexia-related muscle wasting in the 
female provides the rationale for this study.  The novelty of this study arises from it 
being, to our knowledge, the first study to specifically look at mechanisms of cachexia in 
the female Apc
Min/+ 
mouse, as well as the first study to investigate a potential role of 
ovarian endocrine function.  
Purpose & Specific Aims 
The overall goal of this proposal is to determine if ovarian function can alter cachexia 
progression in the female Apc
Min/+ 
mouse through IL-6 signaling and the regulation of 
skeletal muscle metabolism. The central hypothesis of the proposed study is that loss of 
ovarian function in the female Apc
Min/+ 
mouse causes abrogated progression of cachexia 
through altered IL-6 sensitivity, which increases skeletal muscle metabolic dysfunction 
and leads to increased skeletal muscle loss. Outcomes related to the specific aims of the 
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study include body composition, in vivo functional capacity, abnormal blood 
biochemistry, tissue IL-6 signaling, and disrupted skeletal muscle metabolism. 
In order to prove the proposed study’s overall hypothesis three specific aims are 
proposed.  
 
Specific Aim #1 will determine the relationship between of circulating IL-6 to cancer 
cachexia progression in the female Apc
Min/+ 
mouse (revised 4/23/15)  
 
Specific Aim #2 will determine if IL-6 regulation of cachexia progression is regulated by 
ovarian function in the female Apc
Min/+ 
mouse. 
 
Specific Aim #3 will determine whether cachexia-induced skeletal muscle metabolic 
dysfunction is regulated by ovarian function in the female Apc
Min/+ 
mouse. 
 
 
 
 
Figure 1.1 Overall Working Model: Working model of the focus of each of the three specific 
aims. First, the proposal will examine sex differences in the role of IL-6 signaling during 
cancer cachexia progression in Apc
Min/+ 
mice (AIM 1).  Second, the proposal will 
examine the role of loss of ovarian function (or ovariectomy) and its effect on 
inflammatory signaling during cancer cachexia progression in the female Apc
Min/+ 
mouse. 
Hypogonadism has an established role in cachexia progression of the male Apc
Min/+ 
mouse, but has not been investigated in the female (AIM 2).  Finally, this proposal will 
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examine the effect of cachexia severity and ovarian function on muscle metabolic 
dysregulation during cachexia in the female Apc
Min/+ 
mouse (AIM 3). Dysregulation of 
muscle signaling has been closely examined in the male Apc
Min/+
 mouse but has not been 
elucidated in the female.  
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CHAPTER 2 
REVIEW OF LITERATURE 
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2.1 Colon Cancer 
Colorectal cancer is one of the leading forms of cancer in both men and women [7].  The 
adenomatous polyposis coli (Apc) gene is a tumor suppressor gene that accounts for one 
of the highest rates of loss-of-function in human colon cancer [7].  The Apc gene lies on 
5q21 and includes 15 exons; the translated protein is fairly large at 309 kilodaltons [9].  
Some studies have shown that obesity affects men’s risk of colon cancer more so than 
women’s; other studies have shown no effect [44].  Sporadic colon cancer accounts for 
85% of cases, whereas familial adenomatous polyposis accounts for the other 15% [9].  
This syndrome causes the development of thousands of intestinal and rectal adenomas in 
the second decade of life and is due to a germline mutation of the Apc gene [9].  In fact, 
most colon cancers involve loss-of-function mutations in Apc [8]. Cancer cachexia 
frequently occurs secondary to colon cancer and accounts for 30-50% of deaths due to 
gastrointestinal cancers [45].  In cancer it is unclear whether cytokines are produced by 
tumor cells or inflammatory cells in response to tumor burden [3]. 
2.2 Cancer cachexia 
Cachexia develops secondary to many chronic disease, including AIDS, COPD, chronic 
renal disease, and cancer [1].  Gastrointestinal cancer patients are particularly susceptible 
to cancer cachexia [20].  Estimates of prevalence in cancer patients range from 28-57% 
[1, 2], with an annual mortality rate of 80% [1] and contributing to 20% of cancer-related 
deaths [2, 4].  This translates to over two million cancer-related cachexia deaths per year 
[1].  The most recent definition of cachexia includes an unintentional weight loss, 
secondary to underlying disease, of greater than 5% in 12 months, as well as additional 
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symptoms including anemia, fatigue, anorexia, decreased muscle strength, and increased 
inflammatory markers [1].  During experimental cachexia, fat stores are mobilized prior 
to muscle catabolism [2].  With some cancers, patients show high levels of TNFα, IL-1β, 
and IL-6, which roughly correlate with tumor progression [3].  Antibodies against each of 
these factors have been used with some success, but none has completely attenuated 
cachexia progression [3].  IL-6 is an important mediator of cachexia [20].   
Cachexia is essentially an inflammatory process.  Several inflammatory cytokines 
are known to play roles in the etiology and progression of cachexia. TNFα leads to 
extensive apoptosis of skeletal muscle cells during cachexia [2].  IL-1β and IL-6 promote 
TNFα-mediated cachexia, which then leads to an increase in FoxO1 signaling [3] as well 
as NfκB signaling through TNFR1[2].  IL-1β and IL-6 also contribute to the loss of lean 
body mass during cachexia [46]. Inactive NfκB is suppressed by the IKB family of 
proteins; when stimulated by TNFα, the IKB kinase complex (IKK) degrades IKB, which 
releases and thereby activates NfκB [2].  NfκB plays a major role in the upregulation of 
inflammation during cachexia [3].  Toll-like receptors (TLRs) are pathogen-recognizing 
receptors present on immune cells, tumor cells, and muscle cells that play a role not only 
in pathogen-related inflammation, but cachexia-related inflammation as well [46].  TLR2 
and TLR4 are expressed in skeletal muscle and lead to further increases of cytokine 
production (including IL-1β, IL-6, and TNFα) when stimulated [46].  The transforming 
growth factor (TGF) family of proteins is yet another inflammatory system capable of 
regulating cachexia-induced muscle wasting; TGFβ is the major player, signaling through 
SMAD 2/3 and leading to increased lean mass loss through proteolysis [47]. 
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2.3 Apc
Min/+ 
mouse model 
The Apc
Min/+ 
mouse has a nonsense mutation in codon 850 of the Adenomatous polyposis 
coli gene, (Apc) causing it to spontaneously develop colon polyps [4].  This model is 
especially relevant, as the Apc gene is mutated in the majority of human colorectal 
cancers [9].  Apc is a tumor-suppressor gene that regulates cell proliferation through 
physical interaction with β-catenin, which leads to the ubiquitination and proteasomal 
degradation of β-catenin [9].  When Apc heterozygosity and expression is lost, activation 
of β-catenin by Wnt signaling is increased, leading to increased transcription of β-catenin 
target genes including several proto-oncogenes [9].  Min/+ mice lose heterozygosity of 
Apc in some cells, which leads to overexpression of β-catenin and eventually causes 
tumors [24].  Min/+ mice generally have tumors in the small intestine and not the colon, 
unlike humans; however, the loss of both Apc and estrogen receptor beta (ERβ) in tumor 
cells make it a good model for the human disease [24].  Polyp number plateaus by 12 
weeks of age, but tumor size continues to increase as cachexia develops, up to 20 weeks 
of age [4]. 
2.4 Cachexia and Skeletal Muscle 
 Hypermetabolism due to cancer cachexia results in accelerated breakdown of 
adipose tissue and skeletal muscle in order to provide energy substrates to the tumor and 
host organism [16].  Skeletal muscle atrophy due to cachexia can lead to disability, 
weakness, lessened wound healing, and decreased response to chemotherapeutic agents 
[16].   
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Skeletal muscle is highly affected by cancer cachexia, though all fiber types do not 
undergo wasting uniformly [16, 20].  Fast-twitch (type II) muscle fibers are more 
susceptible to wasting with cancer cachexia than slow-twitch (type I) fibers, as the 
oxidative phenotype is protective against cachexia [2, 20].  Initiation of muscle mass loss 
with cachexia occurs as myonuclei undergo caspase-3-mediated apoptosis, decreasing the 
size of the myonuclear domain [2].  Additionally, dysregulated protein synthesis and 
myofiber regeneration [48], in addition to increased protein degradation, contribute to net 
muscle wasting with cachexia.  
 There are four major proteolytic pathways involved in the loss of skeletal muscle 
mass during cancer cachexia: Calcium-dependent (calpain/calpastatin-dependent), 
lysosomal, caspase-dependent, and ubiquitin/proteasome [2, 3].  The calpain and 
calpastatin proteolytic systems disrupt myofibrillar proteins and lead to eventual 
ubiquitination and proteasomal degradation of such [2].  Lysosomal proteases play only a 
small role in cachexia [2].  The ubiquitin/proteasome pathway is the major proteolytic 
player during cachexia [16], and is regulated by FoxO3 [3].  The other major proteolytic 
system involved in cachexia-related muscle wasting is autophagy; this mechanism is also 
regulated largely by FoxO3 [17]. FoxO3 is generally phosphorylated, and therefore 
inactivated and excluded from the nucleus of the cell, by PI3K/Akt [3].  When activated, 
FoxO3 translocates to the nucleus, where it acts as a transcription factors for skeletal 
muscle-specific E3 ligases including muscle ring finger (MuRF)1 and atrogin-1/MAFbx 
[3], which are highly activated with cachexia [16].  Upstream of PI3K/Akt, the pathway 
is regulated by reactive oxygen species (ROS), TNFα, PGC1α, and IGF-1[3]. 
Independent of FoxO3, UPS signaling can also be induced by oxidative stress and p38 
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MAPK signaling [17]. The UPS is an ATP-dependent process, and can therefore 
contribute to lower efficiency and further dysregulation of mitochondrial energy 
synthesis [16].  
In recent years, it has become apparent that mitochondrial dysfunction plays a 
major role in the etiology of cachexia and directly leads to many of the metabolic 
abnormalities and overall atrophy of skeletal muscle due to cachexia.  Indeed, it is 
thought that mitochondria are the site of energy waste in skeletal muscle that leads to the 
degradation of protein and overall wasting [49]. Oxygen consumption in mitochondria 
isolated from cachectic muscle is lower than in healthy mitochondria [16]. Initial 
cachexia does not affect mitochondrial content, though PGC1α and Mfn1, mitochondrial 
proteins, are decreased at this stage [50].  As cachexia progresses, these changes become 
more apparent and mitochondrial content decreases [50].  Cytochrome C oxidase (COX) 
IV protein levels [14] and activity decrease with cachexia; the latter of which is 
correlated with decreased oxygen consumption in mitochondria [16]. Higher levels of 
uncoupling protein-3 (UCP3) have been noted in wasting muscle cells [49]. It has been 
proposed that this decrease in mitochondrial content leads to an increase in reactive 
oxygen species (ROS), which leads to an increase in oxidative stress, energy stress, and 
apoptosis susceptibility leading to AMPK and FoxO1 activation [50].  However, Apc 
min/+
 
mice show these metabolic changes independent of oxidative stress [50].   
2.5 Role of IL-6 in tumorigenesis and cachexia 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine secreted by many types of immune 
cells [51]; this process is mediated by IL-1β, TNFα, and interferons [52].  Chronically 
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elevated IL-6 is associated with many pathophysiological conditions including cachexia 
and insulin resistance [51].  IL-6 suppresses insulin signal transduction via SOCS1 [2].  
In humans, IL-6 and c-reactive protein (CRP) plasma levels correlate with insulin 
resistance [53].  IL-6 has further been shown to inhibit hepatic insulin signaling in vitro 
and in vivo, though it does not affect insulin receptor signal transduction in skeletal 
muscle [53].   
Classic IL-6 signaling involves IL-6 binding to its membrane-bound receptor 
comprising IL6Rα, the ligand-binding domain, and gp130, the signal-transducing domain 
[54, 55].  The membrane-bound IL-6 receptor has limited tissue expression, including 
hepatocytes, immune cells, and skeletal muscle cells [55].  The alternative signaling 
paradigm is known as trans IL-6 signaling, and is thought to be responsible for many of 
the pro-inflammatory effects of IL-6 during cancer cachexia [56].   Inflammatory 
responses are largely mediated by endothelial cells, which lack mIL-6r and therefore rely 
on trans signaling [56]. Trans IL-6 signaling involves binding of the soluble IL-6 
receptor-IL-6 complex to the ubiquitously-expressed gp130 receptor [55], allowing for 
IL-6 signaling in nontraditional tissues. Soluble IL-6 receptor (sIL6r) is found in many 
body fluids.  Structurally identical to membrane-bound IL-6r and with the same affinity 
for IL-6 as the membrane-bound receptor [56], it can be formed by alternative mRNA 
splicing of the IL-6r gene (IL6ra) (10% of sIL-6r protein), or by shedding of the 
membrane-bound protein by metalloproteinase ADAM17 (90%) [52]. The cleaved 
protein can then dimerize and bind IL-6 in circulation, thereby increasing its half-life 
[57].  This complex formed can then bind to gp130 which is ubiquitously expressed on 
cell membranes, thereby allowing IL-6 signaling to occur in tissues where it normally 
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would not [42].  Cancer patients have higher levels of plasma sIL-6r compared with 
healthy controls [56]. 
Activation of the membrane-bound IL-6 receptor or gp130 receptor activates 
signal transducer and activator of transcription 3 (STAT3), which causes many of IL-6’s 
downstream deleterious effects [27].  Further, STAT3 is essential for gp130-mediated 
cell survival, cell cycle phase transition, cell movement, and cell differentiation [58]. 
Suppressor of cytokine signaling-3 (SOCS3) is the major negative regulator of STAT3, 
and exerts its effects on STAT3 signaling by binding simultaneously to gp130, JAK1, 
and JAK2 on the gp130/IL-6r/JAK/STAT3 complex [59].  SOCS3 can thereby inhibit IL-
6-induced STAT3 signaling and further aggravation of this pro-inflammatory pathway.  
However, when the epidermal growth factor (EGF) receptor (EGFR) is active and 
present, STAT3 can be re-phosphorylated by a second influx of IL-6 despite the 
continued presence of SOCS3 [59]. In muscle, IL-6 can also act as a mitogen, activating 
satellite cell and myocyte proliferation [51].  In addition to the STAT3 pathway, IL-6 can 
activate AMPK, p38 MAPK, and NfκB signaling [11, 60]. Muscle contraction, functional 
overload, and recovery from disuse all  increase IL-6 secretion from muscle [51].  When 
IL-6 is knocked out in mice, IGF-1 signaling decreases 80% [51]. 
Cells secrete proteins, a process known as “shedding,” by releasing extracellular 
vesicles [61].  Cancer cells shed more proteins, including IL-6, than normal cells, thus 
providing a means by which tumors secrete IL-6 [61].  IL-6 causes high levels of 
hepatocellular proliferation, eventually to hepatocellular carcinoma (HCC), the most 
common form of liver cancer [25].  Experimental ablation of IL-6 in mice abolished sex 
differences in occurrence of this cancer [25]. 
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Phosphorylated (activated) STAT3 is higher in 22-week old male Apc
Min/+ 
mice 
than in 13-week old mice, indicating that IL-6 signaling is involved in the development 
of cachexia [20].  Fbxo32 (Atrogin-1) mRNA and protein are also increased by 18-22 
weeks of age in male mice, and correlate with the decrease seen in gastrocnemius muscle 
weight [20].  When IL-6 was overexpressed in male Apc
Min/+ 
mice for two weeks, the 
cross-sectional area of type IIB muscle fibers decreased by 11% in the gastrocnemius 
muscle, indicating that IL-6 is involved in the skeletal muscle wasting seen with cachexia 
in the male [20].  However, overexpression of IL-6 in wildtype mice did not have the 
same effect, indicating the IL-6 is not sufficient to induce muscle wasting [20].  
Conversely, administration of an IL-6 receptor antibody (IL-6ra) to cachectic Apc
Min/+
 
mice attenuated further cachexia progression as well as loss of mitochondria and changes 
in mitochondrial dynamics [50]. 
2.6 Sex differences with Cancer and Cachexia 
Sex differences have been noted with muscle mass and strength in cancer and other forms 
of cachexia [62-64]; however, the vast majority of mechanistic work in cancer cachexia 
has been performed in the male.  In healthy mice, there are no differences in 
intermuscular amino acid kinetics.  In the postabsorptive state, however, there are 
significant differences in amino acid turnover between the sexes.  Additionally, men have 
a higher overall protein turnover rate than women, which also may play a factor in the 
sex differences seen in cachexia. Interestingly, differences between the sexes in cachexia 
have been seen on the molecular level as well.  After 14 days of synergist ablation in 
male and female (Atrogin-1) MAFbx-KO rats, male rats were able to induce muscle 
hypertrophy, while females were not [65]. This points to the possibility that many 
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classical cachectic pathways are differentially regulated by the sexes. Interestingly, our 
lab has shown that hypogonadism play a major role in the etiology of cachexia 
progression in the male [66], however, it is unknown if a similar effect happens in 
females.  Leptin is a molecule that reports the organism’s overall energy status to the 
brain,  Leptin levels are lower in cachectic cancer patients than in healthy controls [67]; 
interestingly, women’s leptin levels tend to be higher than men’s when matched for body 
fat [68]. Sex differences have long been seen in immune function; men generally have 
lower immune responses than women do to a stimulus [69]. Men also have naturally 
higher plasma levels of proinflammatory cytokines including TNFα and IL-6, two key 
cytokines involved in the progression of cachexia. Hepatocellular carcinoma (HCC) is the 
most common liver cancer; however, it occurs three to five times more often in men than 
in women [25].  This cancer is caused by high levels of IL-6, which are abolished in 
women by circulating estrogen [25].  Interestingly, several single-nucleotide 
polymorphisms (SNPs) along the IL-6 gene promoter that affect outcome in IL-6-related 
conditions have sex-related differences in frequency [70].  
2.7 Ovarian Function 
The ovary comprises oocytes in various stages of maturity, surrounded by 
granulosa and theca cells, which produce estrogen and progesterone, respectively, among 
other secreted hormones and cytokines.  These functional units of the ovary are known as 
follicles [71]. 
The hypothalamic-pituitary-gonadal (HPG) axis is similar across all animals, and 
almost all mammals have similarities between their ovarian function [72]. Ovarian 
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function in rodents can be monitored outwardly via the estrus cycle [73].  The estrus 
cycle lasts 4-5 days and consists of four stages based on relative estrogen levels and cell 
population present.  Stages include diestrus, in which estrogen levels are lowest; 
proestrus, featuring rising estrogen levels; estrus, during which estrogen levels are 
highest and ovulation occurs, and metestrus, during which estrogen levels fall [73]. The 
cycle is very regular and is not disrupted by stresses commonly found in animal facility 
settings [73].  Similar to humans, the estrogen spike is caused by a surge in LH and FSH.  
At the antral (early) stage of follicle development, the majority of follicles undergo 
atresia and die, unless they are stimulated to be ovulated [74].  Antral follicles produce 
Anti-Müllerian hormone (AMH), which is used as a marker of ovarian reserve [71]. As 
woman approach menopuase, FSH levels rise as inhibin, a negative feedback molecule, 
levels decrease [72]. At the time of menopause, Inhibins A, B, and C each decrease 
before there is a noticeable decrease in estrogen levels.  Eventually, there are very low 
levels of estrogen, progesterone, and AMH, and ovulation stops [72]. 
Ovariectomized mice have increased body fat, which can be reversed by estrogen 
replacement [32].  Along with higher body fat, ovariectomized mice have higher blood 
glucose, higher insulin, a higher insulin resistance index, higher cholesterol, and higher 
TNFα levels [32].  Before menopause, the incidence of type II diabetes is lower in 
women than in men.  After menopause, insulin sensitivity decreases, coinciding with a 
rise in inflammatory factors and a decrease in proper glucose metabolism [75].  Kidneys 
of ovariectomized mice show decreases in estrogens receptors α and β, as well as 
adiponectin; as the kidney is estrogen-sensitive, this indicates a shift in proper kidney 
function with ovariectomy [32].    
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 OVX mice also have lower levels of energy expenditure and higher levels of 
energy intake [76].  These animals also have a chronically activated inflammatory 
response in adipose tissue [76]; this suggests that ovarian hormones ate involved in the 
modulation of inflammation.   
Estrogen is an ovarian steroid hormone that typically works through a genomic 
pathway; that is, it binds to estrogen-response elements (EREs) on promoter sequences of 
target genes to activate transcription [77].  However, the estrogen/receptor complex can 
also work nongenomically by directly activating targets such as phosphatidylinositol-3-
kinase (PI3K) and mitogen-activated protein kinase (MAPK), which have roles in cell 
proliferation, protection against oxidative stress, and survival [77-80].  This is the 
mechanism by which estrogen conveys its osteoporosis-preventing effects in osteocytes, 
degeneration-preventing effects in neurons, and protective effects in many other cell 
types [77, 79-81].  Estrogen prevents apoptosis in many cells types by upregulating Bcl-
2, an anti-apoptotic mitochondrial protein, and by activating PI3K [81, 82].   Women 
have improved outcomes after ischemia/reperfusion injury to cardiomyocytes, largely due 
to estrogen’s effects in the cardiovascular system; specifically, estrogen activates the 
PI3K/Akt pathway in cardiomyocytes, leading to less inflammation, oxidative stress and 
apoptosis than men [33, 83].   
 Estrogen has significant effects on metabolism.  In a healthy animal muscle cell, 
insulin signals for upregulation of GLUT4 at the cell membrane through the PI3K 
pathway [38].  Estrogen receptor α-knockout mice have very reduced GLUT4 signaling, 
indicating that estrogen is an important modulator of insulin sensitivity [38].  The kidney 
is estrogen-sensitive; estrogen deficiency causes improper handling of energy substrates 
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by the kidney, leading to metabolic imbalances [32].  In fact, estrogen receptor α-
knockout mice show many of the symptoms of the metabolic syndrome, including 
glucose intolerance, insulin resistance, and adiposity [32].  It has been shown that 
overexpression of estrogen sulfotransferase (EST), an enzyme responsible for the 
deactivation of estrogens, causes inhibitions of insulin signaling, indicating that a certain 
level of active estrogen is necessary to maintain proper insulin signaling [31].  Estrogen 
receptor β activation has been shown to increase PGC-1, thereby modulating lipid 
metabolism [31].  Estrogen receptors α and β have further been implicated in the 
maintenance of body composition.  Experimentally, estrogen receptor α has been shown 
to increase hormone-sensitive lipase (HSL) in adipose tissue, which causes conversion of 
triglycerides to free fatty acids, and increases AMPK expression in skeletal muscle [31].  
Estrogen receptor β has been shown to keep body weight stable in high fat diet (HFD)-
fed mice [31].  Because it plays such a major role in glucose and lipid metabolism, 
estrogen receptor β has become a target of great potential for metabolic disease [31].   
 Estrogen’s effects in skeletal muscle are not well-studied, though estrogen 
receptors α and β are both present [84].  It is thought that many of estrogen’s beneficial 
effects in skeletal muscle are due to its antioxidant capacity and anti-inflammatory 
properties.  It has been hypothesized that estrogen stabilizes the cell membrane, 
protecting muscle cells from damage [84].  Though more study is needed, it has been 
shown in various animal muscle atrophy models that estrogen is necessary for recovery 
of muscle size and fiber cross-sectional area [40, 84].  Estrogen receptor α-knockout mice 
have lower contractile strength than wildtype mice, indicating that estrogen has important 
estrogen receptor α-mediated effects on muscular strength [84].  Additionally, 
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perimenopause in women is associated with a decrease in muscle mass and strength, 
though hormone replacement therapy (HRT) has been shown to increase both variables 
[85]. 
 Exposing skeletal muscle cells to estrogen before damaging stimuli protects them 
from apoptosis, as has been seen in many other cell types [86].  Estrogen regulates 
myoblast proliferation and differentiation [86].  In skeletal muscle, estrogen increases 
PPARδ and FoxO1, both of which are involved in the genesis of type I muscle fibers 
[87].  Ovariectomized mice showed significant decreases in genes associated with type I 
muscle fibers including PPARδ, FoxO1, myogenin, myosin light chain, and troponin C, 
and significant increases in genes associated with type II muscle fibers including MyoD 
[87].  However, ovariectomized mice also showed decreases in atrogin-1 and MuRF1 
expression, which may indicate less muscle wasting [87]. 
The rate of colon cancer in men is 35% higher than in women [88, 89], and some 
part of this is due to the beneficial effects of estrogen.  In fact, hormone replacement 
therapy (HRT) is associated with a 30-40% reduction of risk of colorectal cancer [24]. 
Population studies have shown menopause is associated with obesity and colon cancer 
[44].  The effects of estrogen on colon epithelium are numerous and lead to overall lower 
rates of colon cancer.   Hormone replacement therapy is associated with a 30-40% 
reduction in colon cancer risk  Estrogen reduces plasma IGF-1, a risk factor for tumor 
development [90], and increases insulin sensitivity [91].  Insulin and IGF-1 are mitogenic 
to colon cancer cells, and epidemiologic studies have shown a correlation between 
colorectal cancer and insulin levels [91].  Interestingly, however, the loss of estrogen in 
ovariectomized mice has no effect on tumor number [24]; it is possible that it only keeps 
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colonocytes from transforming into malignancies. [24, 88, 91].  Estrogen reduces growth 
in colonocytes via ERβ-mediated effects, including higher rates of apoptosis in pre-
malignant cells [44, 88].  The first sign of colon tumors are often aberrant crypt foci 
(ACFs); mice treated with estrogen had fewer ACFs than untreated mice, though this 
effect is ablated in ERβKO mice [88]. 
The effects of ERβ on colon epithelium have been well-established.  Estrogen can 
reduce the incidence of chemically-induced polyps in ERαKO mice, but not ERβKO 
mice, indicating that this receptor mediates the effects [88].  ERβ controls cell cycling in 
colon epithelium [89-91], and expression is frequently lost in colon tumors [24, 89, 91].  
In fact, ERβ expression is inversely related to tumor differentiation in colon epithelium 
[91]This effect occurs via estrogen responsive element (ERE)-binding dependent 
transcription, as well as through activator protein 1 (AP1) and SP1 [90].  ERαKO and 
ERβKO mice have increased colon tumor numbers and abnormal colon histology [24].   
It has been found that injecting mice with SW480 (colon cancer) cells as well as an ERβ 
construct decreases size of tumors compared to mice injected with only SW480 cells 
[90].  Contrary to the effects of ERβ in colon epithelium, ERα expression has been 
associated with increased incidence of cancer cell proliferation [44].  This follows with 
the general functions of the ERs: ERα induces proliferation and ERβ suppresses 
proliferation [44].  
Conversion of androgen into estrogens is favored in pro-inflammatory 
environments [92].  Bacterial lipopolysaccharide (LPS; endotoxin) induces multiple pro-
inflammatory factors including TNFα and NfκB, leading to apoptosis; these are inhibited 
by Akt-mediated 17β-estradiol and ERα signaling [35]. Endotoxin, interleukins 1 and 6 
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(IL-1β; IL-6) and tumor necrosis factor alpha (TNFα), all pro-inflammatory inflammatory 
factors, are able to activate the hypothalamic-pituitary-adrenal (HPA) axis.  Estrogen 
modulates the HPA axis response, but has different modulatory effects on HPA responses 
to endotoxin and IL-1 [37].  HPA responses to estrogen are attenuated by ovariectomy 
[37].  Estrogen inhibits NfκB, which activates monocyte chemoattractant protein-1 
(MCP1) [26], and along with other co-factors is involved in the transcription of IL-6, 
thereby blocking pro-inflammatory responses [26].  In fact, estrogen and NfκB have a 
mutually inhibitory relationship [33].  
 Many of estrogen’s anti-inflammatory properties have been most thoroughly 
investigated in the context of ischemia-reperfusion (I-R) injury of myocardial cells.  
Estrogen has been shown to decrease p38 MAPK-mediated inflammation following I-R 
[33]; this protection is ablated in ovariectomized female rodents.  Indeed, OVX was 
shown to increase phosphorylated p38, IL-1β, IL-6, TNFα, and caspase-3 cleavage in the 
myocardium [33].  
 Menopause is associated with an increase in inflammatory factors, including 
TNFα, IL-6, and plasminogen activator inhibitor-1 (PAI-1) [75], indicating that estrogen 
regulates levels of these factors in the pre-menopausal state. 
2.8 Ovarian Function and IL-6 
Granulosa cells of the ovary secrete IL-6 and other cytokines throughout the 
menstrual or estrous cycle.  Granulosa cells present both mIL-6r and gp130 [93]. 
Increasing amounts of IL-6 inhibit estrogen production by these cells, regardless of the 
stimulating presence of FSH [93]. During ovulation, rat ovaries produce a large amount 
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of IL-6 [58, 94]. TGFβ and IL-6 are involved in the post-ovulation healing process of the 
ovary [95]. In humans, during the follicular phase of the menstrual cycle (during which 
estrogen is high), IL-6 levels do not change but TNFα levels increase [57].  TNFα levels 
as well as sIL-6r levels increase during the luteal phase, during which there are low 
estrogen levels [57]. Across the whole menstrual cycle, women have higher TNFα and 
sIL-6r plasma levels than males [57]. Levels of IL-6 mRNA are increased in ovarian 
epithelial cells and cancer cells that have been stimulated with luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) [58]. Gonadotropins including LH and FSH have 
been shown to be more potent than sex steroids at stimulating IL-6 production [58].  
Circulating IL-6 increases after menopause [92].  IL-6 levels have been shown to 
increase in younger women who undergo oophorectomy, but this is abolished by 
hormone replacement therapy [92]. Additionally, the hypogonadism seen with 
menopause is associated with increased plasma levels of IL-6, and more negative 
outcomes associated with IL-6 [85].   Hormone replacement therapy after menopause is 
associated with increases in ovarian cancer rates [58]. Interestingly, postmenopausal 
women have increased plasma levels of soluble gp130 and soluble IL-6 receptor [85]. IL-
6 has been implicated in the pathogenesis of polycystic ovarian syndrome (PCOS) [42].  
Women with PCOS had higher serum gp130 concentrations than women without PCOS; 
women with PCOS have significantly lower sIL6r concentrations than women without, 
indicating that IL-6 signaling is occurring via a different mechanism in this syndrome 
[42].  Serum gp130 is related to SHBG levels [42].  
Elite female gymnasts who had not reached menarche have increased IL-6 and TNFα 
expression in leukocyte compared to athletes who had reached menarche and therefore 
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had estrogen levels that were 200% of those athletes who had not yet reached menarche 
[96]. 
In intact mice, it has been shown that both androgens and estrogens are able to 
inhibit IL-6 production [37].  Estrogen directly inhibits IL-6 synthesis and release from 
bone marrow cells through ERα-mediated gene transcription [37, 58].  Estrogen has been 
reported to increase IL-6 expression in circulating mononuclear cells, but to inhibit IL-6 
synthesis in other cell types including osteoblasts [58]. Estrogen prevents necessary 
transcription factors, including NfκB, C/EBPβ [25], and p65 [26] from binding to the IL-
6 promoter, thereby inhibiting transcription [97].  The estrogen receptor α (ERα) also 
blocks NfκB from binding to the MCP-1 promoter and blocks TNFα from inducing high 
levels of MCP-1[26]. Ovariectomized mice show higher plasma IL-6 levels than intact 
mice, but estrogen replacement attenuates this increase [37].  Further, estrogen 
upregulates SOCS3 in hepatocytes [25]. Administration of estrogen has been shown to 
decrease plasma levels of IL-6, IL-1β, and TNFα [85]. In mice given diethylnitrosamine 
(DEN) to induce hepatocellular carcinoma (HCC), a form of liver cancer, estrogen 
abolishes IL-6 secretion from hepatic Kupffer cells by inhibiting IKKβ and Myd88, 
protecting the female from IL-6-induced tumorigenesis [25].  Estrogen can block 
downstream signaling of STAT3 [27]; further, estrogen can upregulate SOCS3 (a 
downstream negative inhibition molecule which inhibits STAT3 signaling) in 
hepatocytes [98]. Administration of estrogen to males and ovariectomized females 
protected them as well as intact females [25].  It was found that STAT3 was being 
activated by IL-6 in the males, but not the females, leading to an important finding about 
the mechanism of estrogen’s effect on IL-6 signaling [25].   
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IL-6 inhibits cilia activity in fallopian tubes; gp130 and IL-6r are also present in 
fallopian tubes [54]. In the uterus, estrogen can both positively and negatively regulate 
IL-6 [54]. Interestingly, estrogen induces a time-dependent decrease in IL-6r expression; 
this can be blocked by inhibiting ERα [54].  
 In multiple myeloma cells, 17β-estradiol completely abolishes IL-6-inducible cell 
proliferation and STAT3 DNA binding [27].  Importantly, estrogen does not inhibit 
STAT3 activation by IL-6; it blocks downstream activity of STAT3 [27]. 
In breast cancer cells, IL-6 is a key factor in the secretion of estrogen.  It strongly 
synergizes with estrogen to activate aromatase and steroid sulphatase in order to further 
stimulate production [99].  Further, IL-6 activates transcriptional activity of ERα via 
estrogen response elements (EREs) [99].   
2.9 Ovarian Function and Cancer 
Hypogonadism is apparent in 40-90% of male cancer patients [66].  Though this has not 
yet been proven in females, the hypogonadism seen with menopause negatively affects 
the metabolism of multiple organ systems including skeletal muscle and the immune 
system [85].  Sex hormone binding globulin (SHBG) is increased in cancer patients, 
leaving less unbound (biologically active) hormone available [66].  Progestins, including 
megestrol acetate (MA) and medroxyprogesterone acetate (MPA), have been shown to 
decrease anorexia seen with cachexia, and possibly inhibiting IL-6 and TNFα [3].  
Unfortunately, it is very difficult to study the role of ovarian function with cancer, as 
most chemotherapeutic agents ablate ovarian function, making most women who undergo 
cancer treatment sterile [100]. A great number of childhood cancer survivors live to 
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adulthood; however, women tend to have fewer primordial and antral (growing, healthy) 
follicles in their ovaries than age-matched controls, generally due to the ionizing effects 
of radiation or chemotherapy [101]. 
2.10 Ovarian Function and Skeletal Muscle 
 OVX mice have significant decreases in gene expression of PPARδ, FoxO1, 
PDK4, and UCP2 in skeletal muscle [87]. PPARδ and FoxO1 affect muscle fiber type; 
both tend to shift towards type I [87].  In addition, OVX mice have decreased myosin 
light chain and troponin C proteins, both of which are prevalent in type I fibers [87]. 
Interestingly, these mice also have more MyoD than sham mice, which drives 
development of type II fibers [87].  OVX mice also have decreased atrogin-1 and MuRF1 
[87], two essential skeletal muscle-specific E3 ligases involved in the degradation of 
skeletal muscle protein with cancer cachexia.  Metabolically, OVX is associated with 
increased adiposity due to upregulation of genes involved with lipid storage including 
lipoprotein lipase (LPL), acetyl-CoA carboxylase-1 (ACC-1), fatty acid synthase (FAS), 
and others; supplementation of estrogen downregulated these genes [102].  
Estrogen has multiple mechanisms by which it can enhance skeletal muscle 
function and quality, including antioxidant properties, stabilizing myofiber membranes 
by intercalation, and downstream gene expression [103]. After muscle damage or 
unaccustomed exercise, estrogen plays a role in stimulating muscle repair and 
regeneration, in part by activating satellite cells [103]. Due to membrane rupture, 
damaged skeletal muscle cells release creatine kinase (CK) and myoglobin after damage 
or unaccustomed exercise; though there is a great amount of variability in the release of 
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CK, women do tend to have lower levels in circulation which is directly attributable to 
estrogen [103].   
In C2C12 mouse myoblast culture, exposing cells to 17β-estradiol before 
exposure to apoptotic stimuli including hydrogen peroxide (H2O2) protects them from 
damage [86].  One of the protective mechanisms of estrogen on skeletal muscle is 
increased expression  of heat-shock proteins (HSPs), which control cell homeostasis by 
acting as protein-folding chaperones and protecting protein structure from physiological 
stresses [86]. Expression of HSPs 25, 27, 70, and 90 is directly modulated by estrogen 
[86].  
Estrogen causes lower skeletal muscle mass in ovaries-intact mice or estrogen-
replete mice compared to OVX mice; this is at least in part attributable to the effects of 
ubiquitin-specific peptidase 19 (USP19), which is upregulated by estrogen receptor alpha 
(ERα) and during muscle atrophy [104]. The promoter of USP19 contains estrogen 
response elements (EREs), to which ERα binds in female mice and male mice given 
estrogen; this does not occur in OVX female mice or control male mice [104].  
2.11 Conclusion 
Though much work has been done in the areas of ovarian function, largely including 
estrogen’s roles, in cancer and skeletal muscle, it is clear that many gaps remain in our 
knowledge.   Very little is known of ovarian function’s effects on muscle outside of what 
we have learned from menopausal women or from animal studies of estrogen’s direct 
effects on muscle.  Additionally, beyond estrogen’s effects in cancer, there is a paucity of 
research on ovarian function as a whole and how it contributes to cancer formation or 
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progression.  As far as cachexia, there is an embarrassing lack of research regarding the 
roles of either ovarian function or estrogen in the treatment or role in the etiology of 
cachexia.  Going forward, it is intended that the present studies will fill some of these 
gaps and begin to fill in the picture of how ovarian function contributes to the etiology 
and progression of cachexia.  
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CHAPTER 3 
SEX DIFFERENCES IN THE RELATIONSHIP OF IL-6 SIGNALING TO CANCER 
CACHEXIA PROGRESSION
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3.1 Abstract 
A devastating aspect of cancer cachexia is severe loss of muscle and fat mass.  Though 
cachexia occurs in both sexes, it is not well-defined in the female.  The Apc 
Min/+ 
mouse is 
genetically predisposed to develop intestinal tumors; circulating IL-6 is a critical 
regulator of cancer cachexia in the male Apc 
Min/+ 
mouse.  The purpose of this study was 
to examine the relationship between IL-6 signaling and cachexia progression in the 
female Apc 
Min/+ 
mouse.  Male and female Apc 
Min/+ 
mice were examined during the 
initiation and progression of cachexia. Another group of females had IL-6 overexpressed 
between 12-14 weeks or 15-18 weeks of age to determine whether IL-6 could induce 
cachexia.  Cachectic female Apc 
Min/+ 
mice lost body weight, muscle mass, and fat mass; 
increased muscle IL-6 mRNA expression was associated with these changes, but 
circulating IL-6 levels were not. Circulating IL-6 levels did not correlate with 
downstream signaling in muscle in the female. Muscle IL-6r mRNA expression and 
SOCS3 mRNA expression as well as muscle IL-6r protein and STAT3 phosphorylation 
increased with severe cachexia in both sexes. Muscle SOCS3 protein increased in 
cachectic females but decreased in cachectic males.  IL-6 overexpression did not affect 
cachexia progression in female Apc 
Min/+ 
mice.  Our results indicate that female Apc 
Min/+ 
mice undergo cachexia progression that is at least initially IL-6-independent.  Future 
studies in the female will need to determine mechanisms underlying regulation of IL-6 
response and cachexia induction.  
Key Words: IL-6r, STAT3, SOCS3, skeletal muscle, Apc 
Min/+ 
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3.2 Introduction 
Cachexia is a devastating condition that occurs secondary to several chronic diseases, 
including AIDS, COPD, chronic renal failure, and many forms of cancer [1].  There is no 
FDA-approved treatment for cachexia, though it occurs in 30-50% of cancers [1-3] and 
has an annual mortality rate of 80% [1]; the investigation into its etiology and progression 
is therefore essential.  The most recent definition of cachexia includes an unintentional 
5% weight loss over twelve months, comprising the loss of muscle and fat [1]. Other 
abnormalities associated with cachexia include anemia, fatigue, muscle weakness, 
increased plasma triglycerides and inflammatory markers, and insulin resistance [1].  
There has been considerable improvement in our understanding of the regulation of 
cancer cachexia progression due to research employing male mouse models [5, 14, 21, 
105, 106]. However, there is evidence that sex differences exist in the development of 
cachexia in rodents [107]. Additionally, sex differences have been observed in the loss of 
muscle strength associated with cachexia severity in humans [108]. Although there is 
clear evidence that cachexia occurs in both males and females, the fundamental 
differences in the pathophysiology due to sex and underlying mechanisms are unknown.  
Systemic inflammation related to cancer is thought to be a mediator of cachexia, as 
several pro-inflammatory pathways are enhanced during the progression of cachexia 
[109, 110].  Sex hormones can modulate the inflammatory response to a variety of stimuli 
[33, 37, 111]. Specifically, estrogen is known to inhibit NfB and tumor necrosis factor  
(TNF) signaling [35, 111], C-reactive protein (CRP)-induced interleukin-6 (IL-6) 
production [36], and signal transducer and activator of transcription-3 (STAT3) signaling 
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downstream of IL-6 [27]. In several rodent models of cachexia and some human cancers, 
IL-6 is associated with the development of muscle wasting and body weight loss [5, 13, 
14, 112, 113]. Classical IL-6 signaling involves binding of the cytokine to the membrane-
bound IL-6 receptor (mIL-6r) on target tissues, which include hepatocytes, immune cells, 
and skeletal muscle [42, 55, 114].  mIL-6r is a heterodimer comprising the ligand-specific 
gp80 unit and the signal-transducing gp130 unit [54].  Activation of mIL-6r induces 
downstream activation of many signaling pathways, including JAK/STAT, p38, and ERK 
[11, 55, 115, 116].  Several of these pathways have been implicated in the regulation of 
muscle mass loss during cancer cachexia [11, 28].   
The Apc
Min/+ 
mouse is genetically predisposed to develop intestinal tumors and 
becomes cachectic secondary to the tumor burden [20, 105]. Our lab initially 
characterized cachexia in retired female Apc
Min/+ 
breeders [18]; however, the progression 
and etiology of cachexia in the female Apc
Min/+ 
mouse
 
has not been described.  
Development of cachexia in the male Apc
Min/+
mouse has an established IL-6 dependence 
[4-6, 14, 20, 22, 106].  Administration of an IL-6 receptor antibody to cachectic male 
Apc
Min/+
 mice can attenuate further cachexia progression [106].  When IL-6 is 
systemically overexpressed in the male, more body weight is lost and cachexia is more 
severe, indicating a causative role [5, 11, 14].  However, the response of female Apc
Min/+
 
mice to IL-6 overexpression has not been examined.  Sex differences have been noted in 
the inflammatory milieu of humans [68, 69] and mice [25, 33] under multiple 
pathological circumstances.  Additionally, estrogen has been shown to inhibit IL-6 
transcription and signaling in several tissues [25, 27, 36, 92, 97], which may also lead to 
sex differences in IL-6 response during cancer cachexia progression. Therefore, the 
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purpose of the present study was to examine the relationship of circulating IL-6 to cancer 
cachexia progression in the female Apc
Min/+
 mouse. Our hypothesis is that cachexia 
progression in the female Apc
Min/+ 
mouse would not be associated with increased 
circulating IL-6 levels as has been reported in the male.  This hypothesis was tested 
through three experiments.  The first experiment followed a cohort of female and male 
Apc
Min/+ 
mice to 18 weeks of age, at which point the association between cachexia 
severity and circulating IL-6 level was determined.  In the second experiment, 12-week 
old female Apc
Min/+ 
mice had IL-6 systemically overexpressed for two weeks (until 14 
weeks of age) to determine if supraphysiological IL-6 levels could induce cachexia as we 
have previously shown in the male [5, 6, 60]. In the third experiment, 15-week old female 
Apc
Min/+ 
mice had IL-6 systemically overexpressed for three weeks (until 18 weeks of 
age) to determine if supraphysiological IL-6 levels could accelerate cachexia progression 
as we have previously shown in the male [20]. 
3.3 Methods 
Animals 
Female Apc
Min/+
mice (N=32), male Apc
Min/+ 
mice (N=12), female C57BL/6 mice (N=6), 
and male C57BL/6 mice (N=6) were bred and maintained at the University of South 
Carolina Animal Resource Facility.   Apc
Min/+ 
mice used were offspring from breeders 
originally purchased from Jackson Labs (Bar Harbor, ME, USA).   Male and female mice 
were taken during the three-month period from a standing inbred Apc
Min/+ 
breeding 
colony.  Apc
Min/+ 
mice used were on a C57BL/6 background.  Mice were kept on a 12:12h 
light/dark cycle beginning at 7:00 AM and were given unrestricted access to standard 
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rodent chow (Harlan Teklad Rodent Diet, #8604).  Mice were weighed weekly. Blood 
was collected by retro-orbital eye bleed at 12, 14, 16, 18, and 20 weeks for IL-6 analysis.  
All experiments were approved by the University of South Carolina’s Institutional 
Animal Care and Use Committee.   
Procedures  
Three experiments were performed. Experiment 1 examined the progression of cachexia. 
Female Apc
Min/+
mice (n=18) were sacrificed at 18 weeks of age.  Male Apc
Min/+ 
mice 
were sacrificed at 18-20 weeks of age. Female (n=6) and male (n=6) C57BL/6 (B6) were 
sacrificed at 18 weeks of age as non-cancer controls.  Prior to sacrifice, blood was taken 
for analysis of IL-6 levels. Experiment 2 examined 2 weeks of IL-6 over-expression in 12 
week-old, weight stable female Apc
Min/+ 
mice as we have previously completed in the 
male [60]. Female Apc
Min/+ 
mice were electroporated with a control plasmid or with an 
IL-6 overexpression plasmid (n=4 per group) at 12 weeks and were sacrificed at 14 
weeks.  Blood was taken at sacrifice (post-treatment) to determine plasma IL-6 levels. 
Mice from this experiment were not used for any other analysis.  Experiment 3 examined 
IL-6 over-expression in 15-week-old female Apc
Min/+ 
mice corresponding with the 
initiation of cachexia, a time course we have previously examined in the male [20]. At 15 
weeks of age mice were randomly separated into IL-6 over-expression (n=6), control 
plasmid (N=3), or non-electroporated control (n=3) treatment groups.  All 
female Apc
Min/+ 
mice were sacrificed at 18 weeks of age. Blood was taken at sacrifice 
(post-treatment) for determination of plasma IL-6 levels. No differences were found in 
body weight (p=0.78) or muscle mass (p=0.36) between control plasmid and non-
electroporated mice. Therefore, the control plasmid and non-electroporated 
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female Apc
Min/+ 
mice were then pooled for analysis. Additionally, these 6 mice are in the 
cohort of 18 female Apc
Min/+ 
mice related to Experiment 1.  In all experiments, blood, 
inguinal fat, hindlimb muscles, and spleen were removed at the time of sacrifice. 
Hindlimb muscle mass measurements comprise the sum of left soleus, plantaris, 
gastrocnemius, tibialis anterior, extensor digitalis longus, and quadriceps masses. 
IL-6 overexpression by electroporation  
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase circulating 
IL-6 levels in mice as previously described [117]. The right quadriceps muscle was used 
to synthesize and secrete exogenous IL-6 into circulation from the injected expression 
plasmid, and was not used for any analyses in the study. The gastrocnemius muscle used 
in the study was not subjected to electroporation. Briefly, mice were injected with 50 μg 
of IL-6 plasmid driven by the CMV promoter, or control plasmid (pV1J), into the right 
quadriceps muscle. Mice were anesthetized with a 2% mixture of isoflurane (IsoSol, 
VEDCO, St. Joseph, MO, USA) and oxygen (1 L/min). The leg was shaved, and a small 
incision was made over the quadriceps muscle. Fat was dissected away from the muscle, 
and the plasmid was injected in a 50 μl volume of sterile phosphate-buffered saline 
(PBS). A series of eight 50 ms, 100 V pulses was used to promote uptake of the plasmid 
into myonuclei, and the incision was closed with a wound clip. In Experiment 2, 
electroporation was performed at 12 weeks and mice were sacrificed at 14 weeks of age.  
In Experiment 3, electroporation was performed at 15 weeks and mice were sacrificed at 
18 weeks of age. 
 
 37 
 
RNA isolation and RT-PCR 
RNA isolation, cDNA synthesis, and real-time PCR were performed as previously 
described [118].  Reagents from Applied Biosystems (Foster City, CA, USA) were used.  
Briefly, proximal gastrocnemius muscle was homogenized in TRIzol (Life Technologies, 
Grand Island, NY, USA) and mixed with chloroform, then centrifuged.  The RNA phase 
was removed and washed several times with ethanol in DEPC-treated water.  cDNA was 
synthesized using 1 g of RNA.  RT-PCR was performed on an Applied Biosystems 
7300 thermocycler.  A Taqman gene expression assay was used to determine IL-6 mRNA 
expression (Life Technologies).  IL-6 receptor (forward, 5’-
CTGCCAGTATTCTCAGCAGCTG-3’, and reverse, 5’-
CCTGTGTGGGGTTCCAGAGGAT-3’); SOCS3 (forward, 5’-
TGCAGGAGAGCTGATTCTAC-3’, and reverse, 5’-TGACGCTCAACGTGAAGAAG-
3’); gp130 and GAPDH primer sequences have been published elsewhere [119].   
Western blotting 
Western blots were performed as described previously [106, 120].  Briefly, 
gastrocnemius muscle samples were run on 6-8% acrylamide gels and transferred 
overnight to PVDF membrane (Thermo Scientific, Waltham, MA, USA).  After transfer, 
Ponceau stains were imaged to verify equal loading. The membrane was blocked for 1 
hour in 5% milk-TBS-Tween 20, and incubated with primary antibodies at 1:2000 
dilution overnight at 4⁰C.  After several washes, membranes were incubated with 
secondary antibodies at 1:2000 dilution for 1 hour.  Blots were visualized with 
WesternBright ECL (BioExpress, Kaysville, UT, USA). SOCS3 antibody was obtained 
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from Abcam (Cambridge, MA, USA).  STAT3, phopho-STAT3 (Y705), anti-mouse IgG, 
and anti-rabbit IgG antibodies were obtained from Cell Signaling (Danvers, MA, USA).   
Grip strength measurement 
Grip strength measurements were determined as previously described [5]. Mice 
underwent 2 sets of 5 grip strength trials.  The first mouse was removed from its cage, 
held firmly by the base of the tail, and allowed to grasp the top of the grate attached to the 
force gauge (Chatillon, Largo, FL, USA) with its paws.  The mouse was firmly pulled 
down the grate, and grip strength was recorded in Newtons.  The mouse completed the 5 
trials of the first set and was returned to its cage.  Each mouse tested went through the 
same procedure for its first trial, and mice were cycled through in the same order for the 
second trial. 
Fasting glucose  
Mice were fasted for five hours prior to blood glucose measurements.  Blood glucose 
measurements were performed using a handheld glucometer (Bayer CONTOUR®, 
Whippany, NJ, USA ) according to the manufacture’s instructions. 
IL-6 Enzyme-linked immunosorbent assay 
Plasma IL-6 concentrations were determined as previously described [5]. A commercial 
IL-6 ELISA kit was obtained from Invitrogen (Fredrick, MD, USA) and the 
manufacturer’s protocol was followed.  Briefly, blood was centrifuged after sacrifice; 
plasma was removed and stored at -80°C until analysis.  A Costar clear 96-well plate 
(Corning, NY, USA) was coated with IL-6 capture antibody and allowed to incubate 
overnight.  The next morning, the plate was blocked with assay diluent buffer.  The plate 
was washed; plasma samples and IL-6 standards were diluted with assay diluent buffer 
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and added in duplicate to the plate.  The plate was again washed and sAV-HRP reagent 
was added to wells.  After several washes, TMB substrate was added to wells and color 
was allowed to develop.  The reaction was stopped with sulfuric acid and absorbance was 
read in a BioRad iMark plate reader (Hercules, CA, USA) at 450 nm. 
IL-6R Enzyme-linked immunosorbent assay 
Muscle IL-6R protein levels were determined using a DuoSet ELISA kit (R&D Systems, 
Minneapolis, MN, USA) as previously described [121].  Briefly, gastrocnemius muscle 
tissue was homogenized in buffer containing 50mM HEPES, 4mM EGTA, 10mM 
EDTA, 15mM Na4P2O7, 100mM -glycerophosphate, 25mM NaF, 5mM NaVO4, 0.1% 
Triton-X, and 0.1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA).  A 
Costar 96-well plate (Corning) was coated with IL-6r capture antibody and allowed to 
incubate overnight.  The next morning, the plate was blocked with assay diluent.  After 
washing, IL-6r standards and 50-500 µg protein of samples were added to wells in 
duplicate.  The plate was again washed and detection antibody was added.  Another wash 
was performed and streptavidin-HRP was added to the plate.  After a final wash, 
substrate solution was added to the plate and color was allowed to develop before the 
addition of stop solution.  Absorbance was read at 450 and 570 nm in a BioRad iMark 
plate reader (BioRad).  Standard and sample concentration was determined using a third-
order polynomial curve. 
Intestinal polyp quantification 
Quantification of intestinal polyps was determined as previously described [19].  Briefly, 
intestinal sections were fixed in formalin at time of sacrifice.  At time of analysis, 
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sections were rinsed in deionized water and dipped briefly in 0.1% methylene blue.  
Polyps from segment 4 were counted under a dissecting microscope; it has been 
determined that tumor number in segment 4 is representative of total tumor number 
[122].   
Statistical analysis 
All results are reported as means ± SEM.  Differences between degrees of cachexia 
severity were analyzed by one-way ANOVA using Tukey post hoc test where 
appropriate.  Differences between sexes and genotypes were determined by two-way 
ANOVA with Student-Newman-Keuls post hoc test where appropriate.  Correlations 
were determined by Pearson’s test for correlation. Differences between 12-14 week and 
15-18 week IL-6 treatment groups were determined by Student’s t-test.  Level of 
significance was set at 0.05. 
3.4 Results 
Differential cachexia progression in male and female Apc
Min/+ 
mice (Experiment 1) 
Both male and female Apc
Min/+ 
mice undergo varying degrees of cachexia; 
however, efforts to characterize progression have focused overwhelmingly on the male. 
Our lab has previously described the male [5, 13, 106], but limited data has been 
presented related to the female response [23].   Both male (n=12) and female (n=18) 
Apc
Min/+ 
mice lost a significant amount of body weight from their peak weight (Figure 
1A); however, males lost a greater percentage of body weight than females (p<0.0001).   
Apc
Min/+ 
mice generally have the greatest density of tumors in segment 4 of the small 
intestine, and the number of tumors in this segment correlates with total tumor number  
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[122].  The number of tumors in male and female Apc
Min/+ 
mice, though significantly 
higher than male and female B6 mice (p<0.0001), did not differ (Figure 1B), indicating 
that the differences in body weight loss were not due to tumor burden.  Regardless of sex, 
Apc
Min/+ 
mice had significantly higher circulating IL-6 levels than B6 mice (p<0.0001). 
Despite the consistency in tumor burden, male Apc
Min/+ 
mice had higher circulating IL-6 
levels than females (p<0.0001) (Figure 1C).  Both male and female Apc
Min/+ 
mice had 
significantly larger spleens than B6 mice of the same sex (p<0.0001), indicating a higher 
level of systemic inflammation (Figure 1D); however, male Apc
Min/+ 
had larger spleens 
than females (p=0.03). 
Progression of cachexia in female Apc
Min/+ 
mice (Experiment 1) 
To determine the changes seen with progression of cachexia in the female 
Apc
Min/+ 
mouse, a cohort of 18 week old female Apc
Min/+ 
mice (n=18) were stratified 
based on body weight change from peak (Table 1).   The cohort was divided based on 
body weight loss; “Weight Stable” comprises mice with less than 2% body weight loss 
from peak weight (n=6), “Initial Cachexia” comprises mice with 2-9% body weight loss 
(n=6), and “Cachexia” comprises mice with greater than 10% body weight loss (n=6).  
Body weight loss ranged from 0% to -15.8%; ~30% of the mice were classified as 
“cachectic,” with severe body weight loss, fat and muscle mass loss, and decreased 
muscle strength (Table 1). As expected, body weight change from peak weight was 
significantly different between all groups (Table 1).  Spleen weight did not differ between 
weight stable and the initiation of cachexia. Cachectic female Apc
Min/+ 
mice had 
significantly larger spleens than either of the other groups (p=0.01) (Table 1).  Segment 4 
tumor count did not differ between weight stable and the initiation of cachexia. Cachectic 
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Apc
Min/+ 
mice had significantly more tumors than either of the other groups (p=0.002) 
(Table 1).  This indicates a relationship between tumor burden and cachexia development 
in the female that has also been reported in the male [105]. Hindlimb muscle mass and 
inguinal fat mass did not differ between weight stable and initiation of cachexia.  
Cachectic Apc
Min/+ 
females had significantly less hindlimb muscle mass and inguinal fat 
mass than weight stable or the initial cachexia groups (Table 1).  Importantly, there were 
no differences in circulating IL-6 levels between any of the groups (Table 1).  Cachectic 
Apc
Min/+ 
females had significantly lower voluntary forelimb grip strength than either of 
the other groups, though this difference was eliminated when normalized to body weight 
(Table 1).   
  All female Apc
Min/+ 
mice continued to gain weight until 16 weeks of age; 
differences in body weight between groups are only seen after this point (Figure 2A; 
p=0.016).  Across all female Apc
Min/+ 
mice, there was a significant relationship between 
hindlimb muscle mass and body weight loss (Figure 2B; p<0.0001, R
2
=0.64). Inguinal fat 
mass demonstrated a curvilinear relationship (p=0.0002, R
2
=0.58) with body weight loss, 
with fat mass having the most direct relationship with body loss during the initiation of 
cachexia (Figure 2C).  Taken together, this indicates that during the progression of 
cachexia in the female Apc
Min/+ 
mouse the loss of inguinal fat mass occurs early, while 
muscle mass loss demonstrates a consistent decline over time.  
Muscle IL-6 signaling-associated mRNA expression in male and female Apc
Min/+ 
mice 
(Experiment 1) 
The levels of circulating IL-6 in female Apc
Min/+ 
mice were not associated with 
body weight loss, hindlimb muscle mass, or inguinal fat mass (Table 2). However, 
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muscle mRNA expression of IL-6 was significantly correlated with both body weight loss 
and hindlimb muscle mass (Table 2). There was a main effect of cachexia independent of 
sex to increase muscle IL-6 receptor mRNA expression (p=0.043; Figure 3A). In female 
Apc
Min/+ 
mice, muscle IL-6 receptor mRNA expression was significantly correlated with 
muscle gp130 mRNA and SOCS3 mRNA expression (Table 2).   Neither sex nor 
cachexia had a significant effect on muscle gp130 mRNA expression (Figure 3B). 
Although gp130 mRNA expression was not associated with body weight loss in female 
Apc
Min/+ 
mice, it was significantly associated with muscle SOCS3 mRNA expression 
(Table 2). Cachexia increased muscle SOCS3 mRNA expression independent of sex 
(p=0.01; Figure 3C).  However, muscle SOCS3 mRNA expression was not correlated 
with body weight loss in female Apc
Min/+ 
mice (Table 2).  
Muscle IL-6 signaling-associated protein expression in male and female Apc
Min/+ 
mice 
(Experiment 1) 
Muscle IL-6 receptor protein expression was examined in gastrocnemius muscle 
of male and female B6 and Apc
Min/+ 
mice.
  
Interestingly, male B6 mice have significantly 
higher levels of muscle IL-6r than female B6 mice (Figure 4A; p=0.006).  In female 
Apc
Min/+ 
mice, muscle IL-6r increases with cachexia severity (Figure 4B; p=0.002); 
however, cachectic male Apc
Min/+ 
mice have significantly higher expression than 
cachectic females (Figure 4B; p=0.02). 
  
Muscle STAT3 phosphorylation was examined during the progression of cachexia 
in female Apc
Min/+ 
mice (Figure 4C). Muscle STAT3 phosphorylation (Y705) was 
normalized to female B6 levels of phosphorylation. Total STAT3 muscle expression did 
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not change with the progression of cachexia (B6: 1 ± 0.05; Weight stable: 1.03 ± 0.03; 
Cachexia: 1.02 ± 0.07). Muscle STAT3 phosphorylation was significantly different 
across groups (p=0.010). Muscle STAT3 phosphorylation significantly increased in 
cachectic muscle when compared to the initially cachectic female Apc
Min/+ 
mice 
(p=0.049). The induction of STAT3 phosphorylation had a strong trend towards 
correlation with body weight loss in female Apc
Min/+ 
mice, but there was no association 
with circulating IL-6 levels (Table 2). There was no difference in muscle STAT3 
phosphorylation between female and male cachectic muscle (Figure 4C).  These results 
demonstrate that muscle STAT3 phosphorylation is not related to circulating IL-6 level 
during the progression of cachexia in female Apc
Min/+ 
mice. 
SOCS3 protein expression was examined in muscle of male and female B6 and 
cachectic Apc
Min/+ 
mice.  As with the IL-6 receptor, male B6 mice had significantly 
higher levels of SOCS3 protein than female B6 mice (Figure 4D; p=0.015).  However, 
cachexia had differential effects on SOCS3 protein expression between the sexes.   
SOCS3 protein expression was significantly higher in female Apc
Min/+ 
mice than female 
B6 (Figure 4D; p=0.03); however, there was a strong trend towards a decrease in SOCS3 
protein with cachexia in the male versus the B6 male (Figure 4D; p=0.053). 
Effect of IL-6 overexpression on cachexia initiation in Apc
Min/+ 
females (Experiment 2) 
We have previously shown that IL-6 overexpression in male Apc
Min/+
 mice is 
sufficient to initiate or accelerate cachexia progression [5, 20].  To determine the effect of 
IL-6 on the initiation of cachexia in the female Apc
Min/+ 
mouse, we overexpressed IL-6 
from 12-14 weeks of age, when tumor burden is fully present but cachexia has not been 
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initiated.  Plasma IL-6 levels were significantly higher in mice treated with the IL-6 
overexpression vector (Table 3). There were no differences in body weight between 
treatments groups at the initiation of IL-6 overexpression, and IL-6 treatment did not alter 
body weights after two weeks (Table 3). In spite of IL-6 overexpression, 12-14 week-old 
female Apc
Min/+ 
mice continued to grow (Table 3). Inguinal fat mass and hindlimb muscle 
mass did not significantly change in response to IL-6 overexpression (Table 3).  Tumor 
number was quantified at the end of the study. Although tumor numbers were variable, 
there were no significant differences between treatment groups (not shown).  
Effect of IL-6 overexpression on cachexia progression in Apc
Min/+
 females (Experiment 3) 
To determine the effect of IL-6 on cachexia progression in the female Apc
Min/+ 
mouse, 
we overexpressed IL-6 between 15 and 18 weeks of age, which generally corresponds 
with the development of cachexia. Plasma IL-6 levels were significantly higher in mice 
overexpressing IL-6 (p=0.002, Figure 5A), though it is important to note that the control 
mice had significantly higher levels of IL-6 than B6 females (p=0.01, data not shown).  
IL-6 overexpression above this cancer-induced increase did not induce an acceleration of 
body weight loss in female Apc
Min/+ 
mice that had initiated cachexia (Table 3, Figure 5B). 
It is unlikely that tumor counts would have been affected by IL-6 overexpression, as 
polyp number stabilizes at approximately 12 weeks of age [4]. Tumor number was highly 
variable, but there were no differences between treatment groups in the number of 
intestine segment 4 tumors (not shown).  Spleen weight was not further increased with 
IL-6 overexpression (Table 3).  Hindlimb muscle mass and inguinal fat mass loss were 
not accelerated by IL-6 overexpression in 18 week female Apc
Min/+ 
mice (Figure 5B, 
Table 3). Importantly, muscle STAT3 phosphorylation was not increased by systemic IL-
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6 overexpression (Figure 5D).  These results are in direct contrast to previous work by 
our lab with the male Apc
Min/+
 mouse, which showed decreases in body weight and 
muscle mass, and an increase in spleen weight as a result of IL-6 overexpression in 
addition to the cancer-induced levels between 16 and 18 weeks [20].   
3.5 Discussion 
Circulating IL-6 has been demonstrated to be a regulator of cancer cachexia 
progression in male Apc
Min/+ 
mice.  Circulating IL-6 is a known cachectic factor in human 
cancer populations as well [113, 123-125].  Treatments for cancer cachexia that target IL-
6 signaling are currently being examined [12, 126].  However, it is known that sex 
differences exist in inflammatory responses [33, 111, 127, 128], and sex differences have 
been reported in cancer cachexia progression in both rodents and humans [107, 108, 115].  
We therefore sought to determine the relationship between circulating IL-6 and cachexia 
progression the female Apc
Min/+ 
mouse.  We have demonstrated for the first time that 
circulating IL-6 level is not associated with the degree of cachexia in the female Apc
Min/+ 
mouse, as IL-6 levels were similar between weight stable and cachectic mice.  We also 
report that, unlike the male [5, 20], IL-6 overexpression above cancer-induced levels does 
not induce or accelerate cachexia progression in female Apc
Min/+ 
mice. Additionally, we 
report that sex alters muscle IL-6 transcription during cachexia. Female muscle IL-6 
mRNA expression increased with cachexia severity, which contrasts with male cachexia 
progression [20, 106].  We found that the female muscle may become more sensitive to 
circulating IL-6 levels during the progression of cachexia, since muscle IL-6r protein and 
phosphorylated STAT3 increased with severe cachexia. Though the female Apc
Min/+ 
mouse loses both muscle and fat with the progression of cachexia, the development of 
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this loss occurs differently from that reported in the male [106].  The male Apc
Min/+ 
mouse initiates cachexia with the rapid loss of both muscle and fat [106]. We provide 
evidence that the initiation of cachexia in the female Apc
Min/+ 
mouse involves a rapid loss 
of fat mass, while the loss of muscle mass occurs later in the development of cachexia.   
These data clearly show that sex influences the regulation of cachexia progression in the 
Apc
Min/+ 
mouse.  
As therapies targeting IL-6 for the treatment of cancer cachexia are gaining 
traction [12, 126], it is of utmost importance that basic research support this modality. 
The majority of investigations into human cancer cachexia do not separately analyze men 
and women [123-125, 129], which does not allow for the determination of sex differences 
in IL-6 levels. Recent investigation into single nucleotide polymorphisms (SNPs) in the 
IL-6 and IL-6 receptor promoter sequences has shown that certain SNPs affect levels of 
circulating IL-6 and soluble IL-6r; however, there are no differences between the sexes in 
allele frequency, indicating that sex differences do not likely occur at the transcriptional 
level [130].  While we have consistently found that cachexia development in the male 
Apc
Min/+ 
mouse is directly related to tumor burden and the level of circulating IL-6 [5, 6, 
13, 14, 20, 60, 131], this relationship has not been firmly established in the female. 
Though we found that male and female Apc
Min/+ 
mice had similar tumor burdens, females 
had significantly lower levels of circulating IL-6 than males, even when weight loss was 
comparable. However, the female also appears to have a differential cachectic response to 
IL-6 that is independent of circulating level. Specifically, plasma IL-6 did not increase as 
cachexia progressed, while muscle IL-6 mRNA expression and STAT3 phosphorylation 
were increased.  Additionally, systemic overexpression of circulating IL-6 did not 
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accelerate the progression of cachexia, indicating that higher circulating IL-6 levels are 
not sufficient to induce cachexia in the female Apc
Min/+ 
mouse. We also found that 
circulating IL-6 levels were not correlated with increased muscle IL-6r mRNA 
expression. Though the C26 and Apc
Min/+ 
models of cancer cachexia are IL-6 dependent 
in the male [11, 28, 131], sex differences have been found in the C26 model of cachexia, 
providing evidence that this is not a singular phenomenon related to the Apc
Min/+ 
mouse 
[107].  Importantly, estrogen inhibits IL-6 transcription and signaling in many tissues [25, 
27, 36, 92, 97]; however, IL-6 is a known mediator of diseases in females including 
polycystic ovarian syndrome, ovarian cancer, and osteoporosis [56, 58, 97], indicating 
that females are susceptible to the pathophysiological effects of IL-6 under multiple 
circumstances regardless of estrogen status.  The overall inflammatory environment 
related to the underlying disease may also alter IL-6 action. The circulating levels of IL-
10, IL-4, and interferon-α (IFNα) have been shown to influence IL-6 action [124, 132].  
Interestingly, sex differences in inflammation have been reported in IL-10 knockout mice 
[110]. Further investigation is required to determine if the systemic inflammatory 
environment, particularly the presence of estrogen, is differentially regulating IL-6 
function in female Apc
Min/+ 
mice. 
A key factor that determines tissue response to the inflammatory environment is 
receptor expression. IL-6 initiates intracellular signaling through binding with mIL-6r, 
which interacts with the signal-transducing gp130 [133].  The importance of muscle IL-6 
signaling through mIL-6r and gp130 in the development of cachexia has been clearly 
demonstrated in many tumor models [6, 56, 115, 134].  Signaling through gp130 
activates many signaling pathways, including JAK/STAT, p38 MAPK, and ERK [11, 55, 
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115, 116]. We have previously demonstrated that LLC-induced cachexia in males 
suppresses muscle gp130 expression [109]. However, alterations in the expression level 
of gp130 or IL-6r during cachexia progression in Apc
Min/+ 
mice have not been previously 
reported.   Interestingly, cachectic muscle from both male and female Apc
Min/+ 
mice 
demonstrated an induction of muscle IL6ra mRNA expression and protein expression, 
without a significant change in muscle gp130 mRNA expression. The novel observation 
that male C57BL/6 mice have significantly higher muscle IL-6r protein level than 
females may explain why males have a more robust response to IL-6 than females. As IL-
6 signaling has been linked to the induction of muscle protein degradation [11, 106], it 
remains to be determined why this signal is being amplified in cachectic muscle of both 
sexes at both the mRNA and protein levels. It also appears unlikely that differential 
muscle gp130 and IL-6r expression can account for differential sex responses to 
circulating IL-6 in Apc
Min/+ 
mice.   
In addition to IL-6 interaction with its receptor complex, downstream regulators 
have the potential to alter IL-6 signaling in muscle [135-137].  STAT3 is activated by 
phosphorylation at Y705 by Janus kinases downstream of the IL-6r/ gp130 complex [11].  
Activation of JAK/STAT signaling in cachectic muscle is associated with 
ubiquitin/proteasome and autophagy-mediated protein degradation [11, 106].  SOCS3 has 
the capacity to directly bind to gp130, inhibiting IL-6 signaling [137].  Cachexia 
increased muscle SOCS3 mRNA expression in Apc
Min/+ 
mice of both sexes. However, the 
observation that SOCS3 protein has a differential sex response both in B6 and cachectic 
Apc
Min/+ 
mice may have implications for differential control of STAT3 expression and 
downstream signaling between the sexes.  The pattern of increased SOCS3 mRNA and 
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decreased SOCS3 protein that we report in the male Apc
Min/+
 has been previously noted 
with cachexia in the C26 tumor-bearing model; it has been shown that phosphorylation of 
SOCS3 by Jak can destabilize SOCS3 and lead to its proteasome-mediated degradation 
[28].  Further, there is evidence that a second chronological activation of STAT3 
signaling may occur even in the presence of SOCS3 binding; this activation is induced by 
binding of the epidermal growth factor receptor (EGFR) to IL-6r in the continued 
presence of IL-6, though it is unknown if sex differences exist [59].  We demonstrate a 
strong trend towards increased STAT3 phosphorylation during cachexia progression in 
female Apc
Min/+ 
mice, as previously seen in the male [106].  This also corresponds with 
female muscle becoming more sensitive to inflammatory signaling with the progression 
of cachexia, and may represent the loss of a protective mechanism present in female 
muscle that suppresses inflammatory signaling. However, IL-6 signaling is only one of 
many inflammatory pathways involved in the progression of cachexia, and other 
inflammatory factors may regulate cachexia development in the female Apc
Min/+ 
mouse. 
Further work is needed to determine the regulation of JAK/STAT signaling during the 
progression of cachexia in female muscle and its relationship to wasting. 
We have shown that female Apc
Min/+ 
mice undergo cachexia that is, at least 
initially, independent of IL-6 regulation.  This finding has important ramifications, 
particularly as IL-6 has garnered interest as a potential therapeutic target for cancer 
cachexia.  We report for the first time levels of IL-6r, gp130, and SOCS3 mRNA and 
protein expression in the muscle of male and female Apc
Min/+ 
mice.  We also report the 
novel finding that there is differential expression of muscle IL-6r protein in male and 
female mice. Further, we have reported a difference in the timing of muscle and fat loss 
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between the sexes that may have important ramifications for metabolism and cytokine 
signaling during the progression of cachexia.  It appears that factors involved in the 
regulation of cancer cachexia progression are subject to differential sex regulation, and 
more work is needed to mechanistically understand these differences.  In addition, future 
work will need to determine the mechanisms in skeletal muscle during the progression of 
cachexia related to protein turnover, oxidative metabolism, and apoptosis that undergo 
differential regulation in the female. 
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Table 3.1: Characteristics of female Apc
Min/+
 mice (Experiment 1).  Weight change 
(%): Percent weight change from peak body weight to weight at sacrifice [(weight at 
sacrifice-peak weight)/peak weight]. Hindlimb muscle mass comprises left soleus, 
plantaris, gastrocnemius, tibialis anterior, extensor digitalis longus, and quadriceps mass. 
n, number. seg 4, segment 4 of the small intestine. mg, milligrams. pg, picograms. ml, 
milliliters. N, Newtons. * indicates significantly different from weight stable (p<0.05).  † 
indicates significantly different from initial cachexia (p<0.05). 
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Table 3.2: Relationships between circulating IL-6 and skeletal muscle signaling 
during cachexia development (Experiment 1).  Correlations calculated in 18-week 
female Apc
Min/+ 
mice of varying degrees of cachexia (n=18). R
2
, coefficient of 
determination; p, p-value.  Correlations determined by Pearson’s correlation.  mRNA 
levels are expressed as fold change from female C57BL/6 mice. * indicates significant 
correlation between factors (p<0.05). 
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Table 3.3: Characteristics of 14-week and 18-week female Apc 
Min/+ 
mice with IL-6 
overexpression (Experiments 2 and 3). Female Apc 
Min/+ 
 mice had the right quadriceps 
muscle electroporated with control plasmid or IL-6 overexpression plasmid. G, grams; 
mg, milligrams; dl, deciliter; pg, picograms; ml, milliliters; seg 4, segment 4 of the small 
intestine; N, Newtons.  * denotes significant difference from control group (p<0.05). 
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3.7 Figure Legends 
Figure 3.1: Characteristics of male and female Apc 
Min/+ 
mice (Experiment 1): A) 
Average body weight change from peak weight in male and female Apc 
Min/+ 
mice (n=12 
males, n=18 females).  Male Apc 
Min/+
 mice had more body weight loss than female Apc 
Min/+
 mice. B) There is no difference in the average number of tumors in segment 4 of the 
small intestine between male and female Apc 
Min/+ 
mice. C) Average level of plasma IL-6 
(pg/ml).    D)  Average spleen weight in male and female Apc 
Min/+ 
mice.  Male Apc 
Min/+
 
mice had larger spleens than female Apc 
Min/+
 mice. * indicates significantly different 
from B6 mice of the same sex (p<0.05); † indicates significant difference from male Apc 
Min/+ 
(p<0.05).  
Figure 3.2: Cachexia progression in female Apc 
Min/+ 
mice (Experiment 1): A) 
Average body weight from 10-18 weeks for weight stable, initial cachexia, and cachexia 
groups (n=6 per group).  Groups are significantly different at 18 weeks of age (p=0.016, 
repeated measures ANOVA).  B) Hindlimb muscle mass has a negative correlation with 
body weight loss during cachexia in the female Apc 
Min/+
 mouse (Pearson’s correlation, 
p<0.0001).  C) Inguinal fat mass has a negative correlation with body weight loss during 
cachexia in the female Apc 
Min/+
 mouse (Pearson’s correlation, p=0.0002).  Horizontal 
dotted lines in B and C show average B6 muscle and fat masses.  Dotted line at -5% body 
weight loss intended to show the contrast between fat and muscle loss before and after 
5% body weight loss. * indicates significant differences between groups (p<0.05). 
Figure 3.3: Muscle IL-6 signaling-associated mRNA levels (Experiment 1): A) IL-6 
receptor mRNA expression is significantly higher in male and female Apc 
Min/+ 
mice than 
B6 mice.    B) There is no difference in gp130 mRNA expression between male or female 
Apc 
Min/+ 
mice or B6 mice.  C) SOCS3 mRNA expression is higher in male and female 
Apc 
Min/+ 
mice than B6 mice.  All differences were analyzed by two-way ANOVA. # 
indicates main effect of Apc 
Min/+ 
(p<0.05).   
Figure 3.4: Muscle IL-6 signaling-associated protein levels (Experiment 1): A) 
Muscle IL-6 receptor levels (pg/ug total protein) are significantly higher in male B6 than 
in female B6 mice (0.28 ± 0.04 vs 0.07 ± 0.04, p=0.01, Student’s t-test) B) Muscle IL-6 
receptor levels (pg/ug total protein) increases with cachexia severity in female Apc
Min/+ 
mice (one-way ANOVA, p<0.0001). Cachectic levels were different from all other groups 
(p<0.05, Tukey post hoc).  IL-6 receptor levels are significantly higher in male cachexia 
than female cachexia (0.78 ± 0.11 vs. 0.42 ± 0.09, p=0.02, Student’s t-test). C) Upper: 
Representative blots shown. All samples per group were run on a gel with all weight 
stable samples, and then normalized during analysis. Lower: Quantification of 
pSTAT3/STAT3 blots.  The ratio of phosphorylated STAT3 (Y705)/STAT3 increases with 
cachexia severity in the female Apc
Min/+ 
mouse (one-way ANOVA, p=0.01).   There is no 
difference in phosphorylation of STAT3 (Y705) between cachectic females and cachectic 
males (p=0.154, Student’s t-test).  No differences were seen between groups in total 
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STAT3. D) Upper: Representative blots shown. All ApcMin/+ samples were run on a gel 
with male B6 samples for normalization.  Lower: Quantification of SOCS3 blots.  There 
is a significant interaction of sex by genotype in muscle SOCS3 protein expression 
(p=0.006, two-way ANOVA).  Female B6 mice had significantly lower SOCS3 
expression than male B6 mice (p=0.015, Student-Newman-Keuls post hoc). Female 
ApcMin/+ mice had significantly higher SOCS3 expression than female B6 (p=0.029, 
Student-Newman-Keuls post hoc), while male ApcMin/+ mice showed a strong trend 
towards lower SOCS3 expression than male B6 (p=0.053, Student-Newman-Keuls post 
hoc).  $ indicates significant difference from initial cachexia (p=0.005, Tukey post hoc); * 
indicates significantly different from same-sex B6; # indicates significant difference from 
male B6; † indicates significantly different from female. Dotted lines on graphs indicate 
B6 levels.  
Figure 3.5: Effect of IL-6 overexpression in 18 week-old female Apc 
Min/+ 
mice 
(Experiment 3): A) Female Apc 
Min/+
 mice that had IL-6 systemically overexpressed 
from 15-18 weeks of age had higher circulating plasma IL-6 than control mice (p=0.002). 
B) There is no difference in body weight change from peak body weight (%) between 
female Apc 
Min/+
 mice that have had IL-6 systemically overexpressed from 15-18 weeks 
of age and control female Apc 
Min/+
 mice at 18 weeks of age.  C) There is no difference in 
hindlimb muscle mass between female Apc 
Min/+
 mice that have had IL-6 systemically 
overexpressed from 15-18 weeks of age and control female Apc 
Min/+
 mice at 18 weeks of 
age. D) There is no difference in the ratio of phosphorylation of STAT3/STAT3 between 
female Apc 
Min/+
 mice that have had IL-6 systemically overexpressed from 15-18 weeks 
of age and control female Apc 
Min/+
 mice at 18 weeks of age (p=0.662, Student’s t-test).  
Upper: Representative blots showing pSTAT3 and STAT3 expression.  Dashed line 
indicates that samples were run on same gel, but separated by other samples.  Lower: 
Quantification of pSTAT3/STAT3 expression.  Dotted line on graph indicates female B6 
level of phosphorylation/total STAT3.  * indicates pSTAT3/STAT3 levels were 
significantly higher than B6 (p=0.008).   
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Figure 3.1: Characteristics of male and female Apc 
Min/+ 
mice (Experiment 1): A) 
Average body weight change from peak weight in male and female Apc 
Min/+ 
mice (n=12 
males, n=18 females).  Male Apc 
Min/+
 mice had more body weight loss than female Apc 
Min/+
 mice. B) There is no difference in the average number of tumors in segment 4 of the 
small intestine between male and female Apc 
Min/+ 
mice. C) Average level of plasma IL-6 
(pg/ml).    D)  Average spleen weight in male and female Apc 
Min/+ 
mice.  Male Apc 
Min/+
 
mice had larger spleens than female Apc 
Min/+
 mice. * indicates significantly different 
from B6 mice of the same sex (p<0.05); † indicates significant difference from male Apc 
Min/+ 
(p<0.05).  
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Figure 3.2: Cachexia progression in female Apc 
Min/+ 
mice (Experiment 1): A) 
Average body weight from 10-18 weeks for weight stable, initial cachexia, and cachexia 
groups (n=6 per group).  Groups are significantly different at 18 weeks of age (p=0.016, 
repeated measures ANOVA).  B) Hindlimb muscle mass has a negative correlation with 
body weight loss during cachexia in the female Apc 
Min/+
 mouse (Pearson’s correlation, 
p<0.0001).  C) Inguinal fat mass has a negative correlation with body weight loss during 
cachexia in the female Apc 
Min/+
 mouse (Pearson’s correlation, p=0.0002).  Horizontal 
dotted lines in B and C show average B6 muscle and fat masses.  Dotted line at -5% body 
weight loss intended to show the contrast between fat and muscle loss before and after 
5% body weight loss. * indicates significant differences between groups (p<0.05). 
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Figure 3.3: Muscle IL-6 signaling-associated mRNA levels (Experiment 1): A) IL-6 
receptor mRNA expression is significantly higher in male and female Apc 
Min/+ 
mice than 
B6 mice.    B) There is no difference in gp130 mRNA expression between male or female 
Apc 
Min/+ 
mice or B6 mice.  C) SOCS3 mRNA expression is higher in male and female 
Apc 
Min/+ 
mice than B6 mice.  All differences were analyzed by two-way ANOVA. # 
indicates main effect of Apc 
Min/+ 
(p<0.05).   
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Figure 3.4: Muscle IL-6 signaling-associated protein levels (Experiment 1): A) 
Muscle IL-6 receptor levels (pg/ug total protein) are significantly higher in male B6 than 
in female B6 mice (0.28 ± 0.04 vs 0.07 ± 0.04, p=0.01, Student’s t-test) B) Muscle IL-6 
receptor levels (pg/ug total protein) increases with cachexia severity in female Apc
Min/+ 
mice (one-way ANOVA, p<0.0001). Cachectic levels were different from all other groups 
(p<0.05, Tukey post hoc).  IL-6 receptor levels are significantly higher in male cachexia 
than female cachexia (0.78 ± 0.11 vs. 0.42 ± 0.09, p=0.02, Student’s t-test). C) Upper: 
Representative blots shown. All samples per group were run on a gel with all weight 
stable samples, and then normalized during analysis. Lower: Quantification of 
pSTAT3/STAT3 blots.  The ratio of phosphorylated STAT3 (Y705)/STAT3 increases with 
cachexia severity in the female Apc
Min/+ 
mouse (one-way ANOVA, p=0.01).   There is no 
difference in phosphorylation of STAT3 (Y705) between cachectic females and cachectic 
males (p=0.154, Student’s t-test).  No differences were seen between groups in total 
STAT3. D) Upper: Representative blots shown. All ApcMin/+ samples were run on a gel 
with male B6 samples for normalization.  Lower: Quantification of SOCS3 blots.  There 
is a significant interaction of sex by genotype in muscle SOCS3 protein expression 
(p=0.006, two-way ANOVA).  Female B6 mice had significantly lower SOCS3 
expression than male B6 mice (p=0.015, Student-Newman-Keuls post hoc). Female 
ApcMin/+ mice had significantly higher SOCS3 expression than female B6 (p=0.029, 
Student-Newman-Keuls post hoc), while male ApcMin/+ mice showed a strong trend 
towards lower SOCS3 expression than male B6 (p=0.053, Student-Newman-Keuls post 
hoc).  $ indicates significant difference from initial cachexia (p=0.005, Tukey post hoc); * 
indicates significantly different from same-sex B6; # indicates significant difference from 
male B6; † indicates significantly different from female. Dotted lines on graphs indicate 
B6 levels. 
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Figure 3.5: Effect of IL-6 overexpression in 18 week-old female Apc 
Min/+ 
mice 
(Experiment 3): A) Female Apc 
Min/+
 mice that had IL-6 systemically overexpressed 
from 15-18 weeks of age had higher circulating plasma IL-6 than control mice (p=0.002). 
B) There is no difference in body weight change from peak body weight (%) between 
female Apc 
Min/+
 mice that have had IL-6 systemically overexpressed from 15-18 weeks 
of age and control female Apc 
Min/+
 mice at 18 weeks of age.  C) There is no difference in 
hindlimb muscle mass between female Apc 
Min/+
 mice that have had IL-6 systemically 
overexpressed from 15-18 weeks of age and control female Apc 
Min/+
 mice at 18 weeks of 
age. D) There is no difference in the ratio of phosphorylation of STAT3/STAT3 between 
female Apc 
Min/+
 mice that have had IL-6 systemically overexpressed from 15-18 weeks 
of age and control female Apc 
Min/+
 mice at 18 weeks of age (p=0.662, Student’s t-test).  
Upper: Representative blots showing pSTAT3 and STAT3 expression.  Dashed line 
indicates that samples were run on same gel, but separated by other samples.  Lower: 
Quantification of pSTAT3/STAT3 expression.  Dotted line on graph indicates female B6 
level of phosphorylation/total STAT3.  * indicates pSTAT3/STAT3 levels were 
significantly higher than B6 (p=0.008). 
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CHAPTER 4 
 
THE ROLE OF OVARIAN FUNCTION IN IL-6 REGULATION OF INFLAMMATION 
DURING CANCER CACHEXIA PROGRESSION
1
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4.1 Abstract 
 Cancer cachexia is a debilitating condition that occurs secondary to chronic 
disease including cancer; our research has shown that some effects of cachexia are 
affected by sex.    The Apc 
Min/+ 
mouse is genetically predisposed to develop intestinal 
tumors; hypogonadism is strongly associated with cachexia severity in the male, 
though the relationship in the female is uncertain.  Ovarian endocrine functions have 
a variety of targets including inflammation, and it is likely that there is cross-talk 
between the female gonads (ovaries) and inflammatory signaling during cancer 
cachexia progression; however, it is unknown how ovarian endocrine function affects 
the chronic inflammation seen with cancer cachexia.  The purpose of this study is to 
examine the relationship of inflammation, ovarian endocrine function, and cancer 
cachexia progression in the female Apc 
Min/+ 
mouse.  Ovarian function, determined by 
estrus cycle tracking, was monitored from 10 to 18 weeks of age in female Apc 
Min/+ 
mice.  Natural cessation of estrus cycling secondary to disease progression was seen 
in ~30% of mice and was associated with severe cachexia, including greater body 
weight loss, higher fatigue, lower cage activity, and enhanced inflammatory 
signaling.  In contrast, ovariectomy ameliorated body weight loss and rescued muscle 
mass and function.  Our results indicate that loss of ovarian function secondary to 
disease is different than surgical ablation of ovarian function, possibly indicating that 
the non-cycling ovary still has some function that is injurious during cachexia 
progression. Future studies in the female will need to determine the precise 
mechanisms of this change.  
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4.2 Introduction 
Cachexia, the progressive wasting of muscle and adipose tissue secondary to chronic 
disease, represents a significant clinical burden; cancer-related cachexia alone causes two 
million deaths a year [1].  Occurring in one-third to one-half of cancer patients [1, 3], and 
leading to nearly one-third of cancer deaths [2], the need for targeted and effective 
therapies is urgent. Unintentional weight loss, a hallmark of cachexia, is associated with a 
systemic increase of inflammatory cytokines [45], hypermetabolism, fatigue, and muscle 
weakness [117]. Both men and women undergo decreases in muscle mass and strength 
due to cachexia; however, men see a relationship between these deficits and cancer-
related fatigue while women do not [63].  Though both sexes experience the functional 
and metabolic declines associated with cachexia, the etiology and presentation differs 
between sexes [15]. A dichotomy has been seen between male and female animals with 
cancer cachexia as well [15, 107].  Despite these observations, the differential 
mechanisms related to the female response are not yet understood. 
It is known that inflammatory processes related to the host’s immune system and 
possibly tumor microenvironment [3] play a role in the etiology of cancer cachexia. 
Specifically, inflammatory cytokines including IL-1β, TNFα, NfκB, and IL-6 are 
associated with wasting processes during cachexia progression [2, 3, 20, 138, 139].  
Several of these factors cross-regulate one another during cancer cachexia; for example, 
IL-1β and IL-6 promote TNFα, while TNFα and NfκB promote IL-6 transcription [2].  
Additionally, macrophages secrete IL-6 during inflammation in response to toll-like 
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receptor (TLR) activity [52]. Increased systemic inflammation related to signal 
transducer and activator of transcription-3 (STAT3) activation, of which IL-6 is a major 
regulator, plays a major role in muscle wasting [5, 14, 20].  The Apc 
Min/+ 
mouse has a 
nonsense mutation in the Apc gene, leading to intestinal adenomas and cachexia  
secondary to the tumor burden [20, 105]; we have previously shown that this model 
develops an IL-6-dependent cachexia [6, 14, 60]. Despite attention to IL-6’s role in the 
etiology of cancer cachexia, our lab has shown that the relationship is not straightforward 
in the female as in the male [15].  Menopause causes an increase in overall systemic 
inflammation [85, 140], including the IL-6 pathway and C-reactive protein, an index of 
overall inflammation [68, 92].  Menopause is also associated with increases in leptin, a 
cytokine associated with adipose tissue regulation. Interestingly, a link has been shown 
between IL-6 and leptin levels; however, the mechanism is unknown [68]. Interestingly, 
SOCS3, a key negative regulator of IL-6/STAT3 signaling, also binds directly to the 
leptin receptor to regulate leptin sensitivity [98]. Likewise, ovariectomy in mice as well 
as humans has been shown to cause increased inflammation and metabolic dysregulation 
[32, 92]. Despite the association between loss of ovarian function and increased 
inflammation, it is unknown whether inflammation levels are increased per se, or whether 
the body becomes more susceptible to the effects of inflammation without a direct 
increase in circulating factors.  
It is likely that there is crosstalk between sex hormones and the inflammatory milieu 
during cachexia progression in the female Apc
Min/+
 mouse, as we have previously shown 
in the male [22].  Ovarian endocrine function regulates countless processes throughout 
the body, including inflammation.  Estrogen has been shown to abolish IL-6 secretion in 
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the liver [25], inhibit NfκB activation of IL-6 [26], and block p38 MAPK-induced 
activation of TNFα [33].  It is therefore plausible that ovarian endocrine function could 
modulate the chronic inflammation seen with cachexia. The ovary itself secretes IL-6 
during the normal menstrual cycle [94, 141]; this is regulated by  FSH (follicle-
stimulating hormone, a gonadotropin) [58], in addition to its role of regulating the pre-
ovulatory estrogen spike in concert with luteinizing hormone (LH). Interestingly, FSH 
and IL-6 cross-regulate one another; IL-6 reduces FSH binding to granulosa cells [95], 
while FSH induces soluble IL-6 receptor (sIL-6r) synthesis [142], a key mediator of the 
trans IL-6 pathway [55, 56]. Ovarian cancer patients have increased levels of plasma sIL-
6r compared to non-cancer controls [56], and cachectic women have lower FSH levels 
than non-cachectic women [62]; these examples may point to a role for IL-6-FSH 
crosstalk during cachexia progression. Anti-Müllerian hormone (AMH) is secreted by 
early primordial follicles in the ovary and is used as an index of fertility in women [71, 
143].  Interestingly, AMH is a member of the TGFβ superfamily [144, 145], several 
members of which have established roles in cachexia progression [47, 146, 147]; 
however, it is unknown whether ovarian AMH plays a role in the etiology.  Another 
factor regulating ovarian hormone levels is leptin, an adipokine [141]; estrogen and 
particularly progesterone can regulate leptin levels, as well.  Leptin levels are closely 
regulated with adipose tissue mass [148], and both are known to decrease with cachexia 
progression [148]. Interestingly, leptin levels are inversely associated with IL-6 levels in 
both male and female cancer patients [148]. IL-6 is known to have physiological [58, 95, 
149] and pathophysiological [42, 56, 142] roles in the ovary, indicating that the ovary is 
sensitive to systemic inflammatory signaling.  Additionally, estrogen has been shown to 
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inhibit IL-6 transcription and signaling in several cell lines and tissues [25-27, 36, 92, 
97]. Interestingly, progesterone analogs including megestrol acetate and 
medroxyprogesterone acetate have been shown to improve caloric intake during cachexia 
[3]; lending further evidence that the loss of ovarian function could have deleterious 
effects during cachexia progression. 
Our lab has previously characterized the male Apc 
Min/+ 
mouse as a hypogonadism 
model related to cachexia development [22]; this has not been investigated in the female, 
though it is likely that there is crosstalk between sex hormones and the inflammatory 
milieu in the female as well as the male.  It is of interest that ovarian granulosa cells bear 
the IL6r/gp130 complex; as IL-6 signaling increases, estrogen production is inhibited in 
these cells.  It is unknown if the increase in IL-6 with cancer causes ovarian dysfunction 
through this mechanism [93]. Additionally, though we have shown that the female 
Apc
Min/+
 mouse does not have the same IL-6 response during cachexia progression as the 
male [15], it is unknown whether ovarian function mediates this difference. Therefore, 
the purpose of this study is to examine the relationship of inflammation, ovarian 
endocrine function, and cancer cachexia progression in the female Apc 
Min/+
 mouse. A 
second purpose was to determine whether IL-6 mediates changes in ovarian endocrine 
function.  This purpose was investigated through a series of experiments.  The first 
experiment followed ovarian function (determined by presence of estrus cycling) in a 
cohort of female Apc 
Min/+ 
mice from 10 weeks until 18 weeks of age, at which point the 
mice were stratified based on body weight change from 15 weeks to 18 weeks of age and 
presence or absence of estrus cycling.  In the second experiment, female Apc
Min/+
 mice 
were ovariectomized (OVX) at 11 weeks of age and followed until 18 weeks of age.  A 
 68 
 
third experiment investigated whether IL-6 overexpression caused ovarian dysfunction, 
and whether it affected the changes seen in ovariectomized mice. 
4.3 Methods 
 Animals 
Female Apc 
Min/+
mice (n=75) and female C57BL/6 mice (n=12) were bred and 
maintained at the University of South Carolina Animal Resource Facility.   Apc
Min/+ 
mice 
used were on a C57BL/6 background and were offspring from breeders originally 
purchased from Jackson Labs (Bar Harbor, ME, USA).   Mice were kept on a 12:12h 
light/dark cycle beginning at 7:00 AM and were given unrestricted access to standard 
rodent chow (Harlan Teklad Rodent Diet, #8604, Harlan, Indianapolis, IN, USA).  Mice 
were weighed weekly.  Food intake was measured at 12 and 18 weeks of age.  All 
experiments were approved by the University of South Carolina’s Institutional Animal 
Care and Use Committee.   
Experimental Design  
Three experiments were performed. Experiment 1 examined the ovarian progression 
during the progression of cachexia. Female Apc 
Min/+
mice (n=24) had estrus cycling 
measured daily from 10-18 weeks of age for determination of ovarian function. Mice 
were sacrificed at 18 weeks of age and stratified based on weight change between 15 and 
18 weeks of age as well as by presence or absence of ovarian function (estrus cycle).  In 
Experiment 2, a cohort (n=10) of female Apc 
Min/+ 
mice were ovariectomized (OVX) at 11 
weeks of age and were monitored until sacrifice at 18 weeks of age. Experiment 3 
examined the interaction between ovarian function and inflammation during the initiation 
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of cachexia.  Female Apc 
Min/+ 
mice underwent OVX or sham surgery at 11 weeks of age, 
followed by overexpression of IL-6 or an empty vector at 13 weeks of age, before 
sacrifice at 15 weeks of age, for four treatment groups: sham-OVX + vector (n=13), 
sham-OVX + IL-6 (n=10), OVX + vector (n=10), and OVX + IL-6 (n=8).  In all 
experiments, blood, inguinal fat, hindlimb muscles, ovaries, uterus, and spleen were 
removed at the time of sacrifice. Hindlimb muscle mass measurements comprise the sum 
of left soleus, plantaris, gastrocnemius, tibialis anterior, extensor digitalis longus, and 
quadriceps masses. 
Determination of estrus cycling and stage of cycle 
Female Apc 
Min/+ 
and C57BL/6 mice had estrus cycling tracked from 10 weeks of age 
until sacrifice at 18 weeks of age.  A sterile cotton swab was dipped in sterile 0.9% 
saline.  The mouse was grasped by the base of the tail, and the cotton swab was gently 
inserted 0.5 cm into the vagina to collect cells.  Cells collected were smeared onto a glass 
slide (VWR, Radnor, PA, USA) and allowed to dry.  Slides were dipped for 5-10 minutes 
in hematoxylin (Ricca Chemical Company, Arlington, TX, USA), rinsed in deionized 
water, and allowed to dry.  Cell populations were visualized with an Olympus BX41 
microscope (Tokyo, Japan) at 100x, and estrus cycle presence and stage were classified 
based on the observations of Caligoni [73]. 
Ovariectomy 
Female Apc 
Min/+ 
and C57BL/6 mice were ovariectomized at 11 weeks of age.  Mice were 
anesthetized by ketamine/acepromazine/xylazine.  Once anesthetized, the mouse was 
placed in a prone position on a sterile absorbent pad. The back was shaved from the 
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caudal edge of the ribcage to the base of the tail.  The shaved region was then sterilized 
with betadine (PDI, Orangeburg, NY, USA) and rubbing alcohol (PDI).  A 2-cm dorsal 
midline incision was made with sterile scissors halfway between the caudal edge of the 
ribcage and the base of the tail.  Fascia was the cleared away by blunt dissection.  As 
second 1-cm long incision was made into the muscle wall.  The ovary and surrounding fat 
pad were extracted through the incision with forceps.  A hemostat was closed around the 
distal oviduct/uterine horn to terminate blood supply to the ovary.  Non-absorbable suture 
(AD Surgical, Sunnyvale, CA) was used to tie off the oviduct, and the ovary was 
removed.  The uterine horn was returned to the peritoneal cavity, and absorbable suture 
(AD Surgical) was used to close the muscle incision.  Wound clips were used to close the 
skin incision, and the process was repeated on the contralateral side.  Mice were given 
0.01 mg/kg buprenorphine (Burprenex ©, Reckitt Benckiser Pharmaceuticals, 
Pendergrass, GA, USA) for pain.  Wound clips were removed 7 days after surgery.  
IL-6 overexpression by electroporation  
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase circulating 
IL-6 levels in mice as previously described [117]. The right quadriceps muscle was used 
to synthesize and secrete exogenous IL-6 into circulation from the injected expression 
plasmid, and was not used for any analyses in the study. The gastrocnemius muscle used 
in the study was not subjected to electroporation. Briefly, mice were injected with 50 μg 
of IL-6 plasmid driven by the CMV promoter, or control plasmid (pV1J), into the right 
quadriceps muscle. Mice were anesthetized with a 2% mixture of isoflurane (IsoSol, 
VEDCO, St. Joseph, MO, USA) and oxygen (1 L/min). The leg was shaved, and a small 
incision was made over the quadriceps muscle. Fat was dissected away from the muscle, 
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and the plasmid was injected in a 50 μl volume of sterile phosphate-buffered saline 
(PBS). A series of eight 50 ms, 100 V pulses was used to promote uptake of the plasmid 
into myonuclei, and the incision was closed with a wound clip.  
Run to Fatigue 
At 12, 15, and 18 weeks of age, mice were subjected to a run-to-fatigue treadmill 
protocol.  After 5 minutes of acclimation at 5 meters/minute and 5 minutes of warm-up at 
10 m/m, the clock was started when speed was increased to 15 m/m.   The treadmill 
protocol was as follows: 20 minutes at 15 m/m, 20 minutes at 18 m/m, 30 minutes at 
20m/m, 30 minutes at 25 m/m, and 28 m/m until all mice stopped.  A mouse was 
considered “fatigued” when it refused to run or could not keep up with the treadmill 
despite gentle nudging for 1 minute.  Time and distance to fatigue were recorded. 
Voluntary Cage Activity 
At 12, 15, and 18 weeks, mice were single-housed and placed in an activity monitor 
(Opto-M3 Activity Meter, Columbus Instruments, Columbus, OH) as previously 
described [5].  Briefly, activity was measured for 12h during the dark cycle (7PM-7AM), 
and the number of beams crossed on the X-Y plane was recorded for 3 nights.  Food 
consumption was recorded during this same period of single-housing. 
RNA isolation and RT-PCR 
RNA isolation, cDNA synthesis, and real-time PCR were performed as previously 
described [118].  cDNA synthesis reagents from Applied Biosystems (Foster City, CA, 
USA) were used.  Bio-Rad SsoAdvanced Universal Probes Supermix and SYBR Green 
Supermix were used for RT-PCR reactions (Hercules, CA).  Briefly, proximal 
gastrocnemius muscle was homogenized in TRIzol (Life Technologies, Grand Island, 
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NY, USA) and mixed with chloroform, then centrifuged.  The RNA phase was removed 
and washed several times with ethanol in DEPC-treated water.  cDNA was synthesized 
using 1 g of RNA.  RT-PCR was performed on an Applied Biosystems 7300 
thermocycler.  Taqman gene expression assay was used to determine IL-6 and TGFβ 
mRNA expression (Life Technologies).  Primers for AMH, TNFa, TLR4, IL-6r, and 
GAPDH were obtained from IDT (Coralville, IA, USA). Primer sequences are as follows.  
AMH (F): 5’TTGCTGAAGTTCCAAGAGCCTCCA-3’ (R): 5’-
GAAACAGCGGGAATCAGAGCCAAA-3’;  
TNFa (F): 5’-CCCAGACCCTCACACTCAGAT-3’ (R): 5’-
TTGTCCCTTGAAGAGAACCTG-3’;  
TLR4 (F): 5’GGAAGGACTATGTGATGTGAC-3’ (R): 5’-
GCTCTTCTAGACCCATGAAATTGG-3’.  
IL-6r and GAPDH primer sequences have been published elsewhere [15, 119].   
Western blotting 
Western blots were performed as described previously [106, 120].  Briefly, 
gastrocnemius muscle samples were run on 6-8% acrylamide gels and transferred 
overnight to PVDF membrane (Thermo Scientific, Waltham, MA, USA).  After transfer, 
Ponceau stains were imaged to verify equal loading. The membrane was blocked for 1 
hour in 5% milk-TBS-Tween 20, and incubated with primary antibodies at 1:2000 
dilution overnight at 4⁰C.  After several washes, membranes were incubated with 
secondary antibodies at 1:2000 dilution for 1 hour.  Blots were visualized with 
WesternBright ECL (BioExpress, Kaysville, UT, USA).  IL-6r antibody was obtained 
from Santa Cruz Biotech (Santa Cruz, CA). STAT3, phopho-STAT3 (Y705), anti-mouse 
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IgG, and anti-rabbit IgG antibodies were obtained from Cell Signaling (Danvers, MA, 
USA).   
IL-6 Enzyme-linked immunosorbent assay 
A mouse IL-6 ELISA kit was obtained from Life Technologies (Frederick, MD), and 
manufacturer’s protocol was followed.  Briefly, 100 µl of samples and standards were 
added in duplicate to the 96-well plate.  Plate was incubated for 2 hours at room 
temperature, followed by 4 washes. 100 µl IL-6 biotin conjugate was added to wells and 
incubated for 30 minutes at room temperature.  Plate was washed 4 times.  100 µl 
Streptavidin-HRP was added to wells and allowed to incubate for 30 minute at room 
temperature.  Plate was then washed 4 times.  100 µl stabilized chromogen was added to 
wells and incubated for 30 minutes in the dark until color developed.  100 µl Stop 
Solution was added to wells and the plate was read at 450nm in a Bio Rad iMark plate 
reader (Carlsbad, CA).  
Soluble IL-6R Enzyme-linked immunosorbent assay 
Soluble IL-6r (sIL-6r) ELISA kit was obtained from MyBioSource (City, State) and 
manufacturer’s protocol was followed.   Briefly, 100 µl of standards and samples were 
added to wells.  50 µl of conjugate was added to sample in each well, and plate was 
incubated for 1 hour at 37°C.  Plate was washed five times.  50 µl each of Substrate A 
and B were added to wells.  Plate was again incubated at 37°C for 15 minutes until color 
developed.  50 µl Stop Solution was added to wells, and the plate was immediately read 
at 450nm on a BioRad iMark plate reader (Carlsbad, CA). 
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Leptin Enzyme-linked immunosorbent assay 
A commercial mouse leptin ELISA was obtained (Quantikine, R&D Systems, 
Minneapolis, MN) and manufacturer’s instructions were followed. Briefly, standards and 
samples were added to the pre-coated plate and allowed to incubate for two hours at room 
temperature.  The plate was washed five times and leptin conjugate was added to wells.  
Plate was allowed to incubate for two hours at room temperature.  Again, the plate was 
washed five times.  Substrate Solution was added to wells, and plate was incubated in the 
dark for thirty minutes at room temperature.  Stop Solution was added to wells, and the 
plate was read at 450 nm on a BioRad iMark plate reader. 
Intestinal polyp quantification 
Quantification of intestinal polyps was determined as previously described [19].  Briefly, 
intestinal sections were fixed in formalin at time of sacrifice.  At time of analysis, 
sections were rinsed in deionized water and dipped briefly in 0.1% methylene blue.  
Polyps from segment 4 were counted under a dissecting microscope; it has been 
determined that tumor number in segment 4 is representative of total tumor number 
[122].   
Ovarian Histology 
Ovaries were excised from B6, Cycle Present, and Cycle Absent mice and immediately 
transferred to 4% PFA.  Ovaries were mounted in paraffin, sectioned, and stained by 
hematoxylin and eosin by the University of South Carolina School of Medicine 
Instrument Resource Facility.  Pictures were taken using a Nikon E600 microscope 
(Nikon, Tokyo, Japan) at 400x and 1000x. 
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Statistical analysis 
All results are reported as means ± SEM.  Differences between B6, Cycle Present, and 
Cycle Absent were analyzed by one-way ANOVA using Tukey post hoc where 
appropriate.  Differences between timepoints and ovarian status, were determined by 
two-way repeated measures ANOVA with Sidak’s multiple comparisons test where 
appropriate.  Differences between genotype and ovarian status were determined by two-
way ANOVA with Tukey post hoc where appropriate.  Differences between Cycle 
Absent and OVX mice were determined by Student’s t-test.  Differences between Cycle 
Present, Cycle Absent, and OVX mice were determined by one-way ANOVA with Tukey 
post hoc where appropriate.  Differences between Sham + vector, Sham + IL-6, OVX + 
vector, and OVX + IL-6 mice were determined by two-way ANOVA with Tukey post 
hoc where appropriate.  Level of significance was set at 0.05. 
4.4 Results 
Estrus cycle cessation with cachexia 
Female Apc 
Min/+ 
mice (n=24) and female C57BL/6 (B6) mice (n=7) had estrus 
cycles tracked by vaginal cytology daily until sacrifice; this was measured as an index of 
ovarian reproductive function though it does not account for ovarian endocrine function.  
All B6 mice continued cycling normally (data not shown). Nine of the 24 female Apc 
Min/+ 
mice (37.5%) ceased estrus cycling before 16 weeks of age (Figure 1A).  Estrus 
cycling was tracked in Experiment 3 as well; while 4/13 (~31%) of control 15-week 
Apc
Min/+ 
mice ceased estrus cycling, IL-6 overexpression did not induce cessation of 
estrus cycling in female Apc
Min/+ 
mice (data not shown). To further investigate differences 
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between mice that had continued estrus cycling through sacrifice at 18 weeks (“Cycle 
Present”) and mice who had ceased estrus cycling before sacrifice (“Cycle Absent”), 
ovarian histology was performed.  Figure 1B shows representative images at 400x and 
1000x of ovaries taken from B6, Cycle Present, and Cycle Absent mice.  Ovaries of 
Cycle Absent mice show more dying, or atretic, follicles (indicated by arrows) than the 
ovaries of either B6 or Cycle Present mice. We further attempted to characterize the 
difference between Cycle Present and Cycle Absent ovaries through gene expression of 
Anti-Müllerian hormone (AMH), a hormone secreted by primordial ovarian follicles that 
is often used as a marker of the size of the follicular pool, or as a proxy for fertility in 
women.  Interestingly, AMH expression in Cycle Absent ovaries increased 3-fold over 
B6 levels (p<0.0001, Tukey post hoc), while there was little difference between B6 and 
Cycle Present (1 vs. 1.287).  AMH gene expression in Cycle Absent ovaries was 
significantly higher than in the Cycle Present group, as well (p<0.0001, Tukey post hoc). 
Interestingly, uterine weight was significantly lower than B6 uterine not only in Cycle 
Absent Apc
Min/+ 
mice, but in Cycle Present Apc
Min/+ 
mice as well (Figure 1D).  All three 
groups differed from one another, with Cycle Absent having the lowest average uterine 
weight (p<0.001 for each comparison, Tukey post hoc). 
Morphological and functional changes with ovarian dysfunction due to cachexia 
After sacrifice at 18 weeks of age, female Apc 
Min/+ 
mice were stratified into Cycle 
Present and Cycle Absent groups for all other analysis in order to determine the effect of 
loss of ovarian function on cachexia-related outcomes.  A main effect of age and an 
interaction of age x cycle presence were determined by two-way repeated measures 
ANOVA (Figure 2A). Cycle Present and Cycle Absent female Apc 
Min/+ 
mice had similar 
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body weights at 12 and 15 weeks of age (12 weeks: Cycle Present 18.3 ± 0.3g, Cycle 
Absent 18.6 ± 0.5g; 15 weeks: Cycle Present 19.1 ± 0.3g, Cycle Absent 19.3 ± 0.5g; 
Figure 2A).  Importantly, the two groups were of similar weight at the age at which the 
Cycle Absent group ceased estrus cycling.  However, body weights between the two 
groups were significantly different at sacrifice (Cycle Present 19.6 ± 0.2g, Cycle Absent 
17.4 ± 0.6g; Table 1, Figure 2A) (p<0.01, Sidak’s multiple comparisons test). Similarly, 
main effects of age, cycle presence, and an interaction of the two were determined by 
two-way repeated measures ANOVA.  Cycle Present and Cycle Absent mice had no 
difference in body fat percentage at 12 or 15 weeks of age (12 weeks: Cycle Present 12.9 
± 0.6%, Cycle Absent 12.9 ± 0.1%; 15 weeks: Cycle Present 11.5 ± 0.3%, Cycle Absent 
9.7 ± 0.7%), but Cycle Absent mice had significantly lower percentage body fat at 
sacrifice (Cycle Present 11.8 ± 0.5%, Cycle Absent 7.4 ± 0.2%; Figure 2B) (p<0.01, 
Sidak’s multiple comparisons test). At sacrifice, inguinal fat mass differed between B6, 
Cycle Present, and Cycle Absent mice (p<0.05, one-way ANOVA); Cycle Absent mice 
had significantly less fat than either of the other groups (p<0.05 for each comparison, 
Tukey post hoc) (Table 1). Similar to inguinal fat mass, hindlimb muscle mass at 
sacrifice differed between B6, Cycle Present, and Cycle Absent mice (p<0.05, one-way 
ANOVA); Cycle Absent mice had significantly less muscle mass than the other groups 
(p<0.05, Tukey post hoc) (Table 1). Spleen weight was different between each of the 
three groups (p<0.05, one-way ANOVA and Tukey post hoc), indicating that 
inflammation increased over B6 levels in the female Apc
Min/+
, and that inflammation was 
further increased in the Cycle Absent group (Table 1). There was a significant difference 
between the three groups in heart weight, with the Cycle Absent group having 
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significantly heavier hearts than either of the other two groups (p<0.05, one-way 
ANOVA and Tukey post hoc).   
Functional measurements were taken at 12, 15, and 18 weeks of age in B6, Cycle 
Present, and Cycle Absent female Apc
Min/+ 
mice. Voluntary cage activity decreased over 
time in both Cycle Present and Cycle Absent groups. Main effects of age (p=0.0015) and 
cycle presence (0.045) were determined by two-way repeated measures ANOVA.  Cycle 
Present and Cycle Absent groups trended towards difference at 18 weeks (p=0.056, pre-
planned Student’s t-test) (Figure 2C). No differences in distance run by Cycle Present and 
Cycle Absent female Apc
Min/+ 
mice at 18 weeks were seen (Table 1). No differences in 
food intake (Table 1) or food intake/body weight (data not shown) were seen at any age 
across the groups; this is an important point when considering the severe weight loss in 
the Cycle Absent group. Overall, Cycle Absent female Apc 
Min/+ 
mice present with much 
more severe cachexia at 18 weeks of age than Cycle Present female Apc 
Min/+ 
mice. 
Morphological and functional changes with ovariectomy 
Female B6 and Apc
Min/+
 mice were ovariectomized (OVX) at 11 weeks of age 
(Figure 3A) to determine the effects of loss of ovarian function on cachexia progression.  
Regardless of genotype, OVX increased body weight at sacrifice (Table 2).  Ovaries-
intact (Intact) Apc
Min/+ 
females weighed significantly less than intact B6 females, but 
OVX maintained body weight at levels  similar to B6 mice (Table 2).  Though OVX 
caused an increase in body weight over intact mice, no differences were seen in weight of 
the inguinal fat pad (Table 2).  Among Apc
Min/+
 mice, OVX caused significantly greater 
hindlimb muscle mass compared to intact mice (Table 2).  Importantly, uterine weight 
decreased significantly with OVX regardless of genotype, indicating success of the 
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procedure (Table 2).  Among Apc
Min/+ 
females, OVX mice were compared directly to 
Cycle Absent mice in order to compare phenotypes of mice who had lost ovarian function 
by different means. While Cycle Absent mice lost weight between 11 and 18 weeks of 
age, OVX mice gained nearly 15% body weight (Figure 3B). Importantly, Apc
Min/+ 
mice 
continue to grow until 14-15 weeks of age, so this comparison does not reflect weight 
loss from peak weight.  OVX mice had significantly greater percentage of body fat than 
Cycle Absent mice (Figure 3C), while there was no difference in lean mass (Figure 3D).  
Functionally, OVX mice significantly outperformed Cycle Absent mice in run to fatigue 
(Figure 3E) and voluntary cage activity (Figure 3F).  Importantly, however, there was no 
difference in food intake between the two groups (Figure 3G), despite striking differences 
in morphology and function. These differences between Cycle Absent and OVX mice are 
key, as they indicate that the ovarian pathology found in intact, Cycle Absent Apc
Min/+ 
females is not simply early ovarian failure. 
Morphological changes with ovariectomy and IL-6 overexpression 
Female Apc
Min/+ 
underwent OVX or sham surgery at 11 weeks of age, IL-6 
overexpression or vector electroporation at 13 weeks of age, and were sacrificed at 15 
weeks of age (Figure 4A).  Body weight change from 11-15 weeks of age was analyzed 
to determine effects of treatment.  Main effects of OVX (p=0.0012) and IL-6 
overexpression (p=0.017) were determined by two-way ANOVA.  Interestingly, the 
OVX + vector group gained significantly more weight than the OVX+IL-6 group 
(p<0.05, preplanned Student’s t-test), indicating that the addition of IL-6 to an OVX 
female stunted growth.  No differences were seen among groups in change in body fat 
from 11-15 weeks of age.  Interestingly, lean mass change from 11-15 weeks followed 
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the same pattern as body weight change (Figure 4D); an interaction between OVX and 
IL-6 overexpression was determined by two-way ANOVA (p=0.009).  OVX+vector 
group gained significantly more muscle mass than control and OVX+IL-6 groups, 
indicating that the addition of IL-6 to an OVX animal may specifically inhibit muscle 
growth. Taken together with the lack of change in fat mass, it follows that the differences 
in body weight change from 11-15 weeks are due to growth of muscle mass more so than 
fat mass. 
Effect of loss of ovarian function and ovariectomy on tumor burden and circulating 
factors 
Cycle Present, Cycle Absent, and OVX female Apc
Min/+ 
mice were directly 
compared to one another to determine differences in circulating factors that may provide 
insight into the etiology of estrus cycle cessation.  Tumor numbers from the entirety of 
the small intestine and colon were significantly different among groups (p=0.0002, one-
way ANOVA); Cycle Absent had significantly more tumors than Cycle Present or OVX 
(p<0.01 for each comparison, Tukey post hoc) (Figure 5A).  It has been shown that tumor 
burden is correlated with weight loss and cachexia severity [13]; however, the association 
with ovarian dysfunction is novel.  No differences between groups were found for plasma 
IL-6 levels (Figure 5C); however, Cycle Absent had significantly higher plasma IL-6 
levels than OVX (p=0.0003; pre-planned Student’s t-test).  Interestingly, there were no 
changes among groups for soluble IL-6r (Figure 5E); sIL-6r is thought to be a key 
component of the trans IL-6 pathway, and has been shown to increase in cachectic males 
(unpublished data). Further, a significant decrease in sIL-6r was found in Cycle Absent 
mice compared to Cycle Present mice by pre-planned Student’s t-test (p=0.050).  Among 
15-week mice that had undergone either ovariectomy, IL-6 overexpression, or both, 
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interesting trends were seen in these same factors.  There was a main effect of OVX to 
decrease tumor burden, though it has been shown that ovariectomy should not affect 
tumor number (Figure 5B).  As expected, there was a main effect of IL-6 to increase 
plasma IL-6 levels (Figure 5D). Interestingly, there was a main effect of IL-6 
overexpression to decrease sIL-6r (Figure 5F) (two-way ANOVA: p<0.05). 
Effect of loss of ovarian function on circulating inflammatory factors  
Several circulating inflammatory factors were examined to determine whether the 
loss of ovarian function by disease or by ovariectomy affected systemic inflammation. 
Plasma leptin differed across B6, Cycle Present, Cycle Absent, and OVX groups 
(p=0.005, one-way ANOVA); Cycle Absent mice had significantly lower leptin levels 
than C57BL/6 (p<0.05, Tukey post hoc) (Figure 6A).  Plasma Interferon-gamma (IFNγ) 
decreased in both control and OVX Apc
Min/+ 
mice compared to B6 (Figure 6B).  
Surprisingly, plasma MCP-1 decreased in both control and OVX Apc
Min/+ 
mice compared 
to B6 (Figure 6C).  Plasma RANTES increased in Cycle Present mice over B6 levels, but 
was significantly lower in Cycle Absent mice (Figure 6D).  Plasma IL-10, an anti-
inflammatory cytokine, decreased significantly from B6 levels in both control and OVX 
Apc
Min/+ 
mice.  Interestingly, within the control Apc
Min/+ 
mice, IL-10 levels were 
significantly higher in Cycle Absent than Cycle Present mice (Figure 6E).  Plasma M-
CSF increased above B6 levels in control Apc
Min/+ 
mice, but this effect was attenuated by 
OVX, which brought levels down significantly.  Among control Apc
Min/+ 
mice, Cycle 
Absent had significantly lower levels than Cycle Present mice (Figure 6F).  IL-1β, IL-17, 
LIF, TNFα, and VEGF showed no changes across groups (Table 3). 
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Changes in muscle inflammatory signaling with loss of ovarian function and IL-6 
overexpression  
  IL-6 and other cachexia-related inflammatory markers were examined in muscle, 
a cachexia-sensitive tissue, in order to determine the effect of ovarian dysfunction or loss 
of function on inflammatory signaling.   Despite the lack of difference between Cycle 
Present and Cycle Absent plasma IL-6 levels (Figure 4B), Cycle Absent muscle IL-6 
mRNA was significantly higher, despite a large amount of variability, than B6, Cycle 
Present or OVX (Figure 7A)(one-way ANOVA: p=0.014; p<0.05 for each comparison, 
Tukey post hoc).  Additionally, TNFα followed the same trend (p=0.005, one-way 
ANOVA; Cycle Absent differs from Cycle Present (p<0.05) and OVX (p<0.01), Tukey 
post hoc) (Figure 7E).  Interestingly, TGFβ did not follow this same trend.  Although 
significant differences were found between groups (p=0.0448, one-way ANOVA), OVX 
expression was significantly higher than Cycle Present (p<0.05, Tukey post hoc) (Figure 
7C). Among 15-week Apc
Min/+
 mice that had undergone ovariectomy, IL-6 
overexpression, or both, no changes were seen across groups for any of these 
inflammatory cytokines (Figure 7B,D,F).  
Changes in muscle inflammatory receptors with loss of ovarian function and IL-6 
overexpression 
Expression of two critical inflammatory receptors to the development of cachexia 
was examined in both cohorts of mice.  IL-6 receptor mRNA was different across groups 
with varying ovarian statuses (determined by one-way ANOVA, p<0.0001).  Cycle 
Absent mice had 30-fold higher expression than any of the other groups (Figure 8A).  
The same trend was seen for TLR4 expression in these same mice, with Cycle Absent 
mice having 15-fold higher expression than any of the other groups (p<0.0001, one-way 
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ANOVA; p<0.0001 for each multiple comparison, Tukey post hoc). Among 15-week 
Apc
Min/+
 mice that had undergone ovariectomy, IL-6 overexpression, or both, there was 
an interaction of the two treatments to influence IL-6r expression.   However, the Tukey 
post hoc revealed no differences between individual groups (Figure 8B).  There were no 
differences among groups for TLR4 expression (Figure 8D). 
4.5 Discussion 
The purpose of this study was to examine the relationship of inflammation, 
ovarian function, and cachexia progression in the female Apc
Min/+
 mouse.  To this end, we 
saw no differences in circulating inflammatory factors including plasma IL-6 (Figure 
5C), and soluble IL-6 receptor (Figure 5E). However, we saw a large induction of 
cytokine and receptor mRNA in the cycle absent group (Figures 6 and 7), potentially 
indicating that this inflammation is not induced by IL-6. However, OVX returned many 
cytokine levels to B6 or Cycle Present levels. Therefore, we postulate that ovarian 
dysfunction does not directly increase inflammation.  However, we did see an increase in 
gene expression of inflammatory receptors including IL-6r, gp130, and TLR4 in muscle 
(Figure 8), indicating that ovarian dysfunction may cause an increase in susceptibility to 
systemic inflammation.  Further evidence for this hypothesis comes from Experiment 3, 
in which female Apc
Min/+
 mice underwent overexpression of IL-6 in addition to OVX.  
While OVX+vector mice gained the most weight during this experiment, OVX+IL-6 
mice did not gain weight, indicating that loss of ovarian function increases the animal’s 
susceptibility to induced inflammation (Figure 4B).  Interestingly, the weight gained 
during this time by OVX+vector mice consisted largely of muscle mass, and the 
overexpression of IL-6 blocked this muscle mas increase (Figure 4D).  Importantly, there 
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were no differences between control Apc
Min/+ 
mice and IL-6+ sham-OVX mice in body 
weight or muscle mass change.  An especially interesting finding is the lack of increase in 
sIL-6r expression in female Apc
Min/+ 
mice over C57BL/6 levels, and especially in the 
more severely cachectic Cycle Absent mice.  This differs from we have seen previously 
in male Apc
Min/+
 mice (unpublished data), and may indicate that trans IL-6 signaling does 
not play a role in the etiology of cachexia progression in the female as it does in the male 
[119]. 
The most striking finding from this study is that, across all measures, the 
cessation of estrus cycling does not equate with ovariectomy.  Whereas ovariectomy led 
to improvement in female Apc
Min/+ 
mice body composition (Figure 3B,C), function 
(Figure 3E,F), circulating plasma IL-6 (Figure 5A), and muscle inflammatory signaling 
(Figure 7); mice who had ceased estrus cycling (Cycle Absent) fared worse on every 
outcome than their Cycle Present littermates. Importantly, while hypogonadism is 
apparent in Cycle Absent mice, this appears to be an effect rather than a cause of 
cachexia.  An unknown factor leading to increased severity in the female appears to cause 
cessation of estrus cycling, possibly secondary to fat loss (Table 4.1, Figure 4.2B). Tumor 
burden was significantly higher in Cycle Absent mice than Cycle Present (Figure 5A), 
which provides valuable insight into the potential etiology of increased inflammation and 
more severe cachexia in Cycle Absent mice.  While OVX mice had significantly fewer 
tumors than Cycle Absent (Figure 5A), it is extremely important to note that previous 
reports have indicated that OVX does not affect tumor number in Apc
Min/+
 mice [24]. 
Further, while we have seen in two separate cohorts of ovaries-intact female Apc
Min/+
 
mice, both in the present study and in a previous report [15], that approximately 30% 
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become severely cachectic, none of the OVX female Apc
Min/+ 
mice became severely 
cachectic.  We propose that this is a sufficient sample size to indicate that OVX does 
protect the female Apc
Min/+
 mouse from cachexia.   
While we originally hypothesized that Cycle Absent mice and OVX mice would 
be similar in phenotype, the two groups show vast differences.  It is therefore clear that 
female Apc
Min/+
 mice who cease estrus cycling are not simply losing ovarian function, but 
are undergoing a complex ovarian dysfunction syndrome due to underlying disease.  
Ovarian histology indicated an increased number of atretic (dead or dying) ovarian 
follicles in Cycle Absent mice (Figure 1B), which can induce a number of endocrine 
change in the ovary, including inhibition of ovarian steroidogenesis [150].  Atresia of 
follicles generally occurs due to caspase-induced apoptosis regulated by BCL-2 [150]. 
Additionally, we found a significant increase in ovarian gene expression of Anti-
Mullerian hormone (AMH) (Figure 1C).  While menopausal women have an almost 
complete loss of AMH expression [145], the increase we see is more similar to that which 
is seen with polycystic ovarian syndrome (PCOS) [145].   Importantly, atretic follicles do 
not express AMH [145], so the increases we see in both atretic follicles and AMH are not 
directly related.  Interestingly, the similarities with PCOS continue, as women with 
PCOS have lower serum sIL-6r than women without PCOS; in the current study we saw 
that serum sIL-6r was significantly lower in Cycle Absent mice than Cycle Preset mice 
(Figure 4C).  The lower levels of plasma leptin seen in Cycle Absent mice (Figure 6A) 
provide a potential mechanistic link between disease and loss of ovarian function; leptin 
levels are lower in human cachexia patients than healthy controls [67].  Leptin is a major 
regulator of ovarian steroidogenesis and is regulated in turn by estrogen and particularly 
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progesterone [141]. Hypoleptinemia, furthermore, is commonly seen in women with 
hypothalamic amenorrhea and is caused by energy deficiency [151].  
A final potential explanation for differences seen between Cycle Absent mice and 
OVX mice is the dysregulation of the gonadotropins LH and FSH.  While OVX mice, as 
in menopausal humans or animals, have higher circulating LH or FSH than cycling 
females [152, 153], it is likely that the dysfunctional ovaries of Cycle Absent mice 
feedback centrally to cause dysregulation of the secretion of these hormones.  The release 
of both hormones is controlled by the pulsatile release of gonadotropin-releasing 
hormone (GnRH), which is secreted from the hypothalamus and whose pulsatile pattern 
can influence the ratio of and to what extent LH and FSH are released [154]. Given the 
importance of the pattern of GnRH secretion, it is highly likely that Cycle Absent mice 
enter a feedback cycle of greater and greater dysfunction with regards to LH and FSH; 
however, this hypothesis needs to be tested in future studies. In human cases of primary 
ovarian insufficiency (POI), where ovarian function fails before age 40 and at a mean age 
of 17 years [155], a key marker of the syndrome is consistently high levels of FSH (40 
IU/L), similar to menopausal women [152, 156].  However, women with POI also have 
low levels of AMH [156], contrary to what we see in Cycle Absent mice.  Functional 
hypothalamic amenorrhea occurs secondary to several systemic stresses, including 
chronic disease, and is mediated by cortisol or corticotropin-releasing hormone (CRH) 
inhibition of GnRH [157].  This mechanism is a distinct possibility in Cycle Absent mice; 
however, it will require further investigation. Interestingly, another leading cause of 
secondary amenorrhea in humans is traumatic brain injury, lending further evidence to a 
central role in the pathophysiology of premature cycle cessation [157].   
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Morphologically, striking differences were seen among Cycle Present, Cycle 
Absent, and OVX female Apc
Min/+
 mice.  While it is clear that Cycle Absent mice were 
much more severely cachectic than Cycle Present mice, it is not clear why Cycle Absent 
mice stopped estrus cycling.  Tumor burden was much higher in Cycle Absent mice 
(Figure 4A), and it is known that tumor burden is directly related to cachexia severity 
(CITE).  However, it is unsure what the direct link is between tumor burden and cessation 
of estrus cycling.  One hypothesis is that since loss of white adipose tissue (WAT) is one 
of the first tissues to be depleted during cachexia progression [158], the reproductive 
system would shut down in response.  However, we show in the present study that at 15 
weeks of age, the average age at which Cycle Absent mice stop cycling, there is no 
difference in body fat percentage (Figure 2B).  However, there was a significant drop in 
body fat within Cycle Absent animals between 12 and 15 weeks of age (Figure 2B), so 
perhaps there is an intra-animal threshold for minimum body fat for reproductive 
function. 
While tumor burden might explain the differences between Cycle Present and 
Cycle Absent animals, it is unclear how ovariectomy caused female Apc
Min/+ 
mice to gain 
body weight (Figure 3B), gain muscle mass (Table 2), and improve running endurance 
(Figure 3E) without a change in food intake (Table 2, Figure 3G).  It is known that 
estrogen modulates energy intake and substrate utilization [102], so these findings went 
against our original hypothesis.  However, several reports have noted relationships 
between ovariectomy and autophagy; it is possible that the increased autophagy seen in 
several tissues with OVX [159] allows for increased turnover of damaged proteins in 
muscle and systemically, allowing for healthier muscle and greater function.   
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This study aimed to determine the relationship between inflammation, ovarian 
function, and cancer cachexia progression.  It appears that the advent of ovarian 
dysfunction (Cycle Absent mice) does not increase circulating inflammation per se, but 
induces higher sensitivity to baseline inflammation at the tissue level.  OVX seems to 
decrease systemic inflammation, which is in contrast to our original hypothesis.  Further 
work must be done in order to elucidate remaining questions surrounding the cessation of 
estrus cycling with disease and the beneficial effects of OVX. 
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Table 4.1: Characteristics of 18-week female ApcMin/+ mice stratified by ovarian 
status.  Hindlimb muscle mass comprises right gastrocnemius, plantaris, soleus, tibialis 
anterior, extensor digitorum longus, and quadricep. N, number; g, grams; BW, body 
weight; pg, picograms; ml, milliliters; mg, milligrams; mm, millimeters. Measurements 
with superscript lowercase letters indicate significant difference between all groups found 
by one-way ANOVA; groups with same letters are significantly different from one 
another for that measurement (Tukey post hoc). Significance set at p<0.05 for all 
comparisons. 
 
 
 
 
 
 
 
 90 
 
Table 4.2: Characteristics of 18-week female C57BL/6 and ApcMin/+ mice with ovaries 
intact or treated by ovariectomy. Mice were ovariectomized at 11 weeks and sacrificed at 
18 weeks. OVX, ovariectomy; IL-6, interleukin-6; N, number; 15w, 15 weeks of age; 
BW, body weight; g, grams; mm, millimeters; mg, milligrams; TL, tibia length.  * 
indicates main effect of OVX; # indicates main effect of genotype; & indicates 
interaction of OVX x genotype (determined by two-way ANOVA).   Means with same 
superscript lowercase letters indicates significant difference between columns (Tukey 
post hoc, p<0.05). ^ indicates significant difference between ApcMin/+ intact and OVX 
groups (p<0.05, Student’s t-test). 
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Table 4.3: Circulating levels of cytokines in female B6 and ApcMin/+ mice with differing 
ovarian function statuses. Mice from Experiment 1 cohort as well as additional Cycle 
Present and Cycle Absent mice were used for this assay (Experiment 1). All 
measurements shown are pg/ml. IL-1, interleukin-1; IL-10, interleukin-10; IL-17, 
interleukin-17; IFN-, interferon ; MCP-1, monocyte chemoattractant protein-1; 
RANTES, regulated on activation, normal T expressed and secreted / CCL5; LIF, 
Leukemia-inhibiting factor; TNF, tumor necrosis factor ; M-CSF, macrophage colony 
stimulating factor. P-value determined by one-way ANOVA.  Groups within the same 
row with same superscript lowercase letters indicate significant difference between 
groups, determined by Tukey post hoc.  Significance was set at p<0.05 for all 
comparisons. 
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Table 4.4: Descriptive characteristics of female ApcMin/+ mice treated by ovariectomy, 
IL-6 overexpression, or both.  Mice were ovariectomized at 11 weeks, electroporated 
with IL-6 overexpression vector at 13 weeks, and sacrificed at 15 weeks. OVX, 
ovariectomy; IL-6, interleukin-6; N, number; 15w, 15 weeks of age; BW, body weight; g, 
grams; mm, millimeters; mg, milligrams; TL, tibia length.  * indicates main effect of 
OVX; # indicates main effect of IL-6; & indicates interaction of OVX x IL-6 (determined 
by two-way ANOVA).   Means with same superscript lowercase letters indicates 
significant difference between columns (Tukey post hoc, p<0.05) 
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4.7 Figure Legends 
Figure 4.1: Estrus cycle cessation with cachexia (Experiment 1): A) Survival curve 
showing age of cycle cessation in Cycle Absent mice. At 18 weeks, n=9 mice were 
classified as “Cycle Absent” and n=15 mice were classified as “Cycle Present” B) 
Hematoxylin and eosin staining of ovaries taken from B6, Cycle Present, and Cycle 
Absent mice; shown at 400x and 1000x.  Black arrows point to atretic (dead/dying) 
follicles in Cycle Absent ovary. C) Anti-Müllerian Hormone (AMH) gene expression in 
ovaries of B6 and Apc
Min/+ mice stratified into “Cycle Present” and “Cycle Absent.”  
Significant differences between groups were determined by one-way ANOVA 
(p<0.0001).  Cycle Absent significantly differed from both B6 and Cycle Present (Tukey 
post hoc, p<0.0001 for each comparison). D) Uterine weight of B6, Cycle Present, and 
Cycle Absent mice.  Significant differences between groups were determined by one-way 
ANOVA (p<0.0001). All groups were significantly different from one another (p<0.001 
for each comparison, Tukey post hoc). * indicates significant difference from B6; $ 
indicates significant difference from Cycle Present; # indicates significant difference 
from Cycle Absent; significance for all measures was set at p<0.05. 
Figure 4.2: Morphological and functional changes with disease-related cessation of 
ovarian function (Experiment 1): A) Body weights (grams) at 12, 15, and 18 weeks in 
female Apc
Min/+ 
mice stratified into Cycle Present and Cycle Absent groups.  Main effect 
of age (p<0.0001) and interaction of age x cycle presence (p<0.0001) determined by two-
way repeated measures ANOVA.  All Cycle Absent timepoints differ; all Cycle Present 
timepoints differ (Sidak’s Multiple Comparisons test; p<0.01 for each comparison). B) 
Body fat percentages at 12, 15, and 18 weeks of age in Cycle Present and Cycle Absent 
female Apc
Min/+ 
mice .  Main effect of age (p=0.0002), main effect of cycle presence 
(p=0.0006), and interaction of age x cycle presence (p=0.0067) determined by two-way 
repeated measures ANOVA.  Cycle Absent-12 differs from Cycle Absent-15 (p<0.05, 
Sidak’s multiple comparison test). Cycle Absent-12 differs from Cycle Absent-18 
(p<0.001, Sidak’s multiple comparison test). Cycle Present-18 and Cycle Absent-18 
significantly differ (p<0.001, Sidak’s multiple comparisons test). C) Voluntary cage 
activity at 12, 15, and 18 weeks of age in Cycle Present and Cycle Absent female 
Apc
Min/+ 
mice. Main effect of age (p=0.0015) and cycle presence (0.045) determined by 
two-way repeated measures ANOVA.  Cycle Present and Cycle Absent groups trended 
towards difference at 18 weeks (p=0.056), determined by pre-planned Student’s t-test. 
Dotted line represents average week of estrus cycle cessation. + indicates significant 
difference between all cycle absent timepoints; % indicates significant difference 
between all cycle present timepoints; $ indicates significant difference between 12-week 
cycle absent and 15-week cycle; # indicates significant difference between 12-week cycle 
absent and 18-week cycle absent; Significance was set at p<0.05 for all measures.   
Figure 4.3: Morphological and functional changes with ovariectomy (Experiment 2): 
A) Timeline of experimental procedures for Experiment 2. Mice were ovariectomized at 
11 weeks of age and followed until sacrifice at 18 weeks of age. B) Percentage body 
weight change in Cycle Absent and OVX female Apc
Min/+ 
mice from 11-18 weeks of age. 
Cycle Absent and OVX female Apc
Min/+ 
mice groups significantly differ (p<0.05, 
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Student’s t-test). C) Percent body fat at 18 weeks of age in Cycle Absent and OVX 
female Apc
Min/+ 
mice. Cycle Absent and OVX female Apc
Min/+ 
mice groups significantly 
differ (p<0.05, Student’s t-test). D) Lean mass change (grams) from 12-18 weeks of age 
in Cycle Absent and OVX female Apc
Min/+ 
mice. P=0.65 between groups. E) Distance run 
to fatigue (meters) in Cycle Absent and OVX female Apc
Min/+ 
mice. Cycle Absent and 
OVX female Apc
Min/+ mice groups significantly differ (p<0.05, Student’s t-test). F) 
Voluntary cage activity at 18 weeks of age in Cycle Absent and OVX female Apc
Min/+ 
mice. Cycle Absent and OVX female Apc
Min/+ 
mice groups significantly differ (p<0.05, 
Student’s t-test). G) Food intake (grams/day) at 18 weeks of age in Cycle Absent and 
OVX female Apc
Min/+ 
mice. Horizontal dotted lines indicate average B6 measurement.  * 
indicates significant difference between Cycle Absent and OVX groups (p<0.05), 
determined by Student’s t-test.  Significance was set at p<0.05 for all measures. 
Figure 4.4: Morphological and functional changes with ovariectomy and IL-6 
overexpression (Experiment 3): A) Timeline of experimental procedures for 
Experiment 3. B) Percentage body weight change between 11-15 weeks of age in female 
Apc
Min/+ 
mice treated with OVX, IL-6 overexpression, or both.  A main effect of OVX 
(p=0.0012) and a main effect of IL-6 overexpression (p=0.017) were determined by two-
way ANOVA.  OVX +vector group was significantly different from all other groups 
(p<0.05), determined by pre-planned Student’s t-test. C) Percentage body fat between 11-
15 weeks of age in female Apc
Min/+ 
mice. No differences between groups were determined 
by two-way ANOVA. D) Lean mass change (grams) from 11-15 weeks of age in female 
Apc
Min/+ 
mice treated with OVX, IL-6 overexpression, or both. A trend for a main effect 
of IL-6 (p=0.052) and an interaction between OVX and IL-6 (p=0.0093) were detected by 
two-way ANOVA. OVX group significantly differed from control Apc
Min/+ 
and OVX+ 
IL-6 groups (p<0.05), determined by Tukey post hoc. * indicates difference from control 
ApcMin/+ group; ^ indicates significant difference from sham + IL-6 group; $ indicates 
significant difference from OVX+IL-6 group.  Significance was set at p<0.05 for all 
measures. 
Figure 4.5: Effect of loss of ovarian function and IL-6 overexpression on tumor 
burden and circulating IL-6 signaling: A) Number of tumors in the small intestine and 
colon of estrus cycle present, estrus cycle absent, and OVX female Apc
Min/+ 
mice. 
Significant difference between groups (p=0.0002) determined by one-way ANOVA.  
Estrus cycle absent is significantly different from estrus cycle present (p<0.001) and from 
OVX (p<0.01) determined by Tukey post hoc. All groups differ significantly from B6, 
determined by Student’s t-test (p<0.05 for each comparison). B) Number of tumors in the 
small intestine and colon of control, OVX, IL-6 overexpression, and OVX+IL-6 female 
Apc
Min/+ 
mice. Main effect of OVX was determined by two-way ANOVA (p=0.0492).  C) 
Plasma IL-6 levels (pg/ml) in estrus cycle present, estrus cycle absent, and OVX female 
Apc
Min/+ 
mice. One-way ANOVA detected no difference between groups (p=0.091).  
Estrus cycle absent significantly differs from OVX (p=0.0003), determined by pre-
planned Student’s t-test. All groups differ significantly from B6, determined by Student’s 
t-test (p<0.05 for each comparison). D) Plasma IL-6 levels (pg/ml) in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of IL-6 
overexpression was determined by two-way ANOVA (p<0.01). E) Soluble IL-6 receptor 
plasma levels (ng/ml) in estrus cycle present, estrus cycle absent, and OVX female 
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Apc
Min/+ 
mice.  No differences were determined by one-way ANOVA; however, Cycle 
Absent levels are significantly lower than Cycle Present levels by pre-planned Student’s 
t-test (p=0.050). F) Soluble IL-6 receptor plasma levels (ng/ml) in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of IL-6 
overexpression was determined by two-way ANOVA (p<0.05). * indicates significant 
difference from estrus cycle present; # indicates significant difference from OVX; & 
indicates significant difference from B6.  Level of significance was set at p<0.05 for all 
measures. 
Figure 4.6: Effect of Cachexia and Loss of Ovarian Function on Circulating 
Inflammatory Cytokines: A) Plasma leptin levels (pg/ml) in Cycle present, Cycle 
absent, and OVX ApcMin/+ mice.  Significant difference between groups was indicated 
by one-way ANOVA (p=0.005); Cycle Absent was significantly lower than B6 (p<0.05, 
Tukey post hoc). B) Plasma Interferon-gamma (IFN) levels (pg/ml) in C57BL/6 (B6), 
female ApcMin/+, and OVX ApcMin/+ mice. Significant difference between groups was 
determined by one way ANOVA (p=0.0012).  ApcMin/+ and OVX ApcMin/+ mice both 
differ from B6 (p<0.001 and p<0.05, respectively, Tukey post hoc). C) Plasma monocyte 
chemoattractant protein-1 (MCP-1) levels (pg/ml) in C57BL/6 (B6), female ApcMin/+, 
and OVX ApcMin/+ mice.  Significant differences between groups were determined by 
one-way ANOVA (p=0.0002).  ApcMin/+ and OVX ApcMin/+ groups both differ from 
B6 (p<0.001 and p<0.01, respectively, Tukey post hoc). D) Plasma “Regulated on 
Activation, Normal T Expressed and Secreted” (RANTES) levels (pg/ml) in Cycle 
Present and Cycle Absent ApcMin/+ mice. A significant difference between the two was 
determined by Student’s t-test (p=0.017).  E) (left) Plasma interleukin-10 (IL-10) levels 
(pg/ml) in C57BL/6 (B6), female ApcMin/+, and OVX ApcMin/+ mice.  Significant 
differences between groups were determined by one-way ANOVA (p=0.0046).  
ApcMin/+ and OVX ApcMin/+ each differ from B6 level (p<0.05 and p<0.01, 
respectively, Tukey post hoc). (right) Plasma IL-10 levels (pg/ml) in Cycle Present and 
Cycle Absent ApcMin/+ mice. A significant difference between the two was determined 
by Student’s t-test (p=0.010) F) (left) Plasma macrophage colony stimulating factor (M-
CSF) levels (pg/ml) in C57BL/6 (B6), female ApcMin/+, and OVX ApcMin/+ mice. 
Significant difference between groups were determined by one-way ANOVA (p=0.037).  
OVX ApcMin/+ differed significantly from control ApcMin/+ (p<0.05, Tukey post hoc). 
(right) Plasma M-CSF levels (pg/ml) in Cycle Present and Cycle Absent ApcMin/+ mice.  
A significant difference was determined by Student’s t-test (p=0.023).  & indicates 
significant difference from B6; * indicates significant difference from Cycle Present; # 
indicates significant difference from control ApcMin/+.  Significance was set at p<0.05 
for all measures. 
Figure 4.7: Changes in inflammatory signaling with loss of ovarian signaling and 
IL-6 overexpression: A) Muscle IL-6 mRNA in Cycle Present, Cycle Absent, and OVX 
female Apc
Min/+ 
mice.  A significant difference between groups was determined by one-
way ANOVA (p=0.0138).  Cycle Absent is significantly different from all other groups 
(p<0.05 for each comparison, Tukey post hoc) B) Muscle IL-6 mRNA in control, OVX, 
IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice.  No differences were 
determined by two-way ANOVA. C) Muscle TGF mRNA in Cycle Present, Cycle 
Absent, and OVX groups. A significant difference between groups was determined by 
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one-way ANOVA (p=0.0448).  OVX significantly differs from Cycle Present (p<0.05, 
Tukey post hoc). D) Muscle TGF mRNA in control, OVX, IL-6 overexpression, and 
OVX+IL-6 groups. No differences were determined by two-way ANOVA.  E) Muscle 
TNF mRNA in Cycle Present, Cycle Absent, and OVX groups. A significant difference 
between groups was determined by one-way ANOVA (p=0.005). Cycle Absent is 
significantly different from Cycle Present and OVX (p<0.05 and p<0.01, respectively, 
Tukey post hoc). F) Muscle TNF mRNA in control, OVX, IL-6 overexpression, and 
OVX+IL-6  groups. No differences were determined by two-way ANOVA.  *indicates 
significant difference from Cycle Present; # indicates significant difference from OVX; $ 
indicates significant difference from C57BL/6 (p<0.05). 
Figure 4.8: Changes in muscle inflammatory receptors with loss of ovarian function 
and IL-6 overexpression: A) Muscle IL-6r mRNA in Cycle Present, Cycle Absent, and 
OVX groups. A significant difference between groups was determined by one-way 
ANOVA (p<0.0001). Cycle Absent is significantly different from all other groups 
(p<0.001 for each comparison; Tukey post hoc). B) Muscle IL-6r mRNA in control, 
OVX, IL-6 overexpression, and OVX+IL-6 groups. An interaction of OVX x IL-6 was 
determined by two-way ANOVA (p=0.0459). No differences between individual groups 
were determined by Tukey post hoc. C) Muscle TLR4 mRNA in Cycle Present, Cycle 
Absent, and OVX groups. A significant difference between groups was determined by 
one-way ANOVA (p<0.0001). Cycle Absent is significantly different from all other 
groups (p<0.001 for each comparison; Tukey post hoc). D) Muscle TLR4 mRNA in 
control, OVX, IL-6 overexpression, and OVX+IL-6 groups. No differences were 
determined by two-way ANOVA.  * indicates significant difference from Cycle Present; 
# indicates significant difference from OVX; $ indicates significant difference from B6. 
Significance was set at p<0.05 for all measures. 
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Figure 4.1: Estrus cycle cessation with cachexia (Experiment 1): A) Survival curve 
showing age of cycle cessation in Cycle Absent mice. At 18 weeks, n=9 mice were 
classified as “Cycle Absent” and n=15 mice were classified as “Cycle Present” B) 
Hematoxylin and eosin staining of ovaries taken from B6, Cycle Present, and Cycle 
Absent mice; shown at 400x and 1000x.  Black arrows point to atretic (dead/dying) 
follicles in Cycle Absent ovary. C) Anti-Müllerian Hormone (AMH) gene expression in 
ovaries of B6 and Apc
Min/+ 
mice stratified into “Cycle Present” and “Cycle Absent.”  
Significant differences between groups were determined by one-way ANOVA 
(p<0.0001).  Cycle Absent significantly differed from both B6 and Cycle Present (Tukey 
post hoc, p<0.0001 for each comparison). D) Uterine weight of B6, Cycle Present, and 
Cycle Absent mice.  Significant differences between groups were determined by one-way 
ANOVA (p<0.0001). All groups were significantly different from one another (p<0.001 
for each comparison, Tukey post hoc). * indicates significant difference from B6; $ 
indicates significant difference from Cycle Present; # indicates significant difference 
from Cycle Absent; significance for all measures was set at p<0.05. 
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Figure 4.2: Morphological and functional changes with disease-related cessation of 
ovarian function (Experiment 1): A) Body weights (grams) at 12, 15, and 18 weeks in 
female Apc
Min/+ 
mice stratified into Cycle Present and Cycle Absent groups.  Main effect 
of age (p<0.0001) and interaction of age x cycle presence (p<0.0001) determined by two-
way repeated measures ANOVA.  All Cycle Absent timepoints differ; all Cycle Present 
timepoints differ (Sidak’s Multiple Comparisons test; p<0.01 for each comparison). B) 
Body fat percentages at 12, 15, and 18 weeks of age in Cycle Present and Cycle Absent 
female Apc
Min/+ 
mice .  Main effect of age (p=0.0002), main effect of cycle presence 
(p=0.0006), and interaction of age x cycle presence (p=0.0067) determined by two-way 
repeated measures ANOVA.  Cycle Absent-12 differs from Cycle Absent-15 (p<0.05, 
Sidak’s multiple comparison test). Cycle Absent-12 differs from Cycle Absent-18 
(p<0.001, Sidak’s multiple comparison test). Cycle Present-18 and Cycle Absent-18 
significantly differ (p<0.001, Sidak’s multiple comparisons test). C) Voluntary cage 
activity at 12, 15, and 18 weeks of age in Cycle Present and Cycle Absent female 
Apc
Min/+ 
mice. Main effect of age (p=0.0015) and cycle presence (0.045) determined by 
two-way repeated measures ANOVA.  Cycle Present and Cycle Absent groups trended 
towards difference at 18 weeks (p=0.056), determined by pre-planned Student’s t-test. 
Dotted line represents average week of estrus cycle cessation. + indicates significant 
difference between all cycle absent timepoints; % indicates significant difference 
between all cycle present timepoints; $ indicates significant difference between 12-week 
cycle absent and 15-week cycle; # indicates significant difference between 12-week cycle 
absent and 18-week cycle absent; Significance was set at p<0.05 for all measures.   
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Figure 4.3: Morphological and functional changes with ovariectomy (Experiment 2): 
A) Timeline of experimental procedures for Experiment 2. Mice were ovariectomized at 
11 weeks of age and followed until sacrifice at 18 weeks of age. B) Percentage body 
weight change in Cycle Absent and OVX female Apc
Min/+ 
mice from 11-18 weeks of age. 
Cycle Absent and OVX female Apc
Min/+ 
mice groups significantly differ (p<0.05, 
Student’s t-test). C) Percent body fat at 18 weeks of age in Cycle Absent and OVX 
female Apc
Min/+ 
mice. Cycle Absent and OVX female Apc
Min/+ 
mice groups significantly 
differ (p<0.05, Student’s t-test). D) Lean mass change (grams) from 12-18 weeks of age 
in Cycle Absent and OVX female Apc
Min/+ 
mice. P=0.65 between groups. E) Distance run 
to fatigue (meters) in Cycle Absent and OVX female Apc
Min/+ 
mice. Cycle Absent and 
OVX female Apc
Min/+ mice groups significantly differ (p<0.05, Student’s t-test). F) 
Voluntary cage activity at 18 weeks of age in Cycle Absent and OVX female Apc
Min/+ 
mice. Cycle Absent and OVX female Apc
Min/+ 
mice groups significantly differ (p<0.05, 
Student’s t-test). G) Food intake (grams/day) at 18 weeks of age in Cycle Absent and 
OVX female Apc
Min/+ 
mice. Horizontal dotted lines indicate average B6 measurement.  * 
indicates significant difference between Cycle Absent and OVX groups (p<0.05), 
determined by Student’s t-test.  Significance was set at p<0.05 for all measures. 
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Figure 4.4: Morphological and functional changes with ovariectomy and IL-6 
overexpression (Experiment 3): A) Timeline of experimental procedures for 
Experiment 3. B) Percentage body weight change between 11-15 weeks of age in female 
Apc
Min/+ 
mice treated with OVX, IL-6 overexpression, or both.  A main effect of OVX 
(p=0.0012) and a main effect of IL-6 overexpression (p=0.017) were determined by two-
way ANOVA.  OVX +vector group was significantly different from all other groups 
(p<0.05), determined by pre-planned Student’s t-test. C) Percentage body fat between 11-
15 weeks of age in female Apc
Min/+ 
mice. No differences between groups were determined 
by two-way ANOVA. D) Lean mass change (grams) from 11-15 weeks of age in female 
Apc
Min/+ 
mice treated with OVX, IL-6 overexpression, or both. A trend for a main effect 
of IL-6 (p=0.052) and an interaction between OVX and IL-6 (p=0.0093) were detected by 
two-way ANOVA. OVX group significantly differed from control Apc
Min/+ 
and OVX+ 
IL-6 groups (p<0.05), determined by Tukey post hoc. * indicates difference from control 
ApcMin/+ group; ^ indicates significant difference from sham + IL-6 group; $ indicates 
significant difference from OVX+IL-6 group.  Significance was set at p<0.05 for all 
measures. 
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Figure 4.5: Effect of loss of ovarian function and IL-6 overexpression on tumor 
burden and circulating IL-6 signaling: A) Number of tumors in the small intestine and 
colon of estrus cycle present, estrus cycle absent, and OVX female Apc
Min/+ 
mice. 
Significant difference between groups (p=0.0002) determined by one-way ANOVA.  
Estrus cycle absent is significantly different from estrus cycle present (p<0.001) and from 
OVX (p<0.01) determined by Tukey post hoc. All groups differ significantly from B6, 
determined by Student’s t-test (p<0.05 for each comparison). B) Number of tumors in the 
small intestine and colon of control, OVX, IL-6 overexpression, and OVX+IL-6 female 
Apc
Min/+ 
mice. Main effect of OVX was determined by two-way ANOVA (p=0.0492).  C) 
Plasma IL-6 levels (pg/ml) in estrus cycle present, estrus cycle absent, and OVX female 
Apc
Min/+ 
mice. One-way ANOVA detected no difference between groups (p=0.091).  
Estrus cycle absent significantly differs from OVX (p=0.0003), determined by pre-
planned Student’s t-test. All groups differ significantly from B6, determined by Student’s 
t-test (p<0.05 for each comparison). D) Plasma IL-6 levels (pg/ml) in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of IL-6 
overexpression was determined by two-way ANOVA (p<0.01). E) Soluble IL-6 receptor 
plasma levels (ng/ml) in estrus cycle present, estrus cycle absent, and OVX female 
Apc
Min/+ 
mice.  No differences were determined by one-way ANOVA; however, Cycle 
Absent levels are significantly lower than Cycle Present levels by pre-planned Student’s 
t-test (p=0.050). F) Soluble IL-6 receptor plasma levels (ng/ml) in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of IL-6 
overexpression was determined by two-way ANOVA (p<0.05). * indicates significant 
difference from estrus cycle present; # indicates significant difference from OVX; & 
indicates significant difference from B6.  Level of significance was set at p<0.05 for all 
measures. 
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Figure 4.6: Effect of Cachexia and Loss of 
Ovarian Function on Circulating 
Inflammatory Cytokines: A) Plasma leptin 
levels (pg/ml) in Cycle present, Cycle absent, and 
OVX ApcMin/+ mice.  Significant difference 
between groups was indicated by one-way 
ANOVA (p=0.005); Cycle Absent was 
significantly lower than B6 (p<0.05, Tukey post 
hoc). B) Plasma Interferon-gamma (IFN) levels 
(pg/ml) in C57BL/6 (B6), female ApcMin/+, and 
OVX ApcMin/+ mice. Significant difference 
between groups was determined by one way 
ANOVA (p=0.0012).  ApcMin/+ and OVX ApcMin/+ mice both differ from B6 (p<0.001 
and p<0.05, respectively, Tukey post hoc). C) Plasma monocyte chemoattractant protein-
1 (MCP-1) levels (pg/ml) in C57BL/6 (B6), female ApcMin/+, and OVX ApcMin/+ 
mice.  Significant differences between groups were determined by one-way ANOVA 
(p=0.0002).  ApcMin/+ and OVX ApcMin/+ groups both differ from B6 (p<0.001 and 
p<0.01, respectively, Tukey post hoc). D) Plasma “Regulated on Activation, Normal T 
Expressed and Secreted” (RANTES) levels (pg/ml) in Cycle Present and Cycle Absent 
ApcMin/+ mice. A significant difference between the two was determined by Student’s t-
test (p=0.017).  E) (left) Plasma interleukin-10 (IL-10) levels (pg/ml) in C57BL/6 (B6), 
female ApcMin/+, and OVX ApcMin/+ mice.  Significant differences between groups 
were determined by one-way ANOVA (p=0.0046).  ApcMin/+ and OVX ApcMin/+ each 
differ from B6 level (p<0.05 and p<0.01, respectively, Tukey post hoc). (right) Plasma 
IL-10 levels (pg/ml) in Cycle Present and Cycle Absent ApcMin/+ mice. A significant 
difference between the two was determined by Student’s t-test (p=0.010) F) (left) Plasma 
macrophage colony stimulating factor (M-CSF) levels (pg/ml) in C57BL/6 (B6), female 
ApcMin/+, and OVX ApcMin/+ mice. Significant difference between groups were 
determined by one-way ANOVA (p=0.037).  OVX ApcMin/+ differed significantly from 
control ApcMin/+ (p<0.05, Tukey post hoc). (right) Plasma M-CSF levels (pg/ml) in 
Cycle Present and Cycle Absent ApcMin/+ mice.  A significant difference was 
determined by Student’s t-test (p=0.023).  & indicates significant difference from B6; * 
indicates significant difference from Cycle Present; # indicates significant difference 
from control ApcMin/+.  Significance was set at p<0.05 for all measures. 
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Figure 4.7: Changes in inflammatory signaling with loss of ovarian signaling and 
IL-6 overexpression: A) Muscle IL-6 mRNA in Cycle Present, Cycle Absent, and OVX 
female Apc
Min/+ 
mice.  A significant difference between groups was determined by one-
way ANOVA (p=0.0138).  Cycle Absent is significantly different from all other groups 
(p<0.05 for each comparison, Tukey post hoc) B) Muscle IL-6 mRNA in control, OVX, 
IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice.  No differences were 
determined by two-way ANOVA. C) Muscle TGF mRNA in Cycle Present, Cycle 
Absent, and OVX groups. A significant difference between groups was determined by 
one-way ANOVA (p=0.0448).  OVX significantly differs from Cycle Present (p<0.05, 
Tukey post hoc). D) Muscle TGF mRNA in control, OVX, IL-6 overexpression, and 
OVX+IL-6 groups. No differences were determined by two-way ANOVA.  E) Muscle 
TNF mRNA in Cycle Present, Cycle Absent, and OVX groups. A significant difference 
between groups was determined by one-way ANOVA (p=0.005). Cycle Absent is 
significantly different from Cycle Present and OVX (p<0.05 and p<0.01, respectively, 
Tukey post hoc). F) Muscle TNF mRNA in control, OVX, IL-6 overexpression, and 
OVX+IL-6  groups. No differences were determined by two-way ANOVA.  *indicates 
significant difference from Cycle Present; # indicates significant difference from OVX; $ 
indicates significant difference from C57BL/6 (p<0.05). 
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Figure 4.8: Changes in muscle inflammatory receptors with loss of ovarian function 
and IL-6 overexpression: A) Muscle IL-6r mRNA in Cycle Present, Cycle Absent, and 
OVX groups. A significant difference between groups was determined by one-way 
ANOVA (p<0.0001). Cycle Absent is significantly different from all other groups 
(p<0.001 for each comparison; Tukey post hoc). B) Muscle IL-6r mRNA in control, 
OVX, IL-6 overexpression, and OVX+IL-6 groups. An interaction of OVX x IL-6 was 
determined by two-way ANOVA (p=0.0459). No differences between individual groups 
were determined by Tukey post hoc. C) Muscle TLR4 mRNA in Cycle Present, Cycle 
Absent, and OVX groups. A significant difference between groups was determined by 
one-way ANOVA (p<0.0001). Cycle Absent is significantly different from all other 
groups (p<0.001 for each comparison; Tukey post hoc). D) Muscle TLR4 mRNA in 
control, OVX, IL-6 overexpression, and OVX+IL-6 groups. No differences were 
determined by two-way ANOVA.  * indicates significant difference from Cycle Present; 
# indicates significant difference from OVX; $ indicates significant difference from B6. 
Significance was set at p<0.05 for all measures. 
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CACHEXIA-INDUCED MUSCLE METABOLIC DYSREGULATION IN THE FEMALE
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5.1 Abstract 
 Cachexia occurs secondary to chronic conditions including cancer and causes 
debilitating muscle wasting due to severe dysfunction in muscle metabolism and protein 
balance.  While muscle metabolic dysfunction and protein imbalance has been 
characterized in the male, the processes underlying muscle wasting in the female have not 
been identified.  The Apc
Min/+ 
mouse is genetically predisposed to develop intestinal 
tumors; hypogonadism is strongly associated with cachexia severity in the male, though 
the relationship in the female is uncertain.  Ovarian endocrine functions are known to 
impact muscle quality and mitochondrial function; it is therefore likely that the loss of 
ovarian function plays a role in the etiology of female muscle wasting.  The purpose of 
this study is to examine the relationship of ovarian function, cachexia-related pathways in 
the muscle, mitochondrial dysfunction, and muscle wasting during cancer cachexia 
progression in the female Apc
Min/+ 
mouse.  Female Apc
Min/+
 mice were tracked 
functionally until sacrifice at 18 weeks of age.  A subset of female Apc
Min/+
 mice were 
ovariectomized at 11 weeks of age and sacrificed at 18 weeks of age.  A second 
experiment examined the effect of ovariectomy on IL-6 overexpression in female 
Apc
Min/+
 mice initiating cachexia.  Markers of IL-6 signaling, canonical cachexia 
pathways, and mitochondrial biogenesis and dynamics were examined in ovaries-intact 
mice of varying cachexia severity and ovariectomized mice.  Several markers of 
canonical cachexia signaling and IL-6 signaling were increased in severely cachectic 
female Apc
Min/+
 mice.  Surprisingly, mitochondrial dysfunction does not seem to play a 
large role in cachexia in the female.  In contrast, ovariectomy ameliorated much of the 
dysregulated signaling in female Apc
Min/+
 mice.  Ovariectomy and IL-6 overexpression 
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upregulated IL-6 signaling, but had little effect on mitochondrial function in initially 
cachectic female Apc
Min/+
 mice.  Our results indicate that loss of ovarian function has 
direct effects on muscle metabolism during cachexia progression that may alleviate some 
cachexia-associated muscle wasting. Future studies in the female will need to determine 
the precise mechanisms of this change.  
Key Words: muscle metabolism, estrogen, ovariectomy, Apc
Min/+
 
5.2 Introduction 
Cachexia is a devastating loss of muscle and fat mass that accompanies many 
chronic disease states [1].   Symptoms include an unintentional  >5% decline in body 
weight as well as decreased muscle strength, fatigue, and abnormal biochemistry [105]. 
The muscle wasting associated with cachexia leads to weakness, loss of function, and 
decreased ability to heal [16].  The Apc
Min/+
 mouse model develops intestinal polyps 
beginning at four weeks of age and cachexia secondary to the tumor burden [10, 20]; it 
has been widely used by our lab and others to study cachexia [4, 105, 117].  Cachexia is 
an inflammatory condition, and several inflammatory factors play roles in muscle 
wasting, including IL-6, TNFα, and NfKB [2].  
Muscle wasting can occur by one of several protein degradation pathways; the 
major pathway seen in cachexia is the ubiquitin-proteasome system (UPS) [3, 16, 17, 48]. 
IL-6 is increased in most models of cachexia [11] and activates several downstream 
pathways leading to muscle wasting, including JAK/STAT3, ERK, and 
PI3K/Akt/FOXO3 [11].  STAT3 has been shown to be both sufficient and necessary for 
muscle fiber atrophy [11]; we have previously shown that this pathway is subject to sex 
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differences with cachexia [15]. FOXO3, usually phosphorylated and hence inactivated by 
PI3K/Akt, is a key regulator of the UPS [3, 17, 48].  When activated, it is able to enter the 
nucleus and enhance transcription of the E3 ligases MuRF1 and MAFbx/Atrogin1 [3].  
These particular E3 ligases are highly associated with cancer cachexia [16, 48]; in 
particular, increased circulating IL-6 with cachexia can induce high levels of Atrogin-
1[20]. Sex differences have been shown in MAFbx/Atrogin1 knockout rats; female 
muscle was unable to hypertrophy after fourteen days of functional overload, in contrast 
to male muscle [65].  Independent of FOXO3, p38 MAPK, putatively induced by IL-6, 
can also activate the UPS [17]. There are baseline difference between males and females 
with respect to contractile protein regulation and substrate metabolism [160]; 
additionally, males have higher baseline muscle protein turnover than females [161].  It is 
therefore probable that differences exist during muscle wasting, as well.  5’-adenosine 
monophosphate-activated protein kinase (AMPK) is considered a major cellular energy 
sensor, and has been shown to be induced with severe body weight loss during cachexia 
progression [14].  This provides a functional link between body weight loss, muscle mass 
loss, and mitochondrial function, as AMPK can activate MuRF1, Atrogin-1 [14], and 
induce mitochondrial biogenesis and substrate uptake [162] 
In addition to protein degradation, it has been recognized over the past several 
years that mitochondrial dysfunction plays a major role in muscle wasting with cancer 
cachexia. It has previously been shown in Apc
Min/+
 mice that early in cachexia 
progression, mitochondrial biogenesis and dynamics are dysregulated, leading to a 
reduction in mitochondrial content as cachexia progresses [6, 14]. PGC1α, associated 
with mitochondrial biogenesis, is reduced in several tumor implantation models  as well 
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as the Apc
Min/+
 mouse [14]. Fission and fusion, dynamic mitochondrial network 
processes, are induced by stimuli including exercise training, and can be pathologically 
dysregulated during cachexia progression, leading to fragmented and dysfunctional 
mitochondrial networks [14]. Mitochondrial dysfunction can lead to activation of AMPK 
and FOXO3, which leads to further muscle protein degradation [6].  The UPS is an ATP-
dependent process; high energy demand causes lower efficiency of ATP synthesis; it is 
therefore thought that mitochondria are a site of energy wasting with cachexia, leading to 
further dysregulation of metabolism [16]. It has been shown that mitochondria isolated 
from cachectic muscle have decreased cytochrome c oxidase (COX) IV protein [14] and 
activity [16] than mitochondria from healthy muscle.  
Ovarian endocrine function, particularly estrogen, has major effects on muscle 
metabolism and implications for muscle wasting.  Estrogen can directly inhibit 
transcription of IL-6 [37], as well as signaling downstream of STAT3 [27].   
Additionally, estrogen decreases p38 MAPK-mediated inflammation in myocytes [33].  
Interestingly, and of interest to our current model, decreases in muscle expression of 
MuRF1 and Atrogin1 have been seen in ovariectomized (OVX) mice [87].  OVX is also 
associated with a dysregulation of substrate metabolism in muscle, including a 
downregulation of genes associated with lipid storage and lipogenesis [102].  Estrogen 
activates AMPK through estrogen receptor alpha (ERα) [163]; and OVX mice show a 
decrease in AMPK [102].  
 While the processes accompanying muscle wasting with cachexia have been well-
characterized in male animals, a paucity of research exists in the muscle of female 
animals with cachexia.  However, it is clear that there are differences in the etiology and 
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progression of cachexia between males and females [15].  The purpose for this study is to 
determine whether cachexia-induced skeletal muscle metabolic dysfunction is regulated 
by ovarian function in the female Apc
Min/+
 mouse.  The hypothesis for this study is that 
loss of ovarian function will increase metabolic dysregulation, leading to aggravated 
muscle wasting. Further, the loss of ovarian function will disinhibit IL-6 signaling, 
allowing for increased downstream signaling and further muscle wasting. 
5.3 Methods 
 Animals 
Female Apc 
Min/+
mice (n=75) and female C57BL/6 mice (n=12) were bred and 
maintained at the University of South Carolina Animal Resource Facility.   Apc
Min/+ 
mice 
used were on a C57BL/6 background and were offspring from breeders originally 
purchased from Jackson Labs (Bar Harbor, ME, USA).   Mice were kept on a 12:12h 
light/dark cycle beginning at 7:00 AM and were given unrestricted access to standard 
rodent chow (Harlan Teklad Rodent Diet, #8604, Harlan, Indianapolis, IN, USA).  Mice 
were weighed weekly.  Food intake was measured at 12 and 18 weeks of age.  All 
experiments were approved by the University of South Carolina’s Institutional Animal 
Care and Use Committee.   
Experimental Design  
Two experiments were performed. Experiment 1 examined the ovarian progression 
during the progression of cachexia. Female Apc
Min/+
mice (n=24) had estrus cycling 
measured daily from 10-18 weeks of age for determination of ovarian function. Mice 
were sacrificed at 18 weeks of age and stratified based on weight change between 15 and 
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18 weeks of age and were classified as “weight stable” (<1% body weight loss), 
“moderately cachectic” (1-100% body weight loss), or “severely cachectic (>10% body 
weight loss).  In addition, a cohort (n=10) of female Apc
Min/+ 
mice were ovariectomized 
(OVX) at 11 weeks of age and were monitored until sacrifice at 18 weeks of age. In 
addition, 7 B6 females and 5 B6 females ovariectomized at 11 week of age were 
sacrificed at 18 weeks to act as controls. Experiment 2 examined the interaction between 
ovarian function and inflammation during the initiation of cachexia.  Female Apc
Min/+ 
mice underwent OVX or sham surgery at 11 weeks of age, followed by overexpression of 
IL-6 or an empty vector at 13 weeks of age, before sacrifice at 15 weeks of age, for four 
treatment groups: sham-OVX + vector (n=13), sham-OVX + IL-6 (n=10), OVX + vector 
(n=10), and OVX + IL-6 (n=8).  In all experiments, blood, inguinal fat, hindlimb 
muscles, ovaries, uterus, and spleen were removed at the time of sacrifice. Hindlimb 
muscle mass measurements comprise the sum of left soleus, plantaris, gastrocnemius, 
tibialis anterior, extensor digitalis longus, and quadriceps masses. 
 Ovariectomy 
Female Apc
Min/+ 
and C57BL/6 mice were ovariectomized at 11 weeks of age.  Mice were 
anesthetized by ketamine/acepromazine/xylazine.  Once anesthetized, the mouse was 
placed in a prone position on a sterile absorbent pad. The back was shaved from the 
caudal edge of the ribcage to the base of the tail.  The shaved region was then sterilized 
with betadine (PDI, Orangeburg, NY, USA) and rubbing alcohol (PDI).  A 2-cm dorsal 
midline incision was made with sterile scissors halfway between the caudal edge of the 
ribcage and the base of the tail.  Fascia was the cleared away by blunt dissection.  As 
second 1-cm long incision was made into the muscle wall.  The ovary and surrounding fat 
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pad were extracted through the incision with forceps.  A hemostat was closed around the 
distal oviduct/uterine horn to terminate blood supply to the ovary.  Non-absorbable suture 
(AD Surgical, Sunnyvale, CA) was used to tie off the oviduct, and the ovary was 
removed.  The uterine horn was returned to the peritoneal cavity, and absorbable suture 
(AD Surgical) was used to close the muscle incision.  Wound clips were used to close the 
skin incision, and the process was repeated on the contralateral side.  Mice were given 
0.01 mg/kg buprenorphine (Burprenex ©, Reckitt Benckiser Pharmaceuticals, 
Pendergrass, GA, USA) for pain.  Wound clips were removed 7 days after surgery.  
IL-6 overexpression by electroporation  
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase circulating 
IL-6 levels in mice as previously described [117]. The right quadriceps muscle was used 
to synthesize and secrete exogenous IL-6 into circulation from the injected expression 
plasmid, and was not used for any analyses in the study. The gastrocnemius muscle used 
in the study was not subjected to electroporation. Briefly, mice were injected with 50 μg 
of IL-6 plasmid driven by the CMV promoter, or control plasmid (pV1J), into the right 
quadriceps muscle. Mice were anesthetized with a 2% mixture of isoflurane (IsoSol, 
VEDCO, St. Joseph, MO, USA) and oxygen (1 L/min). The leg was shaved, and a small 
incision was made over the quadriceps muscle. Fat was dissected away from the muscle, 
and the plasmid was injected in a 50 μl volume of sterile phosphate-buffered saline 
(PBS). A series of eight 50 ms, 100 V pulses was used to promote uptake of the plasmid 
into myonuclei, and the incision was closed with a wound clip.  
RNA isolation and RT-PCR 
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RNA isolation, cDNA synthesis, and real-time PCR were performed as previously 
described [15, 118].  cDNA synthesis reagents from Applied Biosystems (Foster City, 
CA, USA) were used.  Bio-Rad SsoAdvanced Universal Probes Supermix and SYBR 
Green Supermix were used for RT-PCR reactions (Hercules, CA).  Briefly, proximal 
gastrocnemius muscle was homogenized in TRIzol (Life Technologies, Grand Island, 
NY, USA) and mixed with chloroform, then centrifuged.  The RNA phase was removed 
and washed several times with ethanol in DEPC-treated water.  cDNA was synthesized 
using 1 g of RNA.  RT-PCR was performed on an Applied Biosystems 7300 
thermocycler.  Taqman gene expression assay was used to determine Fbxo32 (Atrogin-1), 
Mfn1, and Fis1 mRNA expression (Life Technologies).  Primer sequences are as follows:  
MuRF1 (F): 5’-ATGAACTTCACGGTGGGTTT-3’ (R): 5’-
GGGATTGCCACAGAGGATTA-3’;  
PGC1a (F): 5’-GACCACAAACGATGACCCTCC-3’ (R): 5’-
CCTGAGAGAGACTTTGGAGGC-3’. 
 PGC1a IL-6r, SOCS3, gp130, and GAPDH primer sequences have been published 
elsewhere [15, 119].   
Western blotting 
Western blots were performed as described previously [106, 120].  Briefly, 
gastrocnemius muscle samples were run on 6-8% acrylamide gels and transferred 
overnight to PVDF membrane (Thermo Scientific, Waltham, MA, USA).  After transfer, 
Ponceau stains were imaged to verify equal loading. The membrane was blocked for 1 
hour in 5% milk-TBS-Tween 20, and incubated with primary antibodies at 1:2000 
dilution overnight at 4⁰C.  After several washes, membranes were incubated with 
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secondary antibodies at 1:2000 dilution for 1 hour.  Blots were visualized with 
WesternBright ECL (BioExpress, Kaysville, UT, USA).  IL-6r antibody was obtained 
from Santa Cruz Biotech (Santa Cruz, CA). STAT3, phopho-STAT3 (Y705), anti-mouse 
IgG, and anti-rabbit IgG antibodies were obtained from Cell Signaling (Danvers, MA, 
USA).   
IL-6R ELISA 
Muscle IL-6r protein content was determined using a commercial IL-6Ra ELISA 
(DuoSet, R&D Systems, Minneapolis, MN) as previously described. Briefly, Capture 
Antibody was used to coat wells of a clear 96-well EIA plate (Costar, Corning, Corning, 
NY) and allowed to incubate overnight.  The second day, plate was blocked for one hour 
using Reagent Diluent.  Plate was washed three times. Standards and samples were added 
and allowed to incubate for two hours.  After washes were repeated, Detection Antibody 
was added to wells and allowed to incubate for two hours.  Washes were repeated and 
Streptavidin-HRP was added to wells and allowed to incubate for twenty minutes.  After 
washes were repeated, Substrate Solution was added to wells and color was allowed to 
develop for twenty minutes.  Stop Solution was added and plate was read at 450 nm on a 
BioRad iMark plate reader (Carlsbad, CA).  
Statistical analysis 
All results are reported as means ± SEM.  Differences between B6, Weight stable, 
Severe, and OVX mice were determined by one-way ANOVA with Tukey post hoc 
where appropriate.  Differences between Sham + vector, Sham + IL-6, OVX + vector, 
and OVX + IL-6 mice were determined by two-way ANOVA with Tukey post hoc where 
appropriate.  Level of significance was set at 0.05 for all comparisons. 
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5.4 Results 
Canonical cachexia-related signaling with loss of ovarian function in female Apc
Min/+
 
mice 
Female B6 and Apc
Min/+
 mice were tracked until sacrifice at 18 weeks of age; a subset 
of mice from each genotype underwent ovariectomy (OVX) at 11 weeks of age.  Ovaries-
intact Apc
Min/+
 mice were classified based on body weight loss as weight stable (<1% 
body weight loss), moderately cachectic (1-10% body weight loss) or severely cachectic 
(>10% body weight loss).  These mice have previously been characterized (Chapter 4).  
Gastrocnemius muscle weight was significantly lower in severely cachectic female 
Apc
Min/+
 mice (>10% body weight loss) than in their weight stable (<1% body weight 
loss) counterparts (p=0.0006, Student’s t-test) (Figure 1A), indicating that muscle 
wasting is a key factor in weight loss with cachexia in the female.  Across ovaries-intact 
and OVX B6 and Apc
Min/+
 females, there was a strong trend for Apc
Min/+
 mice to have 
lower gastrocnemius mass than B6 (p=0.058, two-way ANOVA) (Figure 1A).  
Additionally, a pre-planned Student’s t-test determined that intact ApcMin/+ mice have 
lower gastrocnemius mass than intact B6 females (p=0.016) (Figure 1A). E3 ligases 
MuRF1 and Atrogin-1 are closely associated with cachexia-related muscle wasting [20]; 
these were next examined.  Severely cachectic Apc
Min/+
 mice had nearly a five-fold 
induction of MuRF1 gene expression compared to weight stable mice (p=0.0039) (Figure 
1B).  However, no differences were seen across intact and OVX B6 and Apc
Min/+
 mice by 
two-way ANOVA (Figure 1B).  A pre-planned t-test between control Apc
Min/+
 mice and 
OVX mice revealed a significantly lower expression in OVX mice (p=0.033, Student’s t-
test). Severely cachectic Apc
Min/+
 mice also trended towards an increase in Fbxo32 
(Atrogin-1) gene expression compared to weight stable counterparts (p=0.1064) (Figure 
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1C), while there was a strong trend towards an effect of genotype to increase Fbxo32 
gene expression in Apc
Min/+
 mice compared to B6 mice across intact and OVX mice 
(p=0.068) (Figure 1C).   
Canonical cachexia-related pathways with overexpression of IL-6 in ovariectomized 
female Apc
Min/+
 mice 
A second set of Apc
Min/+
 females underwent OVX and/or IL-6 overexpression to 
determine the effect of the interaction of ovarian function and induced IL-6 signaling on 
cachexia induction; these mice were sacrificed at 15 weeks and have been previously 
described (Chapter 4).  There was a main effect of IL-6 overexpression to decrease 
gastrocnemius muscle mass across ovaries-intact and OVX Apc
Min/+
 mice (p=0.044) 
(Figure 2A).  MuRF1 and Fbxo32 (Atrogin-1) gene expression were examined in these 
mice; however, there were no differences across any of the groups for these markers 
(Figure 2B, C). 
IL-6 receptor expression with loss of ovarian function in female Apc
Min/+
 mice  
We have previously shown IL-6 signaling in 18 week-old female Apc
Min/+
 mice to be 
dysregulated (compared to the Apc
Min/+
 male) during cachexia progression (Chapter 3) 
[15]. Here, we sought to determine whether this dysregulation is due to the influence of 
ovarian signaling.  In agreement with the previous cohort of 18-week females, here we 
found that IL6ra gene expression was highly induced compared to weight stable mice 
(p=0.0387) (Figure 3A) [15].  No differences were seen across B6 and Apc
Min/+
 intact and 
OVX mice, however; this was likely due to the wide variation across Apc
Min/+
 mice 
(Figure 3A). IL-6r protein was examined in intact and OVX Apc
Min/+
 females as well as 
B6 controls.  There was a significant difference across groups (p=0.0003, one-way 
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ANOVA); severely cachectic Apc
Min/+
 had significantly higher expression than all other 
groups (p<0.01 for each comparison, Tukey post hoc) (Figure 3B). Concurrently, there 
was a trend towards higher muscle gp130 gene expression in severe Apc
Min/+
 mice 
compared to weight stable (p=0.085) (Figure 3C). No differences were seen across intact 
and OVX B6 and Apc
Min/+
 mice (Figure 3C).  Muscle gp130 protein significantly differed 
between B6, weight stable, severe, and OVX mice (p=0.022, one-way ANOVA); 
however, a post hoc test showed no differences between specific groups (Figure 3D).  
IL-6-related downstream signaling with loss of ovarian function in female 
ApcMin/+
 mice 
Signaling downstream of the IL-6 receptor was analyzed to determine whether 
pathways activated by IL-6 were affected by ovarian function. Downstream of the 
receptor, protein expression of phosphorylated/total STAT3 (T389) was increased in 
severe 
ApcMin/+
 mice compared to B6 and weight stable (one-way ANOVA: p=0.002; 
p<0.01 for B6 and weight stable comparisons, Tukey post hoc); interestingly, severe 
Apc
Min/+
 mice did not differ from OVX (Figure 4A).  SOCS3 gene expression, a negative 
regulator of JAK/STAT3 signaling, is very highly induced in severe Apc
Min/+
 females 
compared to weight stable (p=0.022) (Figure 4B), similar to what we have seen 
previously [15]. There was no difference across intact and OVX B6 and Apc
Min/+
 mice, 
likely due to wide variation across the intact Apc
Min/+
 mice (Figure 4B). Phosphorylated 
AMPK (T172)/total AMPK, a downstream effector of IL-6 [60] that mediates energy 
partitioning and regulates mitochondrial biogenesis, showed no differences across 
groups, though there was wide variation within the severe group (one-way ANOVA) 
(Figure 4C). 
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IL-6 receptor expression and related downstream signaling with overexpression of IL-6 
in ovariectomized female Apc
Min/+
 mice 
 Gene expression of IL-6ra has been previously reported in the cohort of female 
Apc
Min/+
 mice having undergone OVX and/or IL-6 overexpression (Chapter 4) [15].  
Gp130 gene expression strongly trended towards an effect of IL-6 overexpression to 
increase across intact and OVX groups (p=0.056) as well as a trend towards an 
interaction of OVX x IL-6 (p=0.064) (Figure 5A).  Additionally, a pre-planned Student’s 
t-test revealed a sharp increase in gp130 gene expression in sham+IL-6 mice compared to 
control Apc
Min/+
 (p=0.043) (Figure 5A).  Gp130 protein expression was similar, with 
main effects of both IL-6 overexpression and OVX (p=0.0012 and 0.0003, respectively, 
two-way ANOVA).  Interestingly, pSTAT3/STAT3 (T389) showed a main effect of 
OVX to decrease STAT3 phosphorylation (p=0.006) (Figure 5C); this could have major 
implications for cachexia progression as STAT3 is a key point of regulation for several 
downstream effectors that lead to muscle wasting.  SOCS3 gene expression showed a 
strong trend towards an interaction of IL-6 x OVX (p=0.0553) (Figure 5D).  
Mitochondrial biogenesis, dynamics, and function with loss of ovarian function in female 
Apc
Min/+
 mice 
Mitochondrial function has been recognized over the past several years to be a 
key point of regulation in muscle wasting associated with several disease states including 
cachexia. PGC1α, a key regulator of mitochondrial biogenesis, showed no change 
between severe and weight stable Apc
Min/+
 mice, or between intact and OVX B6 and 
Apc
Min/+
 mice (Figure 6A). No differences were found between severe and weight stable, 
or between intact and OVX B6 and Apc
Min/+
 mice in Mfn1 and Fis1 gene expression 
(Figure 6B, C). Cytochrome c oxidase (COX) activity did not differ between weight 
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stable and severe Apc
Min/+
 mice (Figure 6D); among intact and OVX B6 and Apc
Min/+
 
mice, a main effect of OVX (p<0.0001), a main effect of genotype (p<0.0001), and an 
interaction between the two (p=0.0002) were determined by two-way ANOVA (Figure 
6D). B6 OVX mice had significantly higher activity than all other groups (p<0.0001 per 
comparison, Tukey post hoc); and Apc
Min/+
 mice had significantly lower activity than B6 
mice (p<0.05) (Figure 6D).  
Mitochondrial biogenesis, dynamics, and function with overexpression of IL-6 in 
ovariectomized female Apc
Min/+
 mice 
Among 15-week old female Apc
Min/+
 mice, there was no effect of IL-6 or OVX on 
PGC1α gene expression (Figure 7A).  There was a main effect of IL-6 overexpression to 
decrease Mfn1 gene expression among both intact and OVX Apc
Min/+
 mice (p=0.0297) 
(Figure 7B).    There were no differences among groups on Fis1 gene expression (Figure 
7C).  
5.5 Discussion 
This series of experiments has shown that the loss of ovarian function by ovariectomy 
has drastic consequences on muscle metabolism during cancer cachexia progression in 
the female.  The purpose of this study was to determine whether ovarian function 
regulated muscle signaling during cachexia; we had hypothesized that the loss of ovarian 
function during cancer cachexia would be akin to opening the metaphorical floodgates 
and allowing cachectic factors that would normally be inhibited by estrogen or other 
ovarian products or signaling to run their course, as in the male.  Our results, however, 
were striking.  OVX, when compared to intact Apc
Min/+ 
females, seemed to alleviate many 
of the cachectic markers that lead to muscle wasting.  Importantly, OVX Apc
Min/+
 mice 
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did not only maintain muscle mass; they actually gained muscle mass despite a similar 
tumor burden to intact Apc
Min/+
 mice (Table 1, Table 2).  OVX mice, in addition, had 3-
fold lower MuRF1 gene expression than intact Apc
Min/+ 
mice (Figure 1B), indicating one 
point of muscle wasting regulation that was attenuated by OVX.   This is in contrast to a 
previous report which saw an increase in MuRF1 with OVX [87]. Interestingly, this 
downregulation of Murf1 by OVX is not seen at 15 weeks (Figure 2B).  It is possible that, 
as 15 weeks is “early cachexia,” the E3 ligases may not yet have assumed their roles in 
muscle wasting; this may not occur until later in cachexia, which we see at 18 week.  
This is supported by the expression pattern of MuRF1’s co-conspirer, Atrogin-1.  At 15 
weeks, we see no change across groups, while at 18 weeks we see a drastic upregulation 
of Fbxo32 (Atrogin-1) gene expression in Apc
Min/+ 
mice.  Another area where OVX has 
an effect is in the mitochondria.  While there were few changes in markers of 
mitochondrial biogenesis or dynamics, COX activity showed a main effect of OVX to 
increase activity (Figure 6D).  This is striking, as COX activity is a measure of 
mitochondrial function.   Going a step further, this increase in COX activity despite 
cachexia progression may indicate a true alleviation of mitochondrial dysregulation by 
OVX.  As COX is a subunit of complex IV in the electron transport chain, this is an 
indication that mitochondria of OVX mice may be better able to meet energy demands, 
and this may contribute to the overall healthier muscle phenotype seen in OVX mice. 
A second hypothesis of this study was that loss of ovarian function would disinhibit 
IL-6 signaling, allowing IL-6 signaling to progress cachexia development as in the male. 
Our results to this end show some intriguing relationships between ovarian function, Il-6, 
and IL-6 signaling.  OVX’s effect on IL-6 signaling went against our original hypothesis, 
 121 
 
but has raised some interesting questions and uncovered some new relationships between 
these factors.  IL-6R protein was lower in OVX mice than in severely cachectic Apc
Min/+
 
mice (Figure 3B), despite similar IL-6 circulating levels (data not shown) (Chapter 4).  
As further evidence that OVX can downregulate IL-6 signaling, there was a main effect 
of OVX to decrease gp130 protein levels, even when IL-6 levels are maintained at a high 
level (Figure 5B).  Interestingly, STAT3 activation did not differ between severe mice 
and OVX mice at 18 weeks of age (Figure 4A), leading to speculation that another factor 
may be activating the pathway in OVX mice. However, in our 15-week experiment, there 
was a main effect of OVX to decrease STAT3 activation.  It is interesting to postulate the 
mechanisms at play here- perhaps in early cachexia, OVX is sufficient to suppress IL-6 
signaling, but in later stages of cachexia, other cachectic factors are able to activate 
STAT3 despite OVX’s effect on IL-6 signaling.   
Some of the most interesting findings emerged from the comparison between OVX 
Apc
Min/+ 
mice and OVX+IL-6 Apc
Min/+
 mice, further complicating the interaction between 
these two factors.  For some measures, such as gp130 protein (Figure 5B), OVX+IL-6 
was able to rescue expression where OVX alone had downregulated it compared to the 
control Apc
Min/+
.  Though a comparison between OVX and OVX+IL-6 with regard to 
AMPK activation did not reach significance due to a high amount of variation in the 
latter group, it seems that OVX and IL-6 have a synergistic effect to increase AMPK 
activation, while all other groups, including the sham + IL-6 geoups, showed no increase 
over the control Apc
Min/+
 group. 
Another intriguing pattern emerged through this study; many of the pathways we 
consider “canonical” to the progression of cachexia in the male are dysregulated, if they 
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play a part at all, in the female. We closely examined the IL-6 signaling pathway 
previously (Chapter 3) [15] For instance, IL-6, which is known to induce MuRF1 and 
Atrogin-1 during cachexia in the male [20, 60], fails to do so even when IL-6 levels are 
kept very high.   Of course, this in the 15-week mice, where muscle wasting may not yet 
have begun in earnest.  However, when we examine MuRF1 gene expression between 
severely cachectic females and 18-week females with IL-6 overexpression, we get a 
striking result- MuRF1 expression actually trends lower in the IL-6 overexpression mice 
(Supplemental Data).   AMPK, a key energy-sensing enzyme that plays a central, if 
paradoxical, role in cachexia development [60] and mitochondrial biogenesis, showed no 
increase across groups in either the 18-week of 15-week experiment.  This is in direct 
contrast to the male Apc
Min/+
 mouse, where were see a robust induction of AMPK 
activation during cachexia progression.  On the mitochondrial side, severely cachectic 
males typically have a severe drop in PGC1a expression [14], while we saw a trend 
toward higher PGC1α expression in severely cachectic females.  Intriguingly, PGC1α 
overexpression has been shown to protect from atrophy due to conditions including 
cachexia [105].  Further, male typically show an increase in Fis1 expression [14], a 
marker of a pathway that can lead to mitochondrial fragmentation and mitophagy [14]; 
here, we see no induction of Fis1 even in the severely cachectic 18-week mice.  These 
findings point to a more global network of differences between male and female 
cachectic signaling than simply the IL-6 pathway.  
We have thus shown that female cachexia progression can be interrupted and 
alleviated by the removal of ovaries.  This is of interest, as many cell culture and animal 
models have suggested that estrogen can block IL-6 transcription and downstream 
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signaling [27, 97, 164].  Additionally, we have shown that sex differences in cachexia 
extend far beyond the IL-6 signaling pathway.  This work raises many important 
questions: mechanistically, how does OVX affect IL-6 signaling?  What are the specific 
factors at play?  What is the mechanism of the synergy between OVX and IL-6 to 
increase signals that are not increased by either alone.  Clearly, future work is needed in 
each of these areas to achieve a more complete picture of the female response to 
cachexia. 
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Table 5.1: Descriptive characteristics of 18-week female C57BL/6 and Apc
Min/+ 
mice 
stratified into groups based on body weight change from 15-18 weeks of age.  N=43 mice 
total; remaining ApcMin/+ mice (n=8) not shown fell between cutoff points for “Weight 
stable” and “Cachectic.” B6, C57BL/6; Weight stable, female ApcMin/+ with <2% body 
weight loss from peak; Cachectic, female Apc
Min/+  
with >9% body weight loss from peak; 
OVX, ovariectomized at 11 weeks of age;  N, number; BW, body weight; w, weeks of 
age; pg, picograms; ml, milliliter; mg, milligrams; mm, millimeters. * Indicates 
significant difference from B6 (p<0.05);  ^ indicates significant difference from weight 
stable Apc
Min/+
; # indicates difference from Cachectic Apc
Min/+
. Significance was set at 
p<0.05 for all comparisons. 
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Table 5.2: Descriptive characteristics of female ApcMin/+ mice treated by ovariectomy, 
IL-6 overexpression, or both.  Mice were ovariectomized at 11 weeks, electroporated 
with IL-6 overexpression vector at 13 weeks, and sacrificed at 15 weeks. OVX, 
ovariectomy; IL-6, interleukin-6; N, number; 15w, 15 weeks of age; BW, body weight; g, 
grams; mm, millimeters; mg, milligrams; TL, tibia length.  * indicates main effect of 
OVX; # indicates main effect of IL-6; & indicates interaction of OVX x IL-6 (determined 
by two-way ANOVA).   Means with same superscript lowercase letters indicates 
significant difference between columns (Tukey post hoc, p<0.05) 
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5.7 Figure Legends 
Figure 5.1: Canonical cachexia-related pathways with loss of ovarian function in 
female Apc
Min/+ 
mice. A) (Left) Gastrocnemius muscle mass in weight stable and 
severely cachectic female ApcMin/+ mice. Severely cachectic mice had a significantly 
different mass than weight stable (p=0.0006). (Right) Gastrocnemius muscle mass in 
intact and OVX female C57BL/6 and ApcMin/+ mice. There was a trend towards a main 
effect of genotype (p=0.058); intact B6 significantly differed from intact ApcMin/+ by 
pre-planned Student’s t-test (p=0.016). B) (Left) MuRF1 gene expression fold change in 
weight stable and severely cachectic female ApcMin/+ mice. Severely cachectic mice 
significantly differed from weight stable (p=0.0039). (Right) MuRF1 gene expression 
fold change in intact and OVX female C57BL/6 and ApcMin/+ mice. No differences 
were detected by two-way ANOVA. C) (Left) Fbxo32 (Atrogin 1) gene expression fold 
change in weight stable and severely cachectic female ApcMin/+ mice. Severely 
cachectic mice trended towards a difference from weight stable (p=0.1064). (Right) 
Fbxo32 (Atrogin 1) gene expression fold change in intact and OVX female C57BL/6 and 
ApcMin/+ mice. There was a trend towards an effect of genotype (p=0.068) detected by 
two-way ANOVA. * indicates significant difference from weight stable. $ indicates 
significant difference from intact B6.  # indicates significant difference from intact 
ApcMin/+ Significance was set at p<0.05. 
Figure 5.2: Canonical cachexia-related pathways with overexpression of IL-6 in 
ovariectomized female Apc
Min/+ 
mice. A) Gastrocnemius muscle mass (mg) in control, 
OVX, IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of IL-6 
overexpression was detected by two-way ANOVA (p=0.044). B) Muscle MuRF1 gene 
expression in control, OVX, IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. 
No significant differences between groups were determined by two-way ANOVA.  C) 
Muscle Fbxo32 (Atrogin1) gene expression in control, OVX, IL-6 overexpression, and 
OVX+IL-6 female Apc
Min/+ 
mice.  No significant differences were determines by two-
way ANOVA. Significance was set at p<0.05. 
Figure 5.3: IL-6 receptor expression with loss of ovarian function in female 
ApcMin/+ mice. A)  (Left) Muscle IL6ra gene expression fold change in weight stable 
and severely cachectic female ApcMin/+ mice. Severely cachectic mice significantly 
differed from weight stable (p=0.0387). (Right) Muscle IL6ra gene expression fold 
change in intact and OVX female C57BL/6 and ApcMin/+ mice. No significant 
differences were determined by two-way ANOVA. B) Muscle IL-6r protein in B6, 
weight stable, severely cachectic, and OVX ApcMin/+ mice. A difference between 
groups was determined by one-way ANOVA (p=0.0003); severe is significantly different 
from B6, weight stable, and OVX groups (p<0.01 per comparison, Tukey post hoc). C) 
(Left) Muscle gp130 gene expression fold change in weight stable and severely cachectic 
female ApcMin/+ mice. There was a trend towards a difference detected by Student’s t-
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test (p=0.085). (Right) Muscle gp130 gene expression fold change in intact and OVX 
female C57BL/6 and ApcMin/+ mice. No significant differences were determined by 
two-way ANOVA.  D) Muscle gp130 protein in weight stable, severe, and OVX groups. 
A significant difference between groups was determined by one-way ANOVA (p=0.022); 
however, no differences between groups were determined by Tukey post hoc. * indicates 
significant difference from weight stable; # indicates significant difference from OVX; $ 
indicates significant difference from B6. Significance was set at p<0.05 for all measures. 
Figure 5.4: IL-6-related downstream signaling with loss of ovarian function in 
female ApcMin/+ mice. A) Muscle pSTAT3/STAT3  protein in B6, weight stable, 
severe, and OVX ApcMin/+ groups. A significant difference between groups was 
determined by one-way ANOVA (p=0.002). Severe is significantly different from B6 and 
weight stable groups (p<0.01 per comparison, Tukey post hoc). B)  (Left) Muscle SOCS3 
gene expression fold change in weight stable and severely cachectic female ApcMin/+ 
mice. Severely cachectic mice significantly differed from weight stable (p=0.022). 
(Right) Muscle SOCS3 gene expression fold change in intact and OVX female C57BL/6 
and ApcMin/+ mice. No significant differences were determined by two-way ANOVA. 
C) Muscle pAMPK/AMPK  protein in B6, weight stable, severe, and OVX ApcMin/+ 
groups. No significant differences between groups were determined by one-way 
ANOVA. * indicates significant difference from weight stable; $ indicates significant 
difference from B6. Significance was set at p<0.05 for all measures. 
Figure 5.5: IL-6 receptor expression and related downstream signaling with 
overexpression of IL-6 in ovariectomized female Apc
Min/+ 
mice. A) Muscle gp130 gene 
expression fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 groups. 
Two-way ANOVA determined a trend towards main effect of IL-6 (p=0.056) and trend 
towards interaction of OVX x IL-6 (p=0.064).  Pre-planned Student’s t-test indicated a 
significant difference between control ApcMin/+ and sham+ IL-6 group (p=0.043). B) 
Muscle gp130 protein in control, OVX, IL-6 overexpression, and OVX+IL-6 female 
Apc
Min/+ 
mice. Main effects of OVX (p=0.0003) and IL-6 (p=0.0012) were determined by 
two-way ANOVA. C) Muscle pSTAT3/STAT3 protein in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of OVX was 
determined by two-way ANOVA (p=0.006). D) Muscle SOCS3 gene expression fold 
change in control, OVX, IL-6 overexpression, and OVX+IL-6 groups. A trend towards an 
interaction between OVX x IL-6 was determined by two-way ANOVA (p=0.0553).  A 
trend towards a difference between control and IL-6 + sham groups was determined by 
Student’s t-test (p=0.075). E) Muscle pAMPK/AMPK protein in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. No significant differences between 
groups were determined by two-way ANOVA.  * indicates significant difference from 
control ApcMin/+.  Significance was set at p<0.05 for all measures. 
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Figure 5.6: Mitochondrial biogenesis, dynamics, and function with loss of ovarian 
function in female ApcMin/+ mice. A) (Left) Muscle PGC1a gene expression fold 
change in weight stable and severely cachectic female ApcMin/+ mice. There was no 
difference between the groups (p=0.167). (Right) Muscle PGC1a gene expression in 
intact and OVX female C57BL/6 and ApcMin/+ mice. No significant differences were 
detected by two-way ANOVA.  B) (Left) Muscle Mfn1 gene expression fold change in 
weight stable and severely cachectic female ApcMin/+ mice. There was no difference 
between the groups (p=0.122). (Right) Muscle Mfn1 gene expression fold change in 
intact and OVX female C57BL/6 and ApcMin/+ mice. No differences were detected by 
two-way ANOVA. C) (Left) Muscle Fis1 gene expression fold change in weight stable 
and severely cachectic female ApcMin/+ mice. There was no difference between the 
groups (p=0.444). (Right) Muscle Fis1 gene expression fold change in intact and OVX 
female C57BL/6 and ApcMin/+ mice. D) (Left) Muscle COX activity in weight stable 
and severely cachectic female ApcMin/+ mice. There was no difference between the 
groups (p=0.29). (Right) Muscle COX activity in intact and OVX female C57BL/6 and 
ApcMin/+ mice. A main effect of genotype (p<0.0001), a main effect of OVX 
(p<0.0001), and an interaction between the two (p=0.0002) were determined by two-way 
ANOVA. Tukey post hoc determined that the B6 OVX was significantly different from 
all other groups (p<0.0001 for each comparison) and that ApcMin/+ was significantly 
different from B6 (p<0.05). $ indicates significant difference from B6; & indicates 
significant difference from all other groups. Significance was set at p<0.05. 
Figure 5.7: Mitochondrial biogenesis, dynamics, and function with overexpression 
of IL-6 in ovariectomized female Apc
Min/+ 
mice. A) Muscle PGC1a gene expression 
fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 groups. No 
differences were determined by two-way ANOVA.  B) Muscle Mfn1 gene expression 
fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. 
A main effect of Il-6 was determined by two-way ANOVA (p=0.0297). C) Muscle Fis1 
gene expression fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 
female Apc
Min/+ 
mice. No differences were determined by two-way ANOVA. 
Significance was set at p<0.05 for all measures. 
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 Figure 5.1: Canonical cachexia-related pathways with loss of ovarian 
function in female Apc
Min/+ 
mice. A) (Left) Gastrocnemius muscle mass in weight stable 
and severely cachectic female ApcMin/+ mice. Severely cachectic mice had a 
significantly different mass than weight stable (p=0.0006). (Right) Gastrocnemius muscle 
mass in intact and OVX female C57BL/6 and ApcMin/+ mice. There was a trend towards 
a main effect of genotype (p=0.058); intact B6 significantly differed from intact 
ApcMin/+ by pre-planned Student’s t-test (p=0.016). B) (Left) MuRF1 gene expression 
fold change in weight stable and severely cachectic female ApcMin/+ mice. Severely 
cachectic mice significantly differed from weight stable (p=0.0039). (Right) MuRF1 gene 
expression fold change in intact and OVX female C57BL/6 and ApcMin/+ mice. No 
differences were detected by two-way ANOVA. C) (Left) Fbxo32 (Atrogin 1) gene 
expression fold change in weight stable and severely cachectic female ApcMin/+ mice. 
Severely cachectic mice trended towards a difference from weight stable (p=0.1064). 
(Right) Fbxo32 (Atrogin 1) gene expression fold change in intact and OVX female 
C57BL/6 and ApcMin/+ mice. There was a trend towards an effect of genotype 
(p=0.068) detected by two-way ANOVA. * indicates significant difference from weight 
stable. $ indicates significant difference from intact B6.  # indicates significant difference 
from intact ApcMin/+ Significance was set at p<0.05. 
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 Figure 5.2: Canonical cachexia-related pathways with overexpression of IL-6 
in ovariectomized female Apc
Min/+ 
mice. A) Gastrocnemius muscle mass (mg) in 
control, OVX, IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect 
of IL-6 overexpression was detected by two-way ANOVA (p=0.044). B) Muscle MuRF1 
gene expression in control, OVX, IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. No significant differences between groups were determined by two-way ANOVA.  
C) Muscle Fbxo32 (Atrogin1) gene expression in control, OVX, IL-6 overexpression, and 
OVX+IL-6 female Apc
Min/+ 
mice.  No significant differences were determines by two-
way ANOVA. Significance was set at p<0.05. 
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 Figure 5.3: IL-6 receptor expression with loss of ovarian function in female 
ApcMin/+ mice. A)  (Left) Muscle IL6ra gene expression fold change in weight stable 
and severely cachectic female ApcMin/+ mice. Severely cachectic mice significantly 
differed from weight stable (p=0.0387). (Right) Muscle IL6ra gene expression fold 
change in intact and OVX female C57BL/6 and ApcMin/+ mice. No significant 
differences were determined by two-way ANOVA. B) Muscle IL-6r protein in B6, 
weight stable, severely cachectic, and OVX ApcMin/+ mice. A difference between 
groups was determined by one-way ANOVA (p=0.0003); severe is significantly different 
from B6, weight stable, and OVX groups (p<0.01 per comparison, Tukey post hoc). C) 
(Left) Muscle gp130 gene expression fold change in weight stable and severely cachectic 
female ApcMin/+ mice. There was a trend towards a difference detected by Student’s t-
test (p=0.085). (Right) Muscle gp130 gene expression fold change in intact and OVX 
female C57BL/6 and ApcMin/+ mice. No significant differences were determined by 
two-way ANOVA.  D) Muscle gp130 protein in weight stable, severe, and OVX groups. 
A significant difference between groups was determined by one-way ANOVA (p=0.022); 
however, no differences between groups were determined by Tukey post hoc. * indicates 
significant difference from weight stable; # indicates significant difference from OVX; $ 
indicates significant difference from B6. Significance was set at p<0.05 for all measures. 
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 Figure 5.4: IL-6-related downstream signaling with loss of ovarian function 
in female ApcMin/+ mice. A) Muscle pSTAT3/STAT3  protein in B6, weight stable, 
severe, and OVX ApcMin/+ groups. A significant difference between groups was 
determined by one-way ANOVA (p=0.002). Severe is significantly different from B6 and 
weight stable groups (p<0.01 per comparison, Tukey post hoc). B)  (Left) Muscle SOCS3 
gene expression fold change in weight stable and severely cachectic female ApcMin/+ 
mice. Severely cachectic mice significantly differed from weight stable (p=0.022). 
(Right) Muscle SOCS3 gene expression fold change in intact and OVX female C57BL/6 
and ApcMin/+ mice. No significant differences were determined by two-way ANOVA. 
C) Muscle pAMPK/AMPK  protein in B6, weight stable, severe, and OVX ApcMin/+ 
groups. No significant differences between groups were determined by one-way 
ANOVA. * indicates significant difference from weight stable; $ indicates significant 
difference from B6. Significance was set at p<0.05 for all measures. 
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 Figure 5.5: IL-6 receptor expression and related downstream signaling with 
overexpression of IL-6 in ovariectomized female Apc
Min/+ 
mice. A) Muscle gp130 gene 
expression fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 groups. 
Two-way ANOVA determined a trend towards main effect of IL-6 (p=0.056) and trend 
towards interaction of OVX x IL-6 (p=0.064).  Pre-planned Student’s t-test indicated a 
significant difference between control ApcMin/+ and sham+ IL-6 group (p=0.043). B) 
Muscle gp130 protein in control, OVX, IL-6 overexpression, and OVX+IL-6 female 
Apc
Min/+ 
mice. Main effects of OVX (p=0.0003) and IL-6 (p=0.0012) were determined by 
two-way ANOVA. C) Muscle pSTAT3/STAT3 protein in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. A main effect of OVX was 
determined by two-way ANOVA (p=0.006). D) Muscle SOCS3 gene expression fold 
change in control, OVX, IL-6 overexpression, and OVX+IL-6 groups. A trend towards an 
interaction between OVX x IL-6 was determined by two-way ANOVA (p=0.0553).  A 
trend towards a difference between control and IL-6 + sham groups was determined by 
Student’s t-test (p=0.075). E) Muscle pAMPK/AMPK protein in control, OVX, IL-6 
overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. No significant differences between 
groups were determined by two-way ANOVA.  * indicates significant difference from 
control ApcMin/+.  Significance was set at p<0.05 for all measures. 
 134 
 
 
 Figure 5.6: Mitochondrial biogenesis, dynamics, and function with loss of 
ovarian function in female ApcMin/+ mice. A) (Left) Muscle PGC1a gene expression 
fold change in weight stable and severely cachectic female ApcMin/+ mice. There was no 
difference between the groups (p=0.167). (Right) Muscle PGC1a gene expression in 
intact and OVX female C57BL/6 and ApcMin/+ mice. No significant differences were 
detected by two-way ANOVA.  B) (Left) Muscle Mfn1 gene expression fold change in 
weight stable and severely cachectic female ApcMin/+ mice. There was no difference 
between the groups (p=0.122). (Right) Muscle Mfn1 gene expression fold change in 
intact and OVX female C57BL/6 and ApcMin/+ mice. No differences were detected by 
two-way ANOVA. C) (Left) Muscle Fis1 gene expression fold change in weight stable 
and severely cachectic female ApcMin/+ mice. There was no difference between the 
groups (p=0.444). (Right) Muscle Fis1 gene expression fold change in intact and OVX 
female C57BL/6 and ApcMin/+ mice. D) (Left) Muscle COX activity in weight stable 
and severely cachectic female ApcMin/+ mice. There was no difference between the 
groups (p=0.29). (Right) Muscle COX activity in intact and OVX female C57BL/6 and 
ApcMin/+ mice. A main effect of genotype (p<0.0001), a main effect of OVX 
(p<0.0001), and an interaction between the two (p=0.0002) were determined by two-way 
ANOVA. Tukey post hoc determined that the B6 OVX was significantly different from 
all other groups (p<0.0001 for each comparison) and that ApcMin/+ was significantly 
different from B6 (p<0.05). $ indicates significant difference from B6; & indicates 
significant difference from all other groups. Significance was set at p<0.05. 
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Figure 5.7: Mitochondrial biogenesis, dynamics, and function with overexpression 
of IL-6 in ovariectomized female Apc
Min/+ 
mice. A) Muscle PGC1a gene expression 
fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 groups. No 
differences were determined by two-way ANOVA.  B) Muscle Mfn1 gene expression 
fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 female Apc
Min/+ 
mice. 
A main effect of Il-6 was determined by two-way ANOVA (p=0.0297). C) Muscle Fis1 
gene expression fold change in control, OVX, IL-6 overexpression, and OVX+IL-6 
female Apc
Min/+ 
mice. No differences were determined by two-way ANOVA. 
Significance was set at p<0.05 for all measures. 
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CHAPTER 6 
OVERALL DISCUSSION 
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The overall purpose of this study was to determine whether ovarian function 
could alter cachexia progression in female Apc
Min/+ 
mice through IL-6 signaling and he 
regulation of skeletal muscle metabolism. Through the completion of these three studies, 
we have shown that IL-6 signaling during cancer cachexia is differentially regulated in 
females compared to males, and that ovarian function certainly plays a role in the 
regulation of said IL-6 signaling.  Additionally, ovarian function is very much able to 
regulate muscle metabolic signaling.  Overall, we achieve the purpose of this study and 
showed that ovarian function has a large role in the regulation of cachexia progression; 
however, perhaps not the way we had anticipated.  The working overall hypothesis for 
this study was that loss of ovarian function in the female Apc
Min/+
 mouse would have 
aggravated progression of cachexia through altered IL-6 sensitivity, which would 
increase skeletal muscle dysfunction and lead to aggravated muscle wasting.  As we 
would later find out, “ovarian loss” is not so simple.  The loss of ovarian function due to 
disease, termed “Cycle Absent” in the second study (Chapter 4) turned out to be a very 
different phenotype from the loss of ovarian function by surgery, as shown by the OVX 
group of mice in the second and third studies (Chapters 4 and 5).  While Cycle Absent 
mice certainly did have an accelerated progression of cachexia and were the most 
severely cachectic female Apc
Min/+
 mice, including the most severe muscle wasting, the 
OVX Apc
Min/+
 mice surprisingly were alleviated of many cachectic markers.  While this 
could not have been expected at the beginning of these studies, the differences between 
ovarian dysfunction due to disease and ovarian function loss ovariectomy were important 
findings (which naturally led to more questions) that had ramifications for cachexia 
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progression and may one day lead to improved understanding and consideration of the 
ovary’s role in human disease. 
This series of studies’ legacy may be that it uncovered major differences in 
signaling between males and females.   The first study (Chapter 3) focused on differences 
in IL-6 signaling, but we found differences in the third study (Chapter 5) as well, in 
signaling unrelated to IL-6.  While the NIH has made strides for the inclusion of female 
animals in biomedical research, these studies show why is it not sufficient to only 
examine one sex in complex disease models; further, why the sexes need to be analyzed 
separately.  Had we analyzed males and females together for certain markers in Chapter 
3, no change would have been found, but this would have been obscuring the truth.  
Specifically, it was shown that male Apc
Min/+
 mice  have a decrease in SOCS3 protein 
compared to B6 controls, while female Apc
Min/+
 mice have an increase in SOCS3 protein 
compared to B6 females (Chapter 3) [15].  This may be a key point of differential 
regulation between the sexes during cachexia; SOCS3 is a major negative regulator of 
STAT3 signaling ad may help to explain why, at least initially, females do not experience 
cachexia progression that is as severe as males.  In addition to males having a higher 
level of circulating IL-6 during cachexia, male Apc
Min/+
 mice have a higher level of 
muscle IL-6r protein than females.  Surprisingly, it was shown that even among B6 
animals, males have three-fold higher expression of IL-6R protein in muscle, which may 
help explain why males seem to be more sensitive to IL-6 signaling.  Beyond IL-6 
signaling, it was shown in Chapter 5 that severely cachectic females have a trend towards 
an increase in PGC1α gene expression over their weight stable counterparts; we have 
previously shown that severely cachectic males show a decrease in PGC1α expression 
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[14].  Additionally, while male ApcMin/+ mice show a strong induction of AMPK with 
cachexia severity [60], females showed no changes in AMPK activation across severity 
groups. AMPK is a downstream effector of IL-6 [60], so this may be due to differences in 
IL-6 signaling and sensitivity between the sexes.  While the difference in PGC1α hints at 
mitochondrial differences, we found several more differences within the mitochondria. 
While there was no change across female severity groups or even a difference between 
B6 and ApcMin/+ in Mfn1 gene expression, which plays a key role in mitochondrial 
fusion, ApcMin/+ male show a drastic decrease in this protein [14].  Accordingly, while 
we see no changes across severity groups or genotype for Fis1, a regulator of 
mitochondrial fission, this protein is drastically induced in severely cachectic Apc
Min/+ 
males.  The concurrent drop in mitochondrial fusion and increase in fission points to 
dysregulated mitochondrial dynamics and can lead to increased mitophagy [14].  We see 
no evidence of this dysregulation in the female however, which may indicate that the 
mitochondria is not a major factor in the etiology of cachexia-related muscle wasting as it 
is in the male [14]. Even among basic descriptive characteristics of male and female 
Apc
Min/+
 mice, it was found that we had to modify classifications for the female.  While 
we have previously classified “severe” males as having lost >20% body weight [14, 60, 
106], not a single female Apc
Min/+
 survived to that level of weight loss. Instead, the 
“severe” classification was modified to >9-10% body weight loss in the female, as these 
animals were truly sick at this point by multiple measures. 
Beyond sex differences, we found striking differences between females with 
different ovarian statuses.  In Chapter 4, female Apc
Min/+
 mice were classified as “Cycle 
Present” or “Cycle Absent” depending on whether their estrus cycles had ceased 
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secondary to disease progression.  At first glance, it was assumed that “Cycle Absent” 
ovaries had simply shut down and would show results similar to those of OVX mice.  
This could not have been further from what the results actually showed.  While “Cycle 
Absent” mice were eventually found to have a phenotype more similar to polycystic 
ovarian syndrome, including higher ovarian AMH gene expression, lower circulating sIL-
6r  and lower circulating leptin [42, 67, 151], than to menopausal animals or 
ovariectomized animals as we had previously assumed, the differences between these 
mice and OVX mice could not have been further apart.  Cycle Absent mice represented 
the most severe group of female Apc
Min/+
 mice, with all mice that ceased cycling losing 
more than 9% of their peak body weight (data not shown).  Results were most striking 
when Cycle Absent and OVX were directly compared, as they were with morphological 
and functional data in Chapter 4.  Though, importantly, food intake was the same across 
all groups from B6 to Cycle Absent Apc
Min/+
 to OVX Apc
Min/+
, Cycle Absent lost a drastic 
amount of fat and muscle while OVX mice gained weight; this indicates a severe 
metabolic dysregulation in the Cycle Absent mice.  Across functional measures as well, 
OVX outperformed Cycle Absent mice.  Interestingly, Cycle Absent mice showed a 
definite increase in sensitivity to inflammation independent of IL-6 levels.   In our 15-
week cohort of mice of which some had IL-6 overexpressed, these animals were unable 
to induce the inflammation seen in the Cycle Absent mice.  Questions remain, however, 
about the etiology of estrus cycle cessation with disease.  While the cessation clearly 
leads to deleterious outcomes, it is unknown what signaling is involved in causing this 
ovarian dysfunction.  While the majority of women with cachexia secondary to cancer are 
menopausal [44, 58], many cancers that can lead to cachexia certainly do occur in women 
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of childbearing age [101].  If this same ovarian dysfunction can happen in humans, this is 
truly frightening, not to mention a currently unknown effect of cachexia in women. 
It would seem, with all the data among these three studies, that ovariectomy is the 
answer to cachexia in females.  This is certainly not what had been hypothesized, but the 
data is striking.  Chapter 4 reveals that OVX Apc
Min/+ 
mice have higher body weight, 
stronger muscles, larger muscles, an improved function compared to their ovaries-intact 
counterparts.  Additionally, OVX is associated with a decrease in circulating IL-6 and 
other circulating inflammatory factors, as well as decreased inflammatory signaling 
within the muscle which is surprising given estrogen’s known anti-inflammatory effects 
[26, 37].  It is likely, however, that this decrease in inflammatory signaling is contributing 
to the improved functional and morphological outcomes of these mice.  Further, the 
decreased inflammatory signaling may be related to improved measures in Chapter 5.  
For instance, OVX ApcMin/+ females have decreased MuRF1 gene expression than their 
intact counterparts; this could be a downstream effect of lower systemic inflammatory 
burden.  OVX had a main effect across B6 and ApcMin/+ genotypes to decrease gp130 
protein expression as well as STAT3 activation; this could effectively slow IL-6 signaling 
in ApcMin/+ mice to a fraction of what it would be in intact ApcMin/+ mice, having 
wide-reaching effects as IL-6 signaling leads to several downstream pathways [11], all of 
which culminate in muscle wasting [11].  Intriguingly, there is some interplay between 
OVX and IL-6 when IL-6 expression is kept at a constant level, as in our experiment with 
15-week mice in Chapters 4 and 5. While 15-week OVX mice continued to grow during 
the experimental timeframe, as did the 18-week OVX mice, the addition of a constantly 
higher level of circulating IL-6 blunted this growth, the majority of which was lean mass 
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(Chapter 4).  This same effect was not seen between control ApcMin/+ and sham + IL-6 
mice, indicating an interaction between OVX and IL-6 that deserves further exploration. 
While this series of studies has answered many important questions and cemented 
the importance of investigating female animals as well as males, there are many new 
questions to be answered and much work still to be done.  We have successfully shown 
multiple differences across several pathways where female animals differ from males 
during cachexia progression, but we are far from uncovering the whole picture.   
Cachexia even within male animals is still being elucidated piece-by-piece, and this adds 
another layer of complexity to the discovery of therapeutic targets and the eventual 
clinical utility of perhaps sex-specific treatments. While the results from OVX mice are 
striking, it will be important to parse out the specific mechanisms at work.  The ovary is a 
hub of endocrine signaling in the female body, with its two largest exports being estrogen 
and progesterone.  Estrogen has known anti-inflammatory properties [26, 37] and is 
known to inhibit IL-6 and downstream signaling [25, 27, 37, 92, 97], while its sister 
progesterone (and its analogs) has been used clinically to increase appetite and relieve 
some symptoms in cachectic patients [3].  Why, then, does the ablation of these factors 
along with the ovary lead to improved outcomes?   
While there is still much work to be done not only on the further elucidation of 
cachectic mechanisms and their sex-specific roles, but in discovering therapeutic targets 
that are not too specific to alleviate the web of complexity that is cancer cachexia, there is 
reason to be optimistic.  While IL-6-specific blockades have had mixed results in clinical 
trials [12, 126] (possibly due to the enigmatic role of IL-6 in female cachexia?), perhaps 
insight into the vast differences between the sexes will lead to sex-specific treatments.  
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Research into both sexes will facilitate this, and upon seeing the optimistic results in 
OVX Apc
Min/+ 
mice, perhaps there are helpful lessons to be learned from the ovary, as 
well.   
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A.1 Animals 
Female Apc 
Min/+
mice (n=75) and female C57BL/6 mice (n=12) were bred and 
maintained at the University of South Carolina Animal Resource Facility.   Apc
Min/+ 
mice 
used were on a C57BL/6 background and were offspring from breeders originally 
purchased from Jackson Labs (Bar Harbor, ME, USA).   Mice were kept on a 12:12h 
light/dark cycle beginning at 7:00 AM and were given unrestricted access to standard 
rodent chow (Harlan Teklad Rodent Diet, #8604, Harlan, Indianapolis, IN, USA).  Mice 
were weighed weekly.  Food intake was measured at 12 and 18 weeks of age.  All 
experiments were approved by the University of South Carolina’s Institutional Animal 
Care and Use Committee.  Mice were sacrificed at 18 or 15 weeks using the following 
recipe to anesthetize before tissue dissection: 
 
 
 
 
A.2 Determination of estrus cycling and stage of cycle 
Female Apc 
Min/+ 
and C57BL/6 mice had estrus cycling tracked from 10 weeks of age 
until sacrifice at 18 weeks of age as follows: 
1. A sterile cotton swab was dipped in sterile 0.9% saline.   
2. The mouse was grasped by the base of the tail, and the cotton swab was gently 
inserted 0.5 cm into the vagina to collect cells.   
Ketamine 0.11 90 mg/kg BW 100 mg/ml 
Xylazine 0.09 7 mg/kg BW 20 mg/ml 
Acepromazine 0.03 1 mg/kg BW 10 mg/ml 
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3. Cells collected were smeared onto a glass slide (VWR, Radnor, PA, USA) and 
allowed to dry.   
4. Slides were dipped for 5-10 minutes in hematoxylin (Ricca Chemical Company, 
Arlington, TX, USA), rinsed in deionized water, and allowed to dry.   
5. Cell populations were visualized with an Olympus BX41 microscope (Tokyo, 
Japan) at 100x, and estrus cycle presence and stage were classified based on the 
observations of Caligoni [73]. 
A.3 Ovariectomy 
Female Apc 
Min/+ 
and C57BL/6 mice were ovariectomized at 11 weeks of age using the 
following protocol: 
1. Mice were anesthetized by ketamine/acepromazine/xylazine.   
2. Once anesthetized, the mouse was placed in a prone position on a sterile 
absorbent pad. The back was shaved from the caudal edge of the ribcage to the 
base of the tail.  The shaved region was then sterilized with betadine (PDI, 
Orangeburg, NY, USA) and rubbing alcohol (PDI).   
3. In a sterile field, using sterilized instruments, a 2-cm dorsal midline incision was 
made with sterile scissors halfway between the caudal edge of the ribcage and the 
base of the tail.  Fascia was the cleared away by blunt dissection.  As second 1-cm 
long incision was made into the muscle wall.   
4. The ovary and surrounding fat pad were extracted through the incision with 
forceps.  A hemostat was closed around the distal oviduct/uterine horn to 
terminate blood supply to the ovary.   
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5. Non-absorbable suture (AD Surgical, Sunnyvale, CA) was used to tie off the 
oviduct, and the ovary was removed.  The uterine horn was returned to the 
peritoneal cavity, and absorbable suture (AD Surgical) was used to close the 
muscle incision.  Wound clips were used to close the skin incision, and the 
process was repeated on the contralateral side.   
6. Mice were placed an a heating pad until they awoke and were given 0.01 mg/kg 
buprenorphine (Burprenex ©, Reckitt Benckiser Pharmaceuticals, Pendergrass, 
GA, USA) for pain.  Wound clips were removed 7 days after surgery.  
A.4 IL-6 overexpression by electroporation  
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase circulating 
IL-6 levels in mice as previously described [117], using the following protocol: 
1. The right quadriceps muscle was used to synthesize and secrete exogenous IL-6 
into circulation from the injected expression plasmid, and was not used for any 
analyses in the study. The gastrocnemius muscle used in the study was not 
subjected to electroporation.  
2. Mice were given a 2% mixture of inhalation isoflurane (IsoSol, VEDCO, St. 
Joseph, Mo, USA) and oxygen (1 L/min) before and during procedure. 
3. The right quadriceps area was shaved and cleaned with iodine and ethanol.  A 
small incision (1 cm) was made through the skin and fascia, revealing the muscle.   
4. 50 μg of IL-6 plasmid driven by the CMV promoter, or control plasmid (pV1J), 
suspended in a 50 µl volume of sterile 0.9% saline was slowly injected into the 
right quadriceps muscle.  
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5. A series of eight 50 ms, 100 V pulses was used to promote uptake of the plasmid 
into myonuclei, and the incision was closed with a wound clip.  
A.5 Run to Fatigue 
At 12, 15, and 18 weeks of age, mice were subjected to a run-to-fatigue treadmill 
protocol.  After 5 minutes of acclimation at 5 meters/minute and 5 minutes of warm-up at 
10 m/m, the clock was started when speed was increased to 15 m/m.   The treadmill 
protocol was as follows: 20 minutes at 15 m/m, 20 minutes at 18 m/m, 30 minutes at 
20m/m, 30 minutes at 25 m/m, and 28 m/m until all mice stopped.  A mouse was 
considered “fatigued” when it refused to run or could not keep up with the treadmill 
despite gentle nudging for 1 minute.  Time and distance to fatigue were recorded. 
 
A.6 Voluntary cage activity monitor  
Place conventional mouse cages (single-housed) in channels.  Take the cage card off the 
cage in order to keep from blocking beams.  Make sure the power to the desktop 
computer and the Opto-3 is on.  Under the “Start” menu on the desktop, run the program 
titled “MultiDeviceSoftware.” The program will scan the hardware and make sure all 
channels (8 total) are connected.  Make sure that all channels are enabled.  Click on 
Experiment>Setup.  The program will ask whether the user wants to use the default 
experiment template.  Click “No,” and choose an old file whose protocol is the same as 
the experiment planned.  Name the new file with channel numbers used and mouse 
numbers being tested.  Once experiment begins, make sure all yellow LED lights (A to 
D) are flashing on the front of the Opto-M3.   
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A.7 Dual X-ray absorbiometry (DEXA) Scan  
Make sure the DEXA is plugged into the laptop and both machines are on.  From the 
start-up screen of the laptop program, select “Measure QC phantom.”  Place the quality 
control phantom mouse in the DEXA to be measured.  While phantom is being measured, 
stand outside of the room.  Once DEXA passes QC, it is ready to measure mice.  
Isoflurane machine should be hooked up to oxygen tank in the room.  Turn on oxygen 
tank and isoflurane meter to 2-2.5%.  Place mice in chamber with paper towels lining the 
bottom.  Allow mice to stay in chamber for 5 minutes.  Tape nose cone to edge on DEXA 
scanning region.  Place first mouse in DEXA with nose in nose cone.  Make sure all legs 
are spread to sides and within scanning region.  Begin scan through laptop prompts.  
Stand outside of door while scanning is occurring.  Afterwards, use manual controls to 
change region of analysis.  Exclude the skull and nose cone from region of interest and 
press “enter” to get new values.  Record all values. 
A.8 Grip strength measurement 
Grip strength measurements were determined as previously described [5]. Mice 
underwent 2 sets of 5 forelimb grip strength trials.  The first mouse was removed from its 
cage, held firmly by the base of the tail, and allowed to grasp the top of the grate attached 
to the force gauge (Chatillon, Largo, FL, USA) with its forepaws.  The mouse was firmly 
pulled down the grate, and forelimb grip strength was recorded in Newtons.  The mouse 
completed the 5 trials of the first set and was returned to its cage.  Each mouse tested 
went through the same procedure for its first trial, and mice were cycled through in the 
same order for the second trial. 
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A.9 Fasting glucose  
Mice were fasted for five hours prior to blood glucose measurements.  Blood glucose 
measurements were performed using a handheld glucometer (Bayer CONTOUR®, 
Whippany, NJ, USA ) according to the manufacture’s instructions. 
 
A.10 Retro-orbital eye bleed  
Animals will be fasted for five hours prior to bleeding.  Mice will be placed in isoflurane 
chamber with paper towels lining the bottom.  Oxygen tank will be turned on and 
isoflurane vaporizer will be turned to 2-2.5% .  Mice will stay in chamber for 5 minutes.  
One mouse at a time will be removed and place on an absorbent pad.  The mouse will be 
retrained and a heparinized capillary tube will be gently inserted into the eye socket, 
anterior to the eyeball.  Capillary tube will be gently twisted until blood flow occurs.  1-2 
capillary tubes of blood will be collected and place into an Eppendorf tube on ice.  Mouse 
will be returned to home cage and given a subcutaneous injection of 500 µl saline in 
order to rehydrate.  Blood will then be centrifuged at 10,000 rpm for 10 minutes at 4 
degrees.  Plasma will be pipetted off and added to a new tube.  Plasma samples will be 
kept at -80 degrees until analysis. 
A.11 IL-6 ELISA  
Use the Biosource KMC0062 kit per manufacturer’s instructions.  Thaw out plasma 
samples.  Remove the number of 8-well strips required for assay.  Reconstitute IL-6 
standard and controls according to instructions on vial.  Sit at room temperature for 10 
minutes.  Make a 500 pg/ml standard using 950 ul of standard diluents buffer and 50 ul of 
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the reconstituted standard. 
Make a series of 2-fold serial dilutions.  Label tubes 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 
31.25 pg/ml, 15.7 pg/ml, 7.8 pg/ml, and 0 pg/ml.  Add 300 ul of standard diluent buffer to 
each tube.  Make serial dilutions using the 500 pg/ml standard first.  Add 100 ul of 
standards or controls in duplicate to each well and add 50 ul of standard diluents buffer 
followed by 50 ul of plasma in duplicate to each well.  Incubate at room temperature for 2 
hours.  Dilute wash buffer according to directions and for the appropriate number of 
wells.  Aspirate wells.  Wash 4x with wash buffer.  Invert plate and tap to dry.  Add 100 
ul of IL-6 biotin conjugate to each well and incubate at room temperature for 30 min.  
Aspirate wells.  Wash 4x with wash buffer.  Invert plate and tap to dry.  Prepare HRP-
strepavidin according to instructions.  Use 10 ul and 10 ml for each strip in the assay.  
Add 100 ul of the working HRP-strepavidin solution to each well and incubate at room 
temperature for 30 min.  Aspirate wells.  Wash 4x with wash buffer.  Invert plate and tap 
to dry.  Add 100 ul of the chromagen to each well and incubate at room temperature for 
30 min in the dark.  Add 100 ul of stop solution.  Read on microplate reader at 450 nm. 
A.12 Soluble IL-6R Enzyme-linked immunosorbent assay 
Soluble IL-6r (sIL-6r) ELISA kit was obtained from MyBioSource (San Diego, CA) and 
manufacturer’s protocol was followed.   Briefly, 100 µl of standards and samples were 
added to wells.  50 µl of conjugate was added to sample in each well, and plate was 
incubated for 1 hour at 37°C.  Plate was washed five times.  50 µl each of Substrate A 
and B were added to wells.  Plate was again incubated at 37°C for 15 minutes until color 
developed.  50 µl Stop Solution was added to wells, and the plate was immediately read 
at 450nm on a BioRad iMark plate reader (Carlsbad, CA). 
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A.13 Leptin Enzyme-linked immunosorbent assay 
A commercial mouse leptin ELISA was obtained (Quantikine, R&D Systems, 
Minneapolis, MN) and manufacturer’s instructions were followed. Briefly, standards and 
samples were added to the pre-coated plate and allowed to incubate for two hours at room 
temperature.  The plate was washed five times and leptin conjugate was added to wells.  
Plate was allowed to incubate for two hours at room temperature.  Again, the plate was 
washed five times.  Substrate Solution was added to wells, and plate was incubated in the 
dark for thirty minutes at room temperature.  Stop Solution was added to wells, and the 
plate was read at 450 nm on a BioRad iMark plate reader. 
A.14 IL-6R ELISA 
Muscle IL-6r protein content was determined using a commercial IL-6Ra ELISA 
(DuoSet, R&D Systems, Minneapolis, MN) as previously described. Briefly, Capture 
Antibody was used to coat wells of a clear 96-well EIA plate (Costar, Corning, Corning, 
NY) and allowed to incubate overnight.  The second day, plate was blocked for one hour 
using Reagent Diluent.  Plate was washed three times. Standards and samples were added 
and allowed to incubate for two hours.  After washes were repeated, Detection Antibody 
was added to wells and allowed to incubate for two hours.  Washes were repeated and 
Streptavidin-HRP was added to wells and allowed to incubate for twenty minutes.  After 
washes were repeated, Substrate Solution was added to wells and color was allowed to 
develop for twenty minutes.  Stop Solution was added and plate was read at 450 nm on a 
BioRad iMark plate reader (Carlsbad, CA).  
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A.15 Intestinal polyp quantification 
Quantification of intestinal polyps was determined as previously described [19].  Briefly, 
intestinal sections were fixed in formalin at time of sacrifice.  At time of analysis, 
sections were rinsed in deionized water and dipped briefly in 0.1% methylene blue.  
Polyps from segment 4 were counted under a dissecting microscope; it has been 
determined that tumor number in segment 4 is representative of total tumor number 
[122].   
A.16 Ovarian Histology 
Ovaries were excised from B6, Cycle Present, and Cycle Absent mice and immediately 
transferred to 4% PFA.  Ovaries were mounted in paraffin, sectioned, and stained by 
hematoxylin and eosin by the University of South Carolina School of Medicine 
Instrument Resource Facility.  Pictures were taken using a Nikon E600 microscope 
(Nikon, Tokyo, Japan) at 400x and 1000x. 
A.17 RNA isolation  
Homogenize samples in 1 ml of Trizol on ice (Use new 14 ml Polyproplylen tube). Rinse 
polytrone with EtOH, then dH2O each homogenization.  Transfer homogenate to sterile 
1.5 ml tube on ice.  Spin samples at max speed for 10 min at 4 °C.  Transfer supernatant 
to a new sterile 1.5 ml tube.  Let samples sit at RT for 5 min.  Add 200 µl of chloroform.  
Shake tubes vigorously for 15 s (DO NOT VORTEX).  Incubate at RT for 2-3 min.  
Centrifuge at max for 15 min at 4 °C.  Make a new set of 1.5 ml tube. Add 500 µl of 
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isopropanol each tube.  Transfer clear supernatant containing the RNA to a new sterile 
1.5 ml tube.  Do not disturb protein interface.  Vortex tubes.  Incubate at RT for 10 min 
or -20C for overnight to increase precipitation.  Centrifuge at max for 15 min at 4 °C.  
Dump supernatant.  Add 1 ml of 75% EtOH (DEPC) to RNA pellet and vortex.  Repeat 
step 15 and 16.  Spin at 7500 g (9500 rpm) for 5 min at 4 °C.  Dump supernatant and 
remove remaining liquid with kimwipte.  Do not disturb the RNA pellet.  Air dry tube 
upside down for 15 min.  Add 15 to 40 µl of DEPC water, depending on pellet size.  
Pipette up and down to mix.  Heat in dry-bath at 60 °C for 10 min.  Pipette up and down 
to mix for at leat 30 times.  Read 1.5-2 µl of sample using nano drop at 260 and 280 nm. 
RNA concentration = (OD260*40*0.8)/(volume of RNA read in cuvette)  
OD260/OD280:   >1.8 is good; 1.6 to 1.8 is OK;  <1.6 is not good. 
 
A.18 cDNA synthesis  
Make 10ul of reverse transcriptase cocktail (See ingredients below).  Mix with pipette.  
Spin to collect condensation. 
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Measure 1-2ug RNA and volume up to 10ul.  Mix samples by pipetting up and down 
making a 20ul reaction.  Place samples in Thermocycler (Program #25, or settings as seen 
below) 
 
 
   
A.19 Real-time PCR  
Thaw out primers and get master mix out of freezer.  Get appropriate number of 8-well 
tubes and 8-well strips out of bags.  Thaw out cDNA (diluted either 1:10 or 1:100 with 
sdH2O).  Make cocktail based on number of samples, plus one negative control, plus one 
extra sample.  You are making 20 ul reactions.  Mix by inversion 20x.  Spin to collect to 
bottom of tube. 
     1x   10x 
 2x SYBR Master mix  10.0   100.0 
 20 uM Primer 1  0.08   0.8 
 20 uM Primer 2  0.08   0.8 
 sdH2O    0.84   8.4 
11.0   110.0 
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Add 11.0 ul of cocktail to each tube.  Make sure you are pipetting in 96-well cooling 
block.  Add 9.0 ul of cDNA (1:100 dilution).  If measuring mRNA for something that is 
not very abundant, use 1:10 dilution instead.  Pipette up and down to mix about 20 times.  
Seal 8-wells with 8-strip cap.  Set up thermal cycle to default program and add 
dissociation curve.  Set volume to 20 ul.  Change number of cycles to 50 if necessary. 
A.20 Calculation of real time PCR Ct values  
The Ct value is the cycle threshold.  This is the cycle number above the set threshold 
level which is set manually or automatically and the threshold is set above the 
background.  The delta Ct (ΔCt) is the difference in Ct values from the experimental gene 
from a housekeeping gene (18S, GAPDH, etc.).  Take the mean ΔCt values for each 
group.  This data is presented in the manuscript and for statistics.   If the data is normally 
distributed, the ΔCt values can be used for statistics.  If the data is not normally 
distributed, the ΔCt values can be transformed (ex: log transformation).  This can be used 
to run statistics.  If the data is transformed for statistics, still present the raw ΔCt values in 
the manuscript.  State in the methods that the data was transformed for statistical 
purposes.  Theoretically, a difference in Ct values by a factor of 1 is a 2-fold change in 
mRNA.  However, since PCR is not 100% efficient, this is only an estimate and the exact 
change in mRNA is probably a little less than a factor of 2.  Therefore, this can only be 
mentioned in the text of the results or discussion. 
A.21 2^
-ΔΔCT
 method  
Take the average ΔCT for the control group.  Subtract the control group average ΔCT 
from each individual ΔCT.  This is the ΔΔCT.  To transform, the equation is =2^-ΔΔCT. 
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A.22 Primers  
Find the nMol concentration from the tube, it should be in the range of ~33 nMol.  Add 
TE bx to the tube by a factor of 10. Ex for a 33.20 nMol primer ass 330ul of TE bx.  This 
will result in the primer concentration to be 100uM.  Dilute primers to working 
concentration of 20uM.  Do this by combining  20 ul of the 100uM primer with 80 ul of 
dH20. This is a 1:5 dilution giving you the working 20uM stock.  Place the 100uM 
primer in the appropriate box, most likely Mouse Primers and put the 20uM stock 
solution in the clear plastic box named 20uM working primers. 
A.23 Tissue (protein) homogenization   
Make Mueller Buffer (see next page) and store at -20°C.  Add 1 mL/100 mg tissue of 
Mueller Buffer.  Prepare diluent buffer (see next page).  Half of what you prepared of the 
Mueller buffer will be added.  For example, if you add 200 ul of Mueller buffer for 20 mg 
of tissue, add 100 ul of diluent buffer.  Put the Mueller buffer on ice and have the samples 
suspended in liquid nitrogen.  Have a 1000 mL beaker with deionized H2O and another 
1000 mL beaker with weak acid (splash of glacial acetic acid).  Also, have a test tube 
rack with homogenization tubes and some Kim-wipes nearby.  Have a 600 mL beaker 
with ice and a homogenization tube.  Also have a beaker for waste.  Freeze 
homogenization tube for 5 seconds in liquid nitrogen.  Put the sample in the 
homogenization tube by inverting the eppendorf tube.  If the sample sticks to the side of 
the eppendorf, flick it with your finger to dislodge it.  Immediately add appropriate 
amount of Mueller buffer to the sample.  Homogenize in an up-and-down motion for a 
few seconds at a time with tube on ice.  This prevents heat from accumulating.  Also, turn 
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the homogenizer off and on every few seconds.  When the sample is liquefied, use a 
transfer pipette and put back into original eppendorf.  Rinse the transfer pipette with 
deionized H2O.  Rinse the glass probe first with weak acid, dry with Kim-wipe, rinse 
with deionized H2O, and wipe with Kim-wipe.  Rinse the homogenization tube 3 times 
with weak acid and 3 times with deionized H2O and pour into waste beaker.   After all 
tissues are homogenized, centrifuge the samples for 15 min at 4°C for at 10K rpm.  Make 
a new set of eppendorf tubes. Transfer the supernatant into a new eppendorf tube and add 
half of original amount of Mueller of diluent buffer.  Refreeze the samples at -80 °C for 
storage. 
A.24 Muller and diluent buffer 
Mueller Bx   Stock   Desired   Volume   
dH2O      3.585 mL 
Hepes (pH 7.4) 500 mM  50 mM  0.600 mL 
Triton-X  100%  0.10%  0.006 mL 
EGTA (pH 8.0) 500 mM  4 mM  0.048 mL 
EDTA (pH 8.0) 500 mM  10 mM  0.120 mL 
Na4P2O7  100 mM  15 mM  0.900 mL 
β-glycerophosphate 2 M  100 mM  0.300 mL 
NaF  500 mM  25 mM  0.300 mL 
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NaVO4  1 M  5 mM  0.030 mL 
 
Protease inhibitor      0.060 mL 
     Total 6.000 mL 
Diluent Bx   Stock   Desired   Volume   
Glycerol  100%  50%  1.500 mL 
Na4P2O7  100 mM  50 mM  1.500 mL 
EGTA (pH 8.0) 500 mM  2.5 mM  0.015 mL 
β-mercaptoethanol 500 m M  1 mM  0.006 mL 
 
Protease inhibitor      0.030 mL 
     Total 3.000 mL 
A.25 Bradford protein assay  
Dilute BSA from stock to 1 µg/uL working solution.   Prepare a 1:5 dilution with 
deionized H2O of Bio-rad Bradford reagent.  You will need 600 µL/sample (in 
duplicate), plus enough for each standard (in duplicate), and extra for any re-do samples.  
Put in a glass beaker covered with foil, add a stir bar, cover with Parafilm, and slowly 
stir.  Dilute samples with diluent buffer if necessary. Add 2 µL of samples at the bottom 
of each well (in duplicate). Add 2, 4, 6, 8 and 10 µL of BSA for standard (in duplicate). 
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Add 300 µL of Bradford reagent to each well quickly and wait for 15 min in the dark.  
Place the well plate on the plate reader and read on the spectrophotometer at 595 nm.  All 
absorbance readings need to be within 10% CV in each duplicate.  If not, make another 
standard.  Plot average absorbances on a graph with ‘protein’ on the x-axis and 
‘absorbance’ on the y-axis.   CV defined as the ratio of the standard deviation to the 
mean:   CV(%)=(SD/mean )*100 
A.26 SDS-PAGE  
Make resolving gel:  Assemble the glass plates according to the manufacturer’s 
instructions.  Fill with water to make sure the mold does not leak.  Make correct 
percentage gel (10 ml per gel) in a 50 or 100 ml beaker.  Syringe filter (0.45 µm) all 
components except for TEMED.  Dump out water in mold and use filter paper to dry.  
Add TEMED to beaker and swirl to mix.  Pour gel into mold but leave enough room for 
comb and 0.5-1 cm.  Add 200 ul of isopropanol to top of gel.  Wait 20-30 min for gel to 
solidify.   Make stacking gel:  Make stacking gel (2-3 ml per gel) in a 50 or 100 ml 
beaker except for TEMED.  Dump out unpolymerized acrylamide from resolving gel and 
use blotting paper to absorb excess isopropanol.  Add TEMED to beaker and swirl to 
mix.  Pour stacking gel to top.  Insert comb but leave 0.5 to 1 cm of space between 
bottom of comb and top of resolving gel.  Wait 20-30 min for gel to solidify.   Prepare 
samples:  Boil 2x SDS loading buffer in water bath for 5 minutes. Add 2x SDS loading 
buffer to individual eppendorf tubes for each sample.  Add same amount of protein 
extract to each eppendorf tube.  Cap tubes with boiling cap.  Boil samples for 5 minutes 
in water bath.  Let samples sit for at least 30 seconds before removing boiling caps.  
Briefly centrifuge to collect samples at bottom of tube.  Make running buffer:   Add 
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800 ml of dH2O and 200 ml of 5x SDS running buffer.  Load the gel:   Connect gels to 
holder and put into tank.   Add running buffer to both inner and outer chambers.  Load 
each sample into each well.  Add 10 uL of marker to one lane (not in the middle of the 
gel).  Connect to power supply (black to black and red to red).  Run gel at appropriate 
voltage (160 V for 1 h).  Stop when all dye has leaked into the running buffer.  Transfer 
to membrane:   Presoak membrane in methanol (5 minutes) to enhance the transfer 
process.  Disconnect power and remove gels.  Remove one piece of glass and carefully 
cut away stacking gel and throw away in trash.  Use deionized H2O and a spacer to help 
remove gel into dish with deionized H2O.  Put waffle with black side down in tramsfer 
tray covered in transfer buffer.  Put in sponge.  Put in blotting paper.  Add gel (preferably 
with marker on right, so when transfer is done, marker will be on the left).  Add 
membrane and smooth out bubbles with spacer.  Add blotting paper and smooth out 
bubbles with spacer.  Add sponge and smooth out bubbles with spacer.  Close sandwich.  
Put sandwich in holder (black to black).  Put stir bar at bottom of container.  Add ice 
pack.  Add transfer buffer.  Put holder on stir plate to circulate the running buffer.   Quick 
transfer at 350 mA for 60 min (pack on ice) or transfer overnight 70 mA.  Ponceau 
Staining:  Use tweezers to remove the membrane and put in a plastic dish with enough 
Ponceau stain to cover the membrane with protein side up.  Shake for 2-3 min and then 
pour the stain back into the jar.  Rinse the membrane with deionized water to destain until 
the water is not pink.  Scan into the computer.  Seal membrane in a plastic bag with TBS-
T and store in the refrigerator for western blotting or rinse in TBS-T and store in blotting 
paper at room temperature. 
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A.27 Western blotting  
Put membrane in dish with protein side up.  Block membrane in 5% TBST milk for 30 
min.  Add primary Ab at appropriate dilution in 5% TBST milk.  Incubate overnight at 4 
°C, 1 h at RT, or 60-90 min at room temperature with gentle rocking.  Wash 3 x 5 min 
with TBST with shaking.  Wash 1 x 10 min with TBST with shaking.  Add secondary Ab 
at appropriate dilution in 5% TBST milk  Incubate 1 h at RT with gentle rocking.  Wash 
3 x 5 min with TBST with shaking.  Wash 1 x 10 min with TBST with shaking.  Make 
ECL or ECL prime reagent.  Remove excess TBST by draining edge of membrane with 
Kim-wipe.  Lay membrane in flat dish.  Add ECL (1 min) or ECL prime (5 min) to top of 
membrane.  Remove excess ECL/ECL prime by draining edge of membrane with Kim-
wipe.  Place membrane face down (protein side down) on piece of plastic wrap.  Fold up 
edges and tape membrane in film cassette face up (protein side up).  Put on a piece of 
film on membrane in the darkroom.  To use machine, turn switch from “Standby” to 
“Run” and the red “Feed film” light will turn on.  In dark, open the lid of the developer 
and feed the film until it catches.  You can turn on the light or put in another piece of film 
when the “Feed Film” light comes on again.  Turn machine to “Standby”.  Mark on film 
the edges of the membrane and the protein marker with a sharpie. 
 
A.28 Statistical analysis 
Chapter 3: All results are reported as means ± SEM.  Differences between degrees of 
cachexia severity were analyzed by one-way ANOVA using Tukey post hoc test where 
appropriate.  Differences between sexes and genotypes were determined by two-way 
ANOVA.  Correlations were determined by Pearson’s test for correlation. Differences 
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between 12-14 week and 15-18 week IL-6 treatment groups were determined by 
Student’s t-test.  Level of significance was set at 0.05. 
Chapter 4: All results are reported as means ± SEM.  Differences between B6, Weight 
stable, Severe, and OVX mice were determined by one-way ANOVA with Tukey post 
hoc where appropriate.  Differences between Sham + vector, Sham + IL-6, OVX + 
vector, and OVX + IL-6 mice were determined by two-way ANOVA with Tukey post 
hoc where appropriate.  Level of significance was set at 0.05 for all comparisons. 
Chapter 5: All results are reported as means ± SEM.  Differences between B6, Cycle 
Present, and Cycle Absent were analyzed by one-way ANOVA using Tukey post hoc 
where appropriate.  Differences between timepoints and ovarian status, were determined 
by two-way repeated measures ANOVA with Sidak’s multiple comparisons test where 
appropriate.  Differences between genotype and ovarian status were determined by two-
way ANOVA with Tukey post hoc where appropriate.  Differences between Cycle 
Absent and OVX mice were determined by Student’s t-test.  Differences between Cycle 
Present, Cycle Absent, and OVX mice were determined by one-way ANOVA with Tukey 
post hoc where appropriate.  Differences between Sham + vector, Sham + IL-6, OVX + 
vector, and OVX + IL-6 mice were determined by two-way ANOVA with Tukey post 
hoc where appropriate.  Level of significance was set at 0.05. 
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B.1 Specific Aims 
Cachexia is a devastating condition that occurs secondary to several chronic diseases, 
including AIDS, COPD, chronic renal failure, and many forms of cancer [1].  There is no 
cure or FDA-approved treatment for cachexia, though it occurs in 30-50% of cancers [1-
3] and has an annual mortality rate of 80% [1], underlining the necessity of  investigation 
into its etiology and progression.  The most recent definition of cachexia includes an 
unintentional weight loss of 5% or more secondary to a chronic condition in addition to 
other symptoms including anemia, fatigue, muscle weakness, increased inflammatory 
markers and plasma triglycerides, and insulin resistance [1].Though the condition has 
been well-characterized in the male by our lab and others [4-6, 10, 18-24], almost no 
research into the condition has taken place in the female.  It had long been assumed that 
the male and female underwent the same pathophysiology leading to cachexia; however, 
data from our laboratory has shown differences in the response of the male and female 
(unpublished data).  Though both sexes undergo cachexia, data from our lab has shown 
that the female loses less body weight than the male, and seems to have a differential 
response to IL-6 from the male [20].  Cachectic male and female Apc 
min/+ 
mice have 
similar plasma IL-6 levels (unpublished data).  However, induced overexpression of IL-6 
in the male abrogates the cachectic response [5, 6, 20], but has no effect in the female.  
There is no increase in STAT3 signaling in the female Apc 
min/+ 
mouse with 
overexpression of IL-6 (unpublished data), indicating that something is blocking this 
pathway. Importantly, it has been shown that estrogen, specifically 17β-estradiol, can 
block STAT3 signaling [27].   
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 Ovarian function plays a major role in the health and disease outcomes of 
females.  The role of estrogen, in particular, in the health of both males and females has 
come into focus in the past decade.   Body composition is regulated in part by estrogen 
signaling, and it has been shown that the ablation of such has a significant deleterious 
impact on regulation of muscle and fat mass [29-32]; this dysregulation has potentially 
dire consequences when coupled with the innate dysregulation of cachexia.  Estrogen has 
well-documented benefits against inflammation [33-35], particularly IL-6 [36, 37], that 
may provide some benefit to the female during the onset and progression of cancer 
cachexia.  In addition, the relatively recent discovery of estrogen receptors α and β in 
skeletal muscle has led to new insight into estrogen’s benefits to skeletal muscle mass 
and strength [30, 38, 39].  Specifically, estrogen is necessary for recovery from atrophy 
[29, 40].  Preliminary data from our lab shows that estrous cycling, which normally 
occurs in the C57BL/6 mouse until around 14 months of age [41], ceases during the 
progression of cancer cachexia in the female Apc 
min/+ 
mouse, which indicates interplay 
between the ovary and cachexia. 
IL-6 plays a role in the normal cyclic signaling of the ovary [42], but can lead to 
pathology of the ovary when dysregulated [42, 43].  This supports the hypothesis that 
there is interplay between ovarian function and IL-6.  This, together with the known 
inhibition of IL-6/STAT3 signaling by estrogen [27]  provides the rationale for this study.  
The novelty of this study arises from it being, to my knowledge, the first study to 
specifically look at mechanisms of cachexia in the female Apc 
min/+ 
mouse, as well as the 
first study to investigate a potential role of estrogen signaling. 
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The overall purpose of the proposed study is to determine if ovarian function can alter 
cachexia progression in the female Apc 
min/+ 
mouse through IL-6 signaling and the 
regulation of skeletal muscle metabolism. The working hypothesis of the proposed study 
is that loss of ovarian function in the female Apc 
min/+ 
mouse causes abrogated 
progression of cachexia through altered IL-6 sensitivity, which increases skeletal muscle 
metabolic dysfunction and leads to increased skeletal muscle loss. Outcomes related to 
the specific aims of the study include body composition, in vivo functional capacity, 
abnormal blood biochemistry, tissue IL-6 signaling, and disrupted skeletal muscle 
metabolism. 
In order to prove the proposed study’s overall hypothesis three specific aims are 
proposed.  
Specific Aims 
 
Aim 1. Determine if ovarian function in female Apc 
min/+ 
mice regulates specific 
components of cachexia progression.  
 
Aim 2. Determine if IL-6 regulation of cachexia progression is regulated by ovarian 
function in the female Apc 
min/+ 
mouse. 
 
Aim 3.  Determine whether cachexia-induced skeletal muscle metabolic dysfunction 
is regulated by ovarian function in the female Apc 
min/+ 
mouse. 
 
 
B.2 Research Design 
 
Aim 1. Determine if ovarian function in female Apc 
min/+ 
mice regulates specific 
components of cachexia progression.  
Overall Design: Aim 1 will determine whether there is an association between ovarian 
function and the extent of cachexia progression in the female Apc 
min/+ 
mouse.  The 
working hypothesis of this aim is that normal ovarian function will protect against the 
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progression of cachexia, including body composition changes, functional deficits, and 
abnormal blood biochemistry.  This aim consists of 2 experiments. Experiment 1.1 is a 
time course experiment and will examine cachexia progression in mice with normal and 
abnormal ovarian function at the early (15 week) and late (18 week) stages of cachexia.  
Normal and abnormal ovarian function will be categorized using daily estrous cycling 
data primarily, with verification from plasma estrogen levels taken over the time course.  
Experiment 1.2 will examine the effect of ovariectomy on the progression of cachexia at 
the early (15 week) and late (18 week) stages of cachexia. Outcomes from this aim will 
relate ovarian function to changes in body composition, whole body function, and 
blood biochemistry in ovaries-intact and ovariectomized mice at early cachexia (15 
week) and cachexia (18 week) timepoints.  
 
Experiment 1.1: Determine if abnormal ovarian function during the time course of 
cachexia progression in ovaries-intact female Apc 
min/+ 
mice is associated with 
changes in body composition, functional deficits, and abnormal blood biochemistry. 
Hypothesis 1.1: Normal ovarian function will be associated with less severe changes in 
body composition, functional deficits, and abnormal blood biochemistry than irregular 
ovarian function in the female Apc 
min/+ 
mouse. 
Design: Female Apc 
min/+ 
mice will be followed from 10 weeks of age to sacrifice at 15 
weeks (early stage cachexia, n=12) or sacrifice at 18 weeks (late stage cachexia, n=12).  
Abnormal ovarian function will be classified by continuous measurement of estrous 
cycling and verified by plasma estrogen levels from blood taken at 12, 14, 16, and 18 
weeks of age. Additional measurements will include ovarian mRNA expression of 
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estrogen and progesterone at 15-week and 18-week endpoints.   Body composition 
outcomes will comprise body fat percentage and lean mass percentage determined by 
DEXA as well as total body weight loss at 12, 14, 16, and 18 weeks.  Functional 
outcomes will comprise volitional grip strength, run-to-fatigue time, food intake, and 
cage activity at 12, 14, 16, and 18 weeks.  Blood biochemistry outcomes will comprise 
hematocrit (for determination of anemia), plasma insulin levels, and plasma triglyceride 
levels at 12, 14, 16, and 18 weeks.   
 
 
 
Expected Outcomes Outcomes from this experiment will relate ovarian function to body 
composition, functional outcomes, and biochemical measures over time.  Specifically, 
ovarian function will be categorized as “normal” or “abnormal” by daily measurement of 
estrous cycling. Additionally, ovarian endocrine function will be examined by plasma 
estrogen levels at 12, 14, 16, and 18 weeks, and estrogen/progesterone mRNA from 
ovaries at 15 and 18 week timepoints. Body composition will comprise changes over time 
from 12 weeks (pre-cachexia) to 18 weeks (late stage cachexia) in percentage body fat 
and weight loss.  These will be compared between normal and abnormal ovarian function 
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groups during early stage cachexia (15 week) and late stage cachexia (18 week). 
Functional outcomes will comprise volitional grip strength, run to fatigue time, food 
intake, and cage activity.  Changes over time from 12-18 weeks in these outcomes will be 
compared between normal and abnormal ovarian function groups during early stage 
cachexia (15 week) and late stage cachexia (18 week).  Abnormal blood biochemistry 
outcomes will comprise hematocrit (for determination of anemia), plasma insulin levels, 
and plasma triglyceride levels.  Changes over time from 12-18 weeks in these outcomes 
will be compared between normal and abnormal ovarian function groups during early 
stage cachexia (15 week) and late stage cachexia (18 week).. 
 
Experiment 1.2: Determine if ablation of ovarian endocrine function (ovariectomy) 
in the female Apc 
min/+ 
mouse regulates components of cachexia progression, 
including changes in body composition, functional deficits, and abnormal blood 
biochemistry. 
Hypothesis 1.2: Ovariectomy will lead to more severe progression of cachexia, including 
greater body composition changes, greater functional deficits, and more severe blood 
biochemical abnormalities in the female Apc 
min/+ 
mouse. 
Design: Female Apc 
min/+ 
mice and female C57BL/6 mice will be ovariectomized (OVX) 
at 11 weeks of age and will be followed until sacrifice at 15 weeks (early stage cachexia, 
n=8 Apc
min/+
, n=4 B6) or sacrifice at 18 weeks (late stage cachexia, n=8 Apc 
min/+
, n=4 
B6).  Mice from experiment 1.1 will be used as control for ovariectomy.  Body weight 
will be tracked weekly.  Body composition will be determined by DEXA at 12, 14, 16, 
and 18 weeks of age. Measurement of function including grip strength, run to fatigue 
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time, food intake, and cage activity will be taken at 12, 14, 16, and 18 weeks of age. 
Blood for determination of anemia as well as determination of plasma estrogen, insulin, 
and triglycerides will be collected at 12, 14, 16, and 18 weeks of age.  It is expected that 
plasma estrogen will be depleted within 2 weeks of ovariectomy.  
 
 
 
Expected Outcomes: To stratify by ovarian function, we will compare ovariectomized 
(OVX) and intact (SHAM) mice. Outcomes will include measurements of body 
composition, function, and circulating blood biochemistry over the time course of the 
experiment.  Mice from Experiment 1.1 with the addition of intact female B6 (n=4) mice 
will serve as controls for the effects of ovariectomy.  Ovariectomized B6 controls will be 
crucial to control for the changes in body composition that can occur after ovariectomy.  
Ovarian function outcomes will comprise measurement of estrous cycling in intact mice, 
and plasma estrogen levels to verify efficacy of ovariectomy in OVX mice. Body 
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composition outcomes will comprise changes over time from 12 weeks (pre-cachexia) to 
18 weeks (late stage cachexia) in percentage body fat and weight loss.  These will be 
compared between OVX and SHAM groups during early stage cachexia (OVX-15 weeks 
vs. SHAM-15 weeks) and during late stage cachexia (OVX-18 weeks vs. SHAM-18 
weeks). Functional outcomes will comprise volitional grip strength, run to fatigue time, 
food intake, and cage activity.  Changes over time from 12-18 weeks in these outcomes 
will be compared between OVX and SHAM groups during early stage cachexia (OVX-15 
weeks vs. SHAM-15 weeks) and during late stage cachexia (OVX-18 weeks vs. SHAM-
18 weeks). Abnormal biochemistry outcomes will comprise hematocrit (for determination 
of anemia), plasma insulin levels, and plasma triglyceride levels.  Changes over time 
from 12-18 weeks in these outcomes will be compared between OVX and SHAM groups 
during early stage cachexia (OVX-15 weeks vs. SHAM-15 weeks) and late stage 
cachexia (OVX-18 weeks vs. SHAM-18 weeks). 
 
Overall Aim 1 Interpretation:  
Differences seen in Experiment 1.1 between mice with normal and abnormal 
ovarian function will indicate that cessation of normal estrous cycling alters the 
progression of cachexia in female Apc 
min/+ 
mice.   
More severe changes in body composition including greater loss of body fat 
percentage and body weight in mice with abnormal ovarian function will indicate that 
normal ovarian function is protective of body composition.  
More severe loss of volitional strength or cage activity in mice with abnormal 
ovarian function will indicate that normal ovarian function can protect from these deficits 
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during the progression of cachexia, though it will not be possible to say through this 
experiment whether this is due to effects of ovarian signaling in the muscle.   
A lower run-to-fatigue time in mice with abnormal ovarian function will indicate 
that normal ovarian function protects endurance, though it will not be possible to say 
through this experiment whether this is due to effects on oxidative capacity of the 
muscles or systemic factors.   
Lower food intake in mice with abnormal ovarian function will indicate that 
normal ovarian function protects appetite during cachexia, possibly relating to body 
weight maintenance.   
 More severe anemia in mice with abnormal ovarian function will indicate that 
normal ovarian function is protective against this process during cachexia progression.   
Increased insulin levels in mice with abnormal ovarian function will indicate that 
normal ovarian function is protective against insulin resistance during cachexia 
progression.   
Higher triglyceride levels in mice with abnormal ovarian function will indicate 
that normal ovarian function is protective against the dysregulation of lipid metabolism 
during cachexia progression. 
Differences seen in Experiment 1.2 between OVX and SHAM mice will indicate that 
lack of ovarian function alters the progression of cachexia in female Apc 
min/+ 
mice.   
More severe changes in body composition including greater loss of body fat 
percentage and body weight in OVX mice will indicate that ovarian function is protective 
of body composition.  
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More severe loss of volitional strength or cage activity in OVX mice will indicate 
that ovarian function can protect from these deficits during the progression of cachexia, 
though it will not be possible to say through this experiment whether this is due to effects 
of ovarian signaling in the muscle.   
A lower run-to-fatigue time in OVX mice will indicate that ovarian function 
protects endurance, though it will not be possible to say through this experiment whether 
this is due to effects on oxidative capacity of the muscles or systemic factors.   
Lower food intake in OVX mice will indicate that ovarian function protects 
appetite during cachexia, possibly relating to body weight maintenance.    
More severe anemia in OVX mice will indicate that ovarian function is protective 
against this process during cachexia progression.  Increased insulin levels in OVX mice 
will indicate that ovarian function is protective against insulin resistance during cachexia 
progression.   
Higher triglyceride levels in OVX mice will indicate that ovarian function is 
protective against the dysregulation of lipid metabolism during cachexia progression. 
 
Aim 2. Determine if IL-6 regulation of cachexia progression is regulated by ovarian 
function in the female Apc 
min/+ 
mouse. 
Overall Design: Aim 2 will determine whether the response to endogenous and 
overexpressed IL-6 levels is altered by the loss of ovarian function in ovaries-intact and 
ovariectomized female Apc 
min/+ 
mice.  The working hypothesis of this aim is that 
endogenous IL-6 levels will increase in the absence of ovarian function, and response to 
IL-6 will be abrogated in the absence of ovarian function.  This aim consists of 3 
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experiments. Experiment 2.1 will examine the relationship of circulating IL-6 and 
downstream tissue signaling in mice with normal and abnormal ovarian function at the 
early (15 week) and late stages of cachexia (18 week).  Experiment 2.2 will examine the 
relationship between circulating IL-6 and downstream tissue signaling in ovariectomized 
and intact mice at the early (15 week) and late stage cachexia (18 week). Experiment 2.3 
will examine the effect of overexpressed IL-6 on cachexia progression in ovariectomized 
and intact mice. Outcomes from this aim will relate ovarian function to circulating IL-6 
levels and tissue IL-6 signaling in ovaries-intact and ovariectomized mice at early 
cachexia (15 week) and cachexia (18 week) timepoints, as well as in ovariectomized mice 
with overexpressed IL-6 levels at 15 weeks.   
 
Experiment 2.1: Determine if the loss of ovarian function in ovaries-intact female 
Apc 
min/+ 
mice regulates circulating IL-6 levels and IL-6 signaling in cachexia target 
tissues during the progression of cachexia. 
Hypothesis 2.1: Endogenous circulating IL-6 levels and tissue-level IL-6 signaling, 
including STAT3 activity, AMPK activity, and p38 activity, will increase with 
dysregulation of ovarian function during the progression of cachexia in the female Apc 
min/+ 
mouse. 
Design: The same cohort of mice used in Experiment 1.1 will be used to complete this 
experiment.  Female Apc 
min/+ 
mice will be followed from 10 weeks of age to sacrifice at 
15 weeks (early stage cachexia, n=12) or sacrifice at 18 weeks (late stage cachexia, 
n=12).  Body weight will be tracked weekly and estrous cycling will be determined daily.  
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Blood for determination of plasma estrogen and IL-6 will be collected at 12, 14, 16, and 
18 weeks of age.   
Expected Outcomes This experiment will relate ovarian function to endogenous IL-6 
levels over time and tissue-level downstream signaling in cachexia target tissues 
including liver, muscle and fat during early cachexia (15 weeks) and cachexia (18 
weeks).  Specifically, ovarian function will be categorized as “normal” or “abnormal” 
based on daily estrous cycle measurements as in Experiment 1.1.  Secondarily, plasma 
estrogen levels at 12, 14, 16, and 18 weeks of age will be measured and ovarian estrogen 
and progesterone mRNA from 15 and 18 week timepoints will be measured.   IL-6 levels 
will be determined from plasma taken at 12, 14, 16, and 18 weeks and will be compared 
between mice with normal and abnormal ovarian function during early stage cachexia (15 
week) and late stage cachexia (18 week).  Tissue-level signaling downstream of IL-6 will 
be determined in cachexia target tissues including liver, skeletal muscle, and fat.  Markers 
of signaling pathways downstream of IL-6 will include p-STAT3/STAT3, p-
AMPK/AMPK, p-p65/p65, p-p38/p38, and gp130.  Levels of these proteins will be 
compared between mice with normal and abnormal ovarian function during early stage 
cachexia (15 week) and late stage cachexia (18 week). 
 
Experiment 2.2: Determine if the ablation of ovarian function (ovariectomy) in 
female Apc 
min/+ 
mice regulates circulating IL-6 levels and IL-6 signaling in cachexia 
target tissues during the progression of cachexia. 
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Hypothesis 2.2: Ovariectomy will cause increased endogenous circulating IL-6 levels 
and abrogation of tissue-level IL-6 signaling in the female Apc 
min/+ 
mouse, including 
increased STAT3 activity, AMPK activity, and p38 activity. 
Design: The same cohort of mice used in Experiment 1.2 will be used in this experiment.  
Female Apc 
min/+ 
mice and female C57BL/6 mice will be ovariectomized (OVX) at 11 
weeks of age and will be followed until sacrifice at 15 weeks (early stage cachexia, n=12 
Apc
min/+
, n=4 B6) or sacrifice at 18 weeks (late stage cachexia, n=12 Apc 
min/+
, n=4 B6).  
Blood for determination of plasma estrogen and IL-6 will be collected at 12, 14, 16, and 
18 weeks of age.  It is expected that plasma estrogen will be depleted within 2 weeks of 
ovariectomy.  Mice from experiment 2.1 will be used as intact controls. 
Expected Outcomes Outcomes from this experiment will relate presence of ovarian 
function (OVX versus SHAM) to endogenous IL-6 levels over time and downstream 
signaling in cachexia target tissues including liver, skeletal muscle, and fat during early 
stage cachexia (15 weeks) and late stage cachexia (18 weeks), using animals from 
Experiment 2.1 and intact female B6 (n=4) mice as controls.  Specifically, ovarian 
function will be stratified as OVX or SHAM.  Blood taken at 14 weeks will be used to 
measure plasma estrogen levels in order to verify efficacy of ovariectomy in OVX mice. 
IL-6 levels will be determined from plasma taken at 12, 14, 16, and 18 weeks and will be 
compared between OVX and SHAM groups during early cachexia (OVX-15 weeks vs. 
SHAM-15 weeks) and during cachexia (OVX-18 weeks vs. SHAM-18 weeks).  Signaling 
downstream of IL-6 will be determined in cachexia target tissues including liver, skeletal 
muscle, and fat.  Markers of signaling pathways downstream of IL-6 will include p-
STAT3/STAT3, p-AMPK/AMPK, p-p65/p65, p-p38/p38, and gp130.  Levels of these 
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proteins will be compared between OVX and SHAM groups during early cachexia 
(OVX-15 weeks vs. SHAM-15 weeks) and during cachexia (OVX-18 weeks vs. SHAM-
18 weeks). 
 
Experiment 2.3: Determine if the ablation of ovarian function (ovariectomy) alters 
the cachectic response to IL-6 overexpression in the female Apc 
min/+ 
mouse. 
Hypothesis 2.3: Ovariectomy will cause abrogated IL-6 induction of cachexia in the 
female Apc 
min/+ 
mouse. 
Design: Female Apc 
min/+ 
mice will be followed from 10 weeks of age to sacrifice at 15 
weeks of age.  N=32 mice total; n=16 will undergo ovariectomy (OVX) and n=16 will 
undergo sham surgery (SHAM) at 11 weeks of age.  Two weeks will be allowed for 
hormone washout; n=16 (n=8 OVX and n=8 sham) mice will then undergo IL-6 
overexpression by electroporation at 13 weeks of age, with the remainder of mice being 
electroporated with a control vector.  Functional measurements including grip strength, 
run to fatigue, food intake, and cage activity will be taken at 11 and 15 weeks of age.  
Blood will be taken at 13 and 15 weeks to verify efficacy of ovariectomy and IL-6 
overexpression as well as to measure plasma estrogen (in intact mice), insulin, and 
triglycerides.  Functional measurements including grip strength, run to fatigue, activity 
monitoring, and food intake will be completed at 11 weeks and 15 weeks of age. 
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Expected Outcomes This experiment will relate presence of ovarian function to whole-
body function and tissue-level IL-6 signaling in cachexia target tissues including liver, 
skeletal muscle, and fat in mice with IL-6 systemically overexpressed.  Measurement of 
plasma IL-6 levels at 15 weeks will verify overexpression.  Functional outcomes 
including grip strength, run to fatigue, cage activity, and food intake will be compared 
between OVX and SHAM mice overexpressing IL-6 (OVX-IL-6 versus SHAM-IL-6) 
and between OVX mice overexpressing IL-6 or a control vector (OVX-IL-6 versus OVX-
vector).  Expression of p-STAT3/STAT3, p-AMPK/AMPK, p-p65/p65, p-p38/p38, and 
gp130 will be measured in liver, skeletal muscle, and fat.  Levels of these proteins will be 
compared between OVX and SHAM mice overexpressing IL-6 (OVX-IL-6 versus 
SHAM-IL-6) and between OVX mice overexpressing IL-6 or a control vector (OVX-IL-
6 versus OVX-vector). 
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Apc 
min/+ 
 mice 
11 weeks 13 weeks 15 weeks 
OVX 
n=16 
IL-6 
n=8 
SHAM 
n=16 
vector 
n=8 
vector 
n=8 
IL-6 n=8 
Sacrifice 
n=32 
 200 
 
 
Overall Aim 2 Interpretation. 
 Differences seen in Experiment 2.1 between mice with normal and abnormal 
ovarian function will indicate whether cessation of normal ovarian function during 
the progression of cachexia alters sensitivity to IL-6 in female Apc 
min/+ 
mice.   
An increase in circulating IL-6 levels in mice with abnormal ovarian function 
compared to mice with normal ovarian function will indicate that normal ovarian function 
suppresses IL-6 levels during the progression of cachexia in female Apc 
min/+ 
mice.   
An increase in the ratio of pSTAT3/STAT3 expression in liver, skeletal muscle, 
or fat in mice with abnormal ovarian function compared to mice with normal ovarian 
function will indicate that normal ovarian function suppresses the STAT3 pathway in this 
tissue.   
An increase in the ratio of pAMPK/AMPK expression in liver, skeletal muscle, or 
fat in mice with abnormal ovarian function compared to mice with normal ovarian 
function will indicate that normal ovarian function suppresses the AMPK pathway in this 
tissue.   
An increase in the ratio of pp65/p65 expression in liver, skeletal muscle, or fat in 
mice with abnormal ovarian function compared to mice with normal ovarian function will 
indicate that normal ovarian function suppresses the NfκB pathway in this tissue.   
An increase in the ratio of pp38/p38 expression in liver, skeletal muscle, or fat in 
mice with abnormal ovarian function compared to mice with normal ovarian function will 
indicate that normal ovarian function suppresses the p38/MAPK pathway in this tissue.   
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An increase in gp130 expression in liver, skeletal muscle, or fat in mice with 
abnormal ovarian function compared to mice with normal ovarian function will indicate 
that normal ovarian function suppresses the ability of that tissue to respond to IL-6.  It 
will be important to note whether these differences in signaling occur in the presence or 
absence of an increase in circulating IL-6 with abnormal ovarian function, as this could 
provide or eliminate a potential mechanism for this action. 
Differences seen in Experiment 2.2 between OVX mice and intact mice will indicate 
whether lack of ovarian function during the progression of cachexia alters 
sensitivity to IL-6 in female Apc 
min/+ 
mice.   
An increase in circulating IL-6 levels in OVX mice compared to mice with 
ovarian function will indicate that ovarian function suppresses IL-6 levels during the 
progression of cachexia in female Apc 
min/+ 
mice.   
An increase in the ratio of pSTAT3/STAT3 expression in liver, skeletal muscle, 
or fat in OVX mice compared to mice with ovarian function will indicate that ovarian 
function suppresses the STAT3 pathway in this tissue.   
An increase in the ratio of pAMPK/AMPK expression in liver, skeletal muscle, or 
fat in OVX mice compared to mice with ovarian function will indicate that ovarian 
function suppresses the AMPK pathway in this tissue.   
An increase in the ratio of pp65/p65 expression in liver, skeletal muscle, or fat in 
OVX mice compared to mice with ovarian function will indicate that ovarian function 
suppresses the NfκB pathway in this tissue.   
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An increase in the ratio of pp38/p38 expression in liver, skeletal muscle, or fat in 
OVX mice compared to mice with ovarian function will indicate that ovarian function 
suppresses the p38/MAPK pathway in this tissue.   
An increase in gp130 expression in liver, skeletal muscle, or fat in OVX mice 
compared to mice with ovarian function will indicate that normal ovarian function 
suppresses the ability of that tissue to respond to IL-6.  It will be important to note 
whether these differences in signaling occur in the presence or absence of an increase in 
circulating IL-6 with abnormal ovarian function, as this could provide or eliminate a 
potential mechanism for this action. 
Functional differences seen in Experiment 2.3 between OVX-IL-6 and SHAM-IL-
6 groups will indicate whether ovarian function protects against the abrogated functional 
deficits caused by overexpression by IL-6 that are seen in the Apc 
min/+ 
male mouse [5, 6, 
20].   
Signaling differences seen in Experiment 2.3 will be interpreted similarly to those 
in Experiment 2.2, but with an interesting caveat.  Differences in signaling between 
OVX-IL-6 and SHAM-IL-6 groups will indicate whether intact ovarian function protects 
against abrogated downstream signaling, even in the presence of overexpressed IL-6. 
Differences between OVX-IL-6 and OVX-vector groups will indicate whether IL-6 is 
able to further abrogate inflammatory signaling beyond the effects of ovariectomy in 
female Apc 
min/+ 
mice. 
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Aim 3.  Determine whether cachexia-induced skeletal muscle metabolic dysfunction 
is regulated by ovarian function in the female Apc 
min/+ 
mouse. 
Overall Design: Aim 3 will determine whether ovarian function is associated with the 
dysregulation of skeletal muscle metabolism including protein turnover and 
mitochondrial function seen with cachexia in the female Apc 
min/+ 
mouse. The working 
hypothesis of this aim is that intact ovarian function is protective against protein turnover 
dysregulation and mitochondrial dysfunction.  This aim consists of 3 experiments. 
Experiment 3 .1 will examine skeletal muscle protein turnover and mitochondrial 
dysfunction in mice with normal and abnormal ovarian function at the early (15 week) 
and late (18 week) stage of cachexia.  Experiment 3.2 will examine skeletal muscle 
protein turnover and mitochondrial dysfunction in ovariectomized and intact mice at the 
early (15 week) and late (18 week) stage of cachexia. Experiment 3.3 will examine 
skeletal muscle protein turnover and mitochondrial dysfunction in ovariectomized and 
intact mice with systemically overexpressed IL-6. Outcomes from this aim will relate 
ovarian function to markers of protein turnover and mitochondrial function in ovaries-
intact and ovariectomized mice at early cachexia (15 week) and cachexia (18 week) 
timepoints, as well as in ovariectomized mice with overexpressed IL-6 levels.  
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Experiment 3.1: Determine if the loss of ovarian function during the progression of 
cachexia in ovaries-intact female Apc 
min/+ 
mice is associated with skeletal muscle 
metabolic dysfunction, including the regulation of protein turnover and 
mitochondrial function.  
Hypothesis 3.1: Dysregulation of skeletal muscle protein turnover, including increased 
degradation and decreased synthesis; and mitochondrial function, including decreased 
mitochondrial content, increased turnover, and decreased oxidative capacity, will be 
abrogated by the cessation of normal ovarian endocrine function during the progression 
of cachexia in ovaries-intact female Apc 
min/+ 
mice. 
Design: The same cohort of mice used in Experiments 1.1 and 2.1 will be used for this 
experiment.  Female Apc 
min/+ 
mice will be followed from 10 weeks of age to sacrifice at 
15 weeks (early stage cachexia, n=8) or 18 weeks (late stage cachexia, n=8).  Body 
weight will be tracked weekly and estrous cycling will be determined daily.  Blood for 
determination of plasma estrogen will be collected at 12, 14, 16, and 18 weeks of age.   
Muscle for analysis will be dissected at time of sacrifice. 
Expected Outcomes This experiment will relate ovarian function to muscle protein 
turnover (synthesis and degradation) and mitochondrial function (content, turnover, and 
oxidative capacity).  Specifically, ovarian function will be categorized as “normal” or 
“abnormal” based on daily measurement of estrous cycling, with verification by plasma 
estrogen levels from blood taken at 12, 14, 16, and 18 weeks of age and 
estrogen/progesterone mRNA from ovaries at 15 and 18 week endpoints.  Muscle protein 
synthesis outcomes will include p-Akt/Akt and mTOR.  These outcomes will be 
compared between mice with normal and abnormal ovarian function during the early 
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stage (15 weeks) and late stage (18 weeks) of cachexia.  Muscle protein degradation 
outcomes will include pFoxO3/FoxO3, Atrogin1, MuRF1, and ubiquitin.  These 
outcomes will be compared between mice with normal and abnormal ovarian function 
during the early stage (15 weeks) and late stage (18 weeks) of cachexia.  Mitochondrial 
content outcomes will include cytochrome C and TFAM. These outcomes will be 
compared between mice with normal and abnormal ovarian function during the early 
stage (15 weeks) and late stage (18 weeks) of cachexia.  Markers of mitochondrial 
turnover will include Fis1 and Mfn1, and markers of oxidative capacity will include COX 
IV activity.  These outcomes will be compared between mice with normal and abnormal 
ovarian function during the early stage (15 weeks) and late stage (18 weeks) of cachexia.  
All muscle outcomes will be measured in soleus (oxidative) and tibialis anterior (TA; 
glycolytic) muscle from mice at early cachexia (15 week) and cachexia (18 week) 
timepoints.  Oxidative and glycolytic muscle will both be analyzed to determine 
differential cachexia response; it is expected that glycolytic muscle is more susceptible to 
effects of cachexia.   
 
Aim 3.2: Determine if the ablation of ovarian function (ovariectomy) alters skeletal 
muscle metabolic regulation, including protein turnover and mitochondrial 
function, during the progression of cachexia in the female Apc 
min/+ 
mouse 
Hypothesis 3.2: Dysregulation of protein turnover, including increased degradation and 
decreased synthesis; and mitochondrial function, including decreased mitochondrial 
content, increased turnover, and decreased oxidative capacity, will be abrogated by 
ovariectomy in female Apc 
min/+ 
mice. 
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Design: The same cohort of mice used in Experiments 1.2 and 2.2 will be used for this 
experiment.  Female Apc 
min/+ 
mice and female C57BL/6 mice will be ovariectomized 
(OVX) at 11 weeks of age and will be followed until sacrifice at 15 weeks (early stage 
cachexia, n=8 Apc
min/+
, n=4 B6) or 18 weeks (late stage cachexia, n=8 Apc 
min/+
, n=4 B6).  
Mice from Experiment 3.1 will be used as intact controls for this experiment.   Blood for 
determination of plasma estrogen will be collected at 12, 14, 16, and 18 weeks of age.  It 
is expected that plasma estrogen will be depleted within 2 weeks of ovariectomy.   
Expected Outcomes:  Outcomes from this aim will relate presence of ovarian function 
(OVX versus SHAM) to muscle protein turnover (synthesis and degradation) and 
mitochondrial function (content, turnover, and oxidative capacity), using animals from 
experiment 3.1 and intact female B6 mice as controls.  Muscle protein synthesis 
outcomes will include p-Akt/Akt and mTOR.  These outcomes will be compared between 
OVX mice and intact mice during the early stage (15 weeks) and late stage (18 weeks) of 
cachexia.  Muscle protein degradation outcomes will include pFoxO3/FoxO3, Atrogin1, 
MuRF1, and ubiquitin.  These outcomes will be compared between OVX mice and intact 
mice with during the early stage (15 weeks) and late stage (18 weeks) of cachexia.  
Mitochondrial content outcomes will include cytochrome C and TFAM. These outcomes 
will be compared between OVX mice and intact mice during the early stage (15 weeks) 
and late stage (18 weeks) of cachexia.  Markers of mitochondrial turnover will include 
Fis1 and Mfn1, and markers of oxidative capacity will include COX IV activity.  These 
outcomes will be compared between OVX mice and intact mice during the early stage 
(15 weeks) and late stage (18 weeks) of cachexia.  All muscle outcomes will be measured 
in soleus (oxidative) and tibialis anterior (TA; glycolytic) muscle from mice at early 
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cachexia (15 week) and cachexia (18 week) timepoints.  Oxidative and glycolytic muscle 
will both be analyzed to determine differential cachexia response; it is expected that 
glycolytic muscle is more susceptible to effects of cachexia.   
 
Experiment 3.3: Determine if the ablation of ovarian function (ovariectomy) alters 
IL-6 overexpression regulation of skeletal muscle metabolism in the female Apc 
min/+ 
mouse. 
Hypothesis 3.3: Ovariectomy will cause abrogated dysregulation of protein turnover, 
including increased degradation and decreased synthesis, and mitochondrial function, 
including decreased mitochondrial content, increased turnover, and decreased oxidative 
capacity, in response to overexpression of IL-6 in the female Apc 
min/+ 
mouse. 
Experiment 3.3: The same cohort of mice used in Experiment 2.3 will be used in this 
experiment.  Female Apc 
min/+ 
mice will be followed from 10 weeks of age to sacrifice at 
15 weeks of age.  N=32 mice total; n=16 will undergo ovariectomy (OVX) and n=16 will 
undergo sham surgery (SHAM) at 11 weeks of age.  Two weeks will be allowed for 
hormone washout; n=16 (n=8 OVX and n=8 sham) mice will then undergo IL-6 
overexpression by electroporation at 13 weeks of age, with the remainder of mice being 
electroporated with a control vector.  Blood will be taken at 13 and 15 weeks to verify 
efficacy of ovariectomy and IL-6 overexpression. 
Outcomes Outcomes from this aim will relate presence of ovarian function (OVX versus 
SHAM) to muscle protein turnover (synthesis and degradation) and mitochondrial 
function (content, turnover, and oxidative capacity), in the presence or absence of IL-6 
overexpression.  Mice will be categorized as OVX or SHAM based on ovariectomy 
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status.  Blood taken at 14 weeks will verify efficacy of ovariectomy in OVX mice.  
Measurement of plasma IL-6 levels will verify overexpression.  Muscle protein synthesis 
outcomes will include p-Akt/Akt and mTOR.  These outcomes will be compared between 
OVX mice with and without IL-6 overexpression (OVX-IL-6 and OVX-vector), and 
between groups of mice with IL-6 overexpression (SHAM-IL-6 and OVX-IL-6). Muscle 
protein degradation outcomes will include pFoxO3/FoxO3, Atrogin1, MuRF1, and 
ubiquitin.  These outcomes will be compared between OVX mice with and without IL-6 
overexpression (OVX-IL-6 and OVX-vector), and between groups of mice with IL-6 
overexpression (SHAM-IL-6 and OVX-IL-6).  Mitochondrial content outcomes will 
include cytochrome C and TFAM. These outcomes will be compared between OVX mice 
with and without IL-6 overexpression (OVX-IL-6 and OVX-vector), and between groups 
of mice with IL-6 overexpression (SHAM-IL-6 and OVX-IL-6). Markers of 
mitochondrial turnover will include Fis1 and Mfn1, and markers of oxidative capacity 
will include COX IV activity.  These outcomes will be compared between OVX mice 
with and without IL-6 overexpression (OVX-IL-6 and OVX-vector), and between groups 
of mice with IL-6 overexpression (SHAM-IL-6 and OVX-IL-6).  All muscle outcomes 
will be measured in soleus (oxidative) and tibialis anterior (TA; glycolytic) muscle from 
mice at early cachexia (15 week) and cachexia (18 week) timepoints.  Oxidative and 
glycolytic muscle will both be analyzed to determine differential cachexia response; it is 
expected that glycolytic muscle is more susceptible to effects of cachexia.   
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Overall Aim 3 Interpretation  
Differences seen in Experiment 3.1 between mice with normal and abnormal 
ovarian function will indicate whether cessation of normal ovarian function during 
the progression of cachexia alters regulation of skeletal muscle metabolism in female 
Apc 
min/+ 
mice.   
A decrease in the pAkt/Akt ratio or mTOR in mice with abnormal ovarian 
function compared to mice with normal ovarian function will indicate that normal ovarian 
function protects protein synthesis in muscle during the progression of cachexia in female 
Apc 
min/+ 
mice.   
An increase in muscle protein degradation outcomes in mice with abnormal 
ovarian function compared to mice with normal ovarian function will indicate that normal 
ovarian function suppresses these pathways in skeletal muscle.   
A decrease in mitochondrial content outcomes in mice with abnormal ovarian 
function compared to mice with normal ovarian function will indicate that normal ovarian 
function protects mitochondrial content.   
An increase in the proteins levels of mitochondrial turnover markers in mice with 
abnormal ovarian function compared to mice with normal ovarian function will indicate 
that normal ovarian function regulates mitochondrial turnover.   
A decrease in COX IV activity in mice with abnormal ovarian function compared 
to mice with normal ovarian function will indicate that normal ovarian function protects 
oxidative capacity in skeletal muscle.   
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Differences seen in Experiment 3.2 between OVX mice and intact mice will 
indicate whether lack of ovarian function during the progression of cachexia alters 
skeletal muscle metabolism in female Apc 
min/+ 
mice.   
A decrease in the pAkt/Akt ratio or mTOR in OVX mice compared to mice with 
ovarian function will indicate that normal ovarian function protects protein synthesis in 
muscle during the progression of cachexia in female Apc 
min/+ 
mice.   
An increase in muscle protein degradation outcomes in OVX mice compared to 
mice with ovarian function will indicate that ovarian function suppresses these pathways 
in skeletal muscle.   
A decrease in mitochondrial content outcomes in OVX mice compared to mice 
with ovarian function will indicate that ovarian function protects mitochondrial content.   
An increase in the proteins levels of mitochondrial turnover markers in OVX mice 
compared to mice with ovarian function will indicate that ovarian function regulates 
mitochondrial turnover.  
 A decrease in COX IV activity in OVX mice compared to mice with ovarian 
function will indicate ovarian function protects oxidative capacity in skeletal muscle.   
 
Differences seen in Experiment 3.3 between OVX mice with and without IL-6 
overexpression, and between intact and OVX mice with IL-6 overexpression, will 
determine the effect of ovariectomy on IL-6 induced effects on skeletal muscle 
metabolism during cachexia progression in female Apc 
min/+ 
mice.   
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A decrease in the pAkt/Akt ratio or mTOR in OVX mice overexpressing IL-6 
compared to SHAM mice with IL-6 overexpression will indicate that ovarian function 
regulates IL-6’s effect on this pathway.   
An increase in muscle protein degradation outcomes in OVX mice overexpressing 
IL-6 compared to SHAM mice with IL-6 overexpression will indicate that ovarian 
function regulates IL-6’s effect on these pathways.   
A decrease in mitochondrial content outcomes in OVX mice overexpressing IL-6 
compared to SHAM mice with IL-6 overexpression will indicate that ovarian function 
regulates IL-6’s effect on mitochondrial content.   
An increase in the proteins levels of mitochondrial turnover markers in OVX mice 
overexpressing IL-6 compared to SHAM mice with IL-6 overexpression will indicate that 
ovarian function regulates IL-6’s effect on mitochondrial turnover.   
A decrease in COX IV activity in OVX mice overexpressing IL-6 compared to 
SHAM mice with IL-6 overexpression will indicate that ovarian function regulates IL-6’s 
effect on oxidative capacity in skeletal muscle.   
 
B.3 Power Analysis 
Experiment 1.1, 2.1, 3.1: Female Apc 
min/+ 
mice will be followed from 10 weeks of age 
to sacrifice at 15 weeks (early stage cachexia) or sacrifice at 18 weeks (late stage 
cachexia).  Abnormal ovarian function will be classified by continuous measurement of 
estrous cycling and verified by plasma estrogen levels from blood taken at 12, 14, 16, and 
18 weeks of age. Additional measurements will include ovarian mRNA expression of 
estrogen and progesterone at 15-week and 18-week endpoints.   Body composition 
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outcomes will comprise body fat percentage and lean mass percentage determined by 
DEXA as well as total body weight loss at 12, 14, 16, and 18 weeks.  Functional 
outcomes will comprise volitional grip strength, run-to-fatigue time, food intake, and 
cage activity at 12, 14, 16, and 18 weeks.  Blood biochemistry outcomes will comprise 
hematocrit (for determination of anemia), plasma insulin levels, and plasma triglyceride 
levels at 12, 14, 16, and 18 weeks.   
Two-tailed Student’s t-tests: abnormal-15 vs. normal-15; normal-18 vs. abnormal-
18 
alpha = 0.05; effect size = 0.5; power= 0.8 ‘ n= 6 per group (12 per timepoint) 
http://euclid.psych.yorku.ca/datavis/online/power/index.html 
Effect size based on findings in  Puppa et al. 2011 with male Apc 
min/+ 
mice over a similar 
time course [4]. 
 
Experiment 1.2, 2.2, 3.2: Female Apc 
min/+ 
mice and female C57BL/6 mice will be 
ovariectomized (OVX) at 11 weeks of age and will be followed until sacrifice at 15 
weeks (early stage cachexia) or 18 weeks (late stage cachexia).  Mice from experiment 
1.1 will be used as control for ovariectomy.  Body weight will be tracked weekly.  Body 
composition will be determined by DEXA at 12, 14, 16, and 18 weeks of age. 
Measurement of function including grip strength, run to fatigue time, food intake, and 
cage activity will be taken at 12, 14, 16, and 18 weeks of age. Blood for determination of 
anemia as well as determination of plasma estrogen, insulin, and triglycerides will be 
collected at 12, 14, 16, and 18 weeks of age.  It is expected that plasma estrogen will be 
depleted within 2 weeks of ovariectomy. 
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2x2 ANOVA: genotype X treatment (B6-SHAM, B6-OVX, MIN-SHAM, MIN-OVX 
at each timepoint) 
Preplanned t-tests: MIN-OVX vs. MIN-SHAM at each timepoint, MIN-OVX vs. B6-
OVX 
alpha = 0.05; effect size = 0.75; power= 0.8 ‘ n= 8 per group  
http://euclid.psych.yorku.ca/datavis/online/power/index.html  
Effect size based on findings in Spangenburg et al. 2012 comparing muscle outcomes in 
OVX and SHAM mice [163]. 
 
Experiment 2.3, 3.3: Female Apc 
min/+ 
mice will be followed from 10 weeks of age to 
sacrifice at 15 weeks of age.  Half will undergo ovariectomy (OVX) and half will 
undergo sham surgery (SHAM) at 11 weeks of age.  Two weeks will be allowed for 
hormone washout; half of each treatment group (OVX or SHAM) will then undergo IL-6 
overexpression by electroporation at 13 weeks of age, with the remainder of mice being 
electroporated with a control vector.  Functional measurements including grip strength, 
run to fatigue, food intake, and cage activity will be taken at 11 and 15 weeks of age.  
Blood will be taken at 13 and 15 weeks to verify efficacy of ovariectomy and IL-6 
overexpression as well as to measure plasma estrogen (in intact mice), insulin, and 
triglycerides.  Functional measurements including grip strength, run to fatigue, activity 
monitoring, and food intake will be completed at 11 weeks and 15 weeks of age. 
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2x2 ANOVA: surgery x vector (OVX-IL-6, OVX-vector, SHAM-IL-6, SHAM-
vector) 
Preplanned t-tests: OVX-IL-6 vs. OVX-vector; OVX-IL-6 vs. SHAM-IL-6 
alpha = 0.05; effect size = 0.75; power= 0.8 ‘ n= 8 per group  
http://euclid.psych.yorku.ca/datavis/online/power/index.html  
Effect size based on findings in Baltgalvis et al. 2009 regarding IL-6 overexpression in 
male Apc 
min/+ 
mice [20] 
B.4 Limitations, Pitfalls, and Alternatives 
-Effects of ovariectomy: Ovariectomy has wide-reaching effects on whole-body 
metabolism and body composition [29, 39, 163, 165], even when performed in wildtype 
mice.  Therefore, a wildtype (B6) group of mice has been added to experiments involving 
ovariectomy, in order to control for these effects.   
-Effects of ovariectomy on IL-6 overexpression: Prior to this study, IL-6 
overexpression has never been performed in an ovariectomized mouse.  Though there is 
ample evidence of estrogen’s effects on IL-6 [27, 36, 92], it is impossible to know what 
the effects will be in vivo until this experiment is carried out.  Therefore, it is a distinct 
possibility that ovariectomy will have no additive effect with IL-6 overexpression in the 
female Apc 
min/+ 
mouse.  However, this experiment is still worthwhile and would still 
garner valuable information in this case.  It would be beneficial to know that ovarian 
function is not suppressing IL-6 in the model of cancer cachexia so that other avenues 
could be explored. 
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-Other options for ablation of ovarian function: Because ovariectomy carries so many 
side effects in the female mouse, it is possible that the results from experiments involving 
ovariectomy will be difficult to interpret.  Should this become a problem during the 
course of this work, there are options for chemical intervention in place of this operation.  
ICI 182,780 is an inhibitor of estrogen receptors α and β that is available commercially 
and has been widely used to explore the effects of estrogen and estrogen deficiency in 
mice [166].  However, the ovary produces hormones besides estrogen, so this alternative 
approach would slightly alter the focus of this research. 
B.5 Preliminary Data 
Table B1. Body weight, tibia length and gonadal fat mass of wild-type and Apc 
Min/+
 mice. Table 
B1 demonstrates body weights at 14 weeks (pre-cachexia) and 20 weeks (cachexia), tibial 
length, gonadal fat, and percent of gonadal fat lost in the female and male Apc 
min/+ 
mouse 
compared to wild type mice.  Male and female Apc 
min/+ 
each undergo cachexia, though 
the female does not exhibit the weight loss seen in the male. 
 
 
 
 
 
 
 
Tibial length Gonadal fat Gonadal fat / tibia % of gonadal
Group N 14 week 20 week (mm) (mg) fat loss vs. Wt.
Male Wt 5 26.5 ± 0.8 28.4 ± 0.9 17.4 ± 0.1 638 ± 80 36.8 ± 4.8 -
Min 6 24.3 ± 0.3 22.1 ± 1.0 17.1 ± 0.1 78 ± 29 4.5 ± 1.7 88%
Female Wt 6 19.8 ± 0.4 21.4 ± 0.4 17.1 ± 0.1 238 ± 20 14.0 ± 1.2 -
Min 9 18.9 ± 0.7 18.8 ± 0.6 16.5 ± 0.2 47 ± 26 2.8  ± 1.5 80%
Body weight (g)
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Table B2. Changes in plasma IL-6 concentration during the development of cachexia. Table B2 
demonstrates endogenous plasma IL-6 levels in male and female Apc 
min/+ 
mice at 14 
weeks (pre-cachexia) and 20 weeks (cachexia). 
 
 
 
Table B3. Changes in plasma IL-6 concentration in female Apc 
min/+ 
mice after 2 weeks of IL-6 
over-expression. Table B3 demonstrates that electroporation of and IL-6 overexpression 
vector is sufficient to increase circulating levels of IL-6 in the female Apc 
min/+ 
mouse. 
 
 
 
 
 
 
 
 
 
Group N 14 weeks 20 weeks
Male Wt 5 0 ± 0 0 ± 0
Min 5 5.5 ± 2.4 38.6  ± 16.7
Female Wt 5 0 ± 0 0 ± 0
Min 5 1.5 ± 1.5 11.0 ± 4.5
Plasma IL-6 (pg/ml)
Group N Pre Post
Wt 6 0 ± 0 126.2 ± 19.1
Min 5 1.5 ± 1.5 95.2  ± 34.0
Plasma IL-6 (pg/ml)
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Table B4. The effect of IL-6 over-expression and exercise on body weights, growth, food 
consumption and voluntary physical activity in female wild-type and Apc
Min/+
 mice. Table B4 
demonstrates that there are no significant differences between vector-treated female Apc 
min/+ 
mice and female Apc 
min/+ 
mice with IL-6 overexpressed from 12-14 weeks of age 
with respect to body weight loss, food consumption, or cage activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C57BL/6 ApcMin/+
CC Vector CC IL-6 Ex Vector Ex IL-6 CC Vector CC IL-6 Ex Vector Ex IL-6
N 5 6 6 4 4 5 5 6
BW 12 weeks 21.0 ± 0.3 20.6 ± 0.4 19.4 ± 0.3 20.6 ± 0.4 20.0 ± 0.7 18.3 ± 0.9 17.1 ± 1.1 17.2 ± 0.3
BW/TL 12 weeks 1.20 ± 0.02 1.20 ± 0.02 1.20 ± 0.01 1.10 ± 0.03 1.20 ± 0.04 1.10 ± 0.04 1.10 ± 0.06 1.10 ± 0.02
BW 14 weeks 21.2 ± 0.3 21.2 ± 0.4 20.7 ± 0.2 21.2 ± 0.4 20.3 ± 0.6 18.1 ± 1.5 17.6 ± 1.7 18.0 ± 0.2
BW/TL 14 weeks 1.20 ± 0.02 1.30 ± 0.03 1.20 ± 0.01 1.20 ± 0.02 1.20 ± 0.03 1.20 ± 0.08 1.10 ± 0.10 1.10 ± 0.01
Tibia length (mm) 17.1 ± 0.1 16.9 ±  0.1 16.9 ±  0.1 16.8 ±  0.1 16.6 ± 0.1 16.5 ± 0.2 16.1 ± 0.3 16.2 ± 0.1
Plasma IL-6 (pg/ml) 0.0 ± 0.0 126.2 ± 19.1 0.0 ± 0.0 116.8 ± 16.6 1.5 ± 1.5 95.2 ± 34.0 14.0 ± 10.6 94.2 ± 19.1
14-week Food 0.16 ± 0.01 0.15 ± 0.02 0.20 ± 0.02 0.16 ± 0.02 0.19 ± 0.03 0.18 ± 0.04 0.15 ± 0.02 0.17 ± 0.02
Consumption (g/g)
14-week Physical 10323 ± 1566 12533 ± 2049 9154 ± 1546 7017 ± 1764 5769 ± 1773 3189 ± 718 7054 ± 3353 4668 ± 1854
Activity counts
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Figure B1 demonstrates that, in the female Apc 
min/+ 
mouse (n=24), A) Average body 
weight loss (%) increases with increasing cachexia severity (p<0.0001) B) Average right 
hindlimb muscle weight (mg) decreases with increasing severity of cachexia (p<0.0001) 
C) Average inguinal fat mass (mg) decreases with increasing cachexia severity 
(p=0.0089). 
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Figure B2 demonstrates that in the female Apc 
min/+ 
mouse, intestinal polyp (tumor) count 
is correlated with percent body weight loss (n=8) (p=0.01). 
 
 
Figure B3 demonstrates percent of female Apc 
min/+ 
mice that continue to undergo normal 
estrus cycling as cancer and cachexia progress.  All mice begin normal cycling by 8 
weeks of age, the normal age of sexual maturation in C57BL/6 mice [167].  Mice begin 
to withdraw from normal cycling at ~11 weeks of age.  By 17 weeks of age, all female 
Apc 
min/+ 
mice have ceased cycling (n=9). 
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Figure B4 demonstrates that in the female Apc 
min/+ 
mouse, there is no relationship 
between endogenous plasma IL-6 level and cachexia severity at 18 weeks of age (n=24). 
 
 
Figure B5 demonstrates that though circulating IL-6 levels are comparable in the male 
(n=6) and female (n=4) Apc 
min/+ 
mouse, the female may show a blunted body weight loss 
response compared to the male. 
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Figure B6 demonstrates that A) there is no relationship between body weight change and 
circulaing IL-6 levels in the female Apc 
min/+ 
mouse (n=24); however, interestingly, B) 
there is a significant relationship between circulating plasma IL-6 levels and increasing 
hindlimb muscle mass (n=24 (p=0.03). 
 
 
 
 
 
 
0 10 20 30 40 50
-25
-20
-15
-10
-5
0
Plasma IL-6 (pg/ml)
B
o
d
y
 w
e
ig
h
t 
c
h
a
n
g
e
 (
%
)
A 
0 10 20 30 40 50
0
100
200
300
400
Plasma IL-6 (pg/ml)
R
ig
h
t 
H
in
d
lim
b
 M
u
s
c
le
 M
a
s
s
 (
m
g
)
B 
 222 
 
 
Figure B7 demonstrates that there is no relationship between IL-6 overexpression and 
body weight loss in the female Apc 
min/+ 
mouse. 
 
 
Figure B8 shows that there is no difference in STAT3 signaling between female Apc 
min/+ 
mice treated with IL-6 overexpression (n=5) and vector-treated mice (n=4). 
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APPENDIX C 
RAW DATA 
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Sac Data 18 weeks 
Group Mouse # Body weight 
Peak 
BW 
BW 
loss 
from 
peak 
% BW 
change 
from peak 
Intact-18 3376 19.2 19.2 0 0.00% 
Intact-18 3427 19.4 19.4 0 0.00% 
Intact-18 3509 19.1 19.1 0 0.00% 
Intact-18 3518 19.4 19.4 0 0.00% 
PFOVX ctrl 4236 20.5 20.6 0.1 -0.49% 
Intact-18 3519 18.9 19 0.1 -0.53% 
Intact-18 3352 21.2 21.4 0.2 -0.93% 
Intact-18 3346 19.4 19.6 0.2 -1.02% 
Intact-18 3587 20.1 20.4 0.3 -1.47% 
Intact-18 3345 18.9 19.4 0.5 -2.58% 
Intact-18 3392 21.7 22.3 0.6 -2.69% 
Intact-18 3344 19.1 19.7 0.6 -3.05% 
Intact-18 3428 18.4 19.6 1.2 -6.12% 
Intact-18 3511 19.5 20.9 1.4 -6.70% 
Intact-18 3382 18.7 20.1 1.4 -6.97% 
Intact-18 3424 18.7 19.5 0.8 -4.10% 
PFOVX ctrl 4233 19.3 21.2 -1.9 -8.96% 
PFOVX ctrl 4228 17 18.7 -1.7 -9.09% 
Intact-18 3434 16.7 18.4 1.7 -9.24% 
Intact-18 3510 17.6 19.4 1.8 -9.28% 
Intact-18 4111 19.7 22.1 2.4 -10.86% 
Intact-18 3429 17.7 20.5 2.8 -13.66% 
Intact-18 3435 15.8 18.4 2.6 -14.13% 
PFOVX ctrl 4234 14.3 17.7 -3.4 -19.21% 
Week 
of cycle 
end 
Fasting 
Glucose Tibia length R Sol L sol 
R 
Plant 
L 
Plant R Gas L Gas 
R 
TA 
L 
TA 
YES 129 15.9 7 7 11 12 91 90 32 41 
YES 159 16.2 7 7 21 16 97 91 38 33 
  
16.7 7 6 14 11 81 88 30 31 
 
104 16 7 6 16 12 95 86 34 36 
  
15.3 7 5 12 14 105 81 22 33 
 
185 16.4 7 7 10 14 95 86 27 35 
YES 137 16.5 7 5 12 13 99 94 27 24 
YES 136 16.1 7 5 9 10 83 89 28 35 
    17 8 7 11 10 96 78 39 32 
YES 131 16.4 5 7 11 11 93 92 30 25 
YES 106 16 11 9 15 15 103 100 31 39 
YES 104 16.4 5 6 8 11 82 81 31 31 
YES 117 16.2 8 5 13 18 92 82 31 35 
  
17.1 6 11 10 12 81 85 28 37 
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YES 165 16.2 6 6 13 10 85 79 21 32 
14 
 
16.1 6 10 17 14 90 70 19 25 
15 
 
16.4 5 7 9 13 64 69 21 24 
15 
 
15.8 7 1 11 10 49 60 17 18 
15.15 108 16 7 6 12 12 67 65 28 27 
14.75 
 
16.8 6 9 11 7 62 50 20 21 
15.5 
 
16.2 7 6 10 11 66 70 28 20 
14.15 220 16.5 10 10 16 22 78 72 20 33 
15.5 139 16.1 6 6 9 10 45 56 23 24 
14.75 
 
15.7 3 3 6 5 41 49 19 17 
           
R EDL L EDL R Quad R RF 
L 
Quad L RF TRMW TMRW/TL Liver Spleen Uterus 
 
5 7 128 63 119 64 274 17.2 973 270 85 22 
6 7 129 70 122 70 298 18.4 966 127 73 15 
9 10 125 60 122 60 266 15.9 846 190 53 19 
5 8 132 63 109 47 289 18.1 1013 330 56 15 
5 9 109 59 130 63 260 17.0 1318 247 36 25 
7 6 132 61 122 44 278 17.0 1048 258 65 18 
9 6 132 70 133 69 286 17.3 1130 248 49 14 
4 4 119 63 126 55 250 15.5 1110 270 38 20 
6 7 108 54 121 66 268 15.8 1206 132 87 26 
8 11 117 62 123 51 264 16.1 892 155 47 11 
12 
 
190 96 147 72 362 22.6 874 82 88 22 
8 7 85 51 119 57 219 13.4 1030 245 41 16 
8 7 125 62 123 50 277 17.1 1105 270 40 15 
9 10 115 61 112 60 249 14.6 1203 559 41 17 
7 3 95 60 88 55 227 14.0 940 259 50 7 
6 4 95 46 82 33 233 14.5 1485 497 32 8 
3 3 87 48 90 49 189 11.5 1609 432 21 10 
4 4 72 40 80 43 160 10.1 1432 380 29 12 
5 7 99 50 96 45 218 13.6 1086 365 32 12 
4 6 78 46 66 37 181 10.8 811 294 24 11 
8 4 93 38 87 33 212 13.1 1325 516 21 8 
6 5 108 58 87 42 238 14.4 1026 408 27 9 
10 7 85 56 80 49 178 11.1 912 249 28 9 
5 5 61 37 66 33 135 8.6 1063 209 19 8 
            
Ute+ovs Heart Heart:BW heart:tibia Mes Fat Epi Fat TF Lymph 
 
IL-6 
Total 
tumors 
107 101 5.26 6.35 131 162 293 32 
 
10 
 
88 99 5.10 6.11 122 122 244 40 
   
72 85 4.45 5.09 103 149 252 41 
 
56.7 
 
71 80 4.12 5.00 90 130 220 35 
 
4.9 
 
 226 
 
61 117 5.71 7.65 184 175 359 21 
 
15.8 
 
83 96 5.08 5.85 93 162 255 32 
 
37.7 
 
63 104 4.91 6.30 269 307 576 37 
 
15.4 13 
58 90 4.64 5.59 172 191 363 
  
7.1 3 
113 107 5.32 6.29 167 95 262 49   0   
58 85 4.50 5.18 123 283 406 37 
 
44 
 
110 99 4.56 6.19 248 293 541 34 
 
144 
 
57 88 4.61 5.37 126 192 318 30 
 
16 5 
55 100 5.43 6.17 90 90 180 39 
 
0 
 
58 99 5.08 5.79 161 81 242 33 
 
233 
 
57 96 5.13 5.93 108 122 230 35   32.6   
40 122 6.52 7.58 111 0 111 36 
 
68.2 
 
31 139 7.20 8.48 159 10 169 45 
 
21.4 
 
41 147 8.65 9.30 222 0 222 32 
 
17.4 
 
44 102 6.11 6.38 103 0 103 31 
 
124 7 
35 88 5.00 5.24 73 0 73 
  
72.4 
 
29 121 6.14 7.47 262 19 281 30 
 
66.6 
 
36 115 6.50 6.97 88 0 88 25 
 
23.5 
 
37 125 7.91 7.76 195 0 195 23 
 
96.9 15 
27 128 8.95 8 91 0 91 26 
 
17.4 
 
           
OVX-18 F1 21.9 23.9 2 -8.37% 
OVX-18 F2 21.3 22 0.7 -3.18% 
OVX-18 F3 21.3 22.2 0.9 -4.05% 
OVX-18 F4 22.9 23.5 0.6 -2.55% 
OVX-18 F5 21.3 23.6 2.3 -9.75% 
OVX-18 3713 19.8 21 1.2 -5.7% 
OVX-18 3954 20 20 0 0.0% 
OVX-18 3955 20.4 20.4 0 0.0% 
OVX-18 3960 19.5 20 0.5 -2.5% 
OVX-18 3962 21.1 21.1 0 0.0% 
B6-18 3464 19.5 19.7 
-
0.2 -1.0% 
B6-18 3465 20.6 21 
-
0.4 -1.9% 
B6-18 3467 20.5 21.4 
-
0.9 -4.2% 
B6-18 3596 20.4 20.4 0 0.0% 
B6-18 3606 21.4 21.4 0 0.0% 
B6-18 3607 19.5 19.5 0 0.0% 
86 4.41 4.4102564 252 72 324 25   0 
98 4.76 4.7572816 134 101 235 23   0 
110 5.37 5.3658537 136 136 272 28   0 
92 4.51 4.5098039   144 144     0 
 227 
 
83 3.88 3.8785047           0 
81 4.15 4.1538462   119 119     0 
B6 OVX 18 3716 21.7 21.7 0 0% 
B6 OVX 18 3879 19.6 20 -0.4 -2% 
B6 OVX 18 3961 22.9 23.3 -0.4 -2% 
B6 OVX 18 3963 21.5 21.9 -0.4 -2% 
B6 OVX 18 3964 23.8 23.8 0 0% 
16 6 8 12 10 79 82 34 30 
16 8 7 11 12 94 90 37 36 
16.8 7 7 13 10 93 88 42 40 
17 8 8 10 11 91 92 38 30 
6 6 102 58 113 42 239 14.9375 956 57 20 
8 9 133 75 128 67 291 18.1875 1260 107 28 
8 8 131 75 123 65 294 17.5 1061 94 47 
11 7 120 70 123 65 278 16.352941 1087 99 27 
101 5.15306122 6.3125 
 
166 166 
  
48.9 
114 4.97816594 7.125 146 184 330 46 
 
280 
107 4.97674419 6.3690476 124 155 279 49 
 
0 
124 5.21008403 7.2941176 163 389 552 42 
 
104 
 
 
Tumor 
Counts-
18 
weeks         
Group Mouse # Cycle? 
% 
BW 
loss 
Segment 
1 Segment 2 
Segment 
3 
Segment 
4 Colon Total 
 
Intact-18 3424 NO 4% 0 7 15 35 3 60 23 
Intact-18 3429 NO 12% 1 5 12 22 2 42 9 
Intact-18 3434 NO 9% 3 5 31 36 1 76 11 
Intact-18 3435 NO 14% 3 10 55 34 4 106 18 
Intact-18 4111 NO 
 
5 22 55 67 3 152 76 
Intact-18 3510 NO 9% 9 22 47 17 2 97 19 
Intact-18 4228 NO 
 
8 10 14 9 1 42 37 
Intact-18 4233 NO 
 
0 21 4 9 1 35 26 
Intact-18 4234 NO 
 
5 8 34 38 1 86 54 
   
9.6% 3.7777778 12.222222 29.666667 29.666667 2 77.333 30.333 
   
3.8% 3.3 7.3 19.5 18.1 1.1 37.8 22.0 
   
1.7% 1.2 2.6 6.9 6.4 0.4 13.4 7.8 
           
Intact-18 3344 
 
3% 0 0 0 0 5 5 1 
Intact-18 3345 
 
3% 3 2 1 1 0 7 1 
Intact-18 3427 
 
0% 2 2 4 1 1 10 1 
Intact-19 3346 
         
Intact-18 3352 
 
1% 1 2 0 0 0 3 1 
 228 
 
Intact-18 3376 
 
4% 2 0 2 8 1 13 3 
Intact-18 3382 
 
7% 2 5 6 0 2 15 2 
Intact-18 3392 
 
4% 3 0 0 2 7 12 4 
Intact-18 3428 
 
6% 2 30 21 5 0 58 3 
Intact-18 4236 
  
2 2 8 3 1 16 13 
Intact-18 3509 
  
3 3 1 1 0 8 4 
Intact-18 3511 
  
4 2 4 5 0 15 12 
Intact-18 3518 
  
2 0 2 1 0 5 4 
Intact-18 3519 
  
2 0 5 0 3 10 6 
           
   
3.5% 2.2 3.7 4.2 2.1 1.5 13.6 4.2 
   
2.3% 1.0 8.0 5.7 2.5 2.2 14.0 4.0 
   
0.8% 0.3 2.8 2.0 0.9 0.8 4.9 1.4 
           
           
OVX-18 F2 
 
-3.2% 1 5 6 2 0 13 5 
OVX-18 F3 
 
-7.4% 4 0 0 0 2 6 1 
OVX-18 3962 
 
0.0% 3 6 19 9 1 39 23 
OVX-18 3960 
 
-2.5% 2 2 14 12 2 32 2 
OVX-18 3955 
 
0.0% 4 9 18 10 0 41 14 
OVX-18 3954 
 
0.0% 5 5 28 12 2 52 17 
   
-2.2% 3.2 4.5 14.2 7.5 1.2 30.5 10.3 
   
2.9% 1.5 3.1 10.0 5.2 1.0 17.6 9.0 
   
1.2% 0.6 1.3 4.1 2.1 0.4 7.2 3.7 
 
15 WEEK TUMOR DATA 
Group Mouse # Segment 1 Segment 2 Segment 3 Segment 4 Colon Total Large 
Intact-15 3847 2 3 0 0 0 5 3 
Intact-15 3852 5 1 2 7 1 16 8 
Intact-15 3826 5 4 3 7 0 19 11 
Intact-15 3980 14 19 55 43 0 131 41 
Intact-15 3979 7 9 18 13 0 47 13 
Intact-15 3850 1 1 4 2 0 8 5 
Intact-15 3981 5 15 16 57 1 94 34 
Intact-15 3984 3 18 36 16 1 74 36 
 
  5.3 8.8 16.8 18.1 0.4 49.3 18.9 
 
  4.0 7.6 19.6 20.7 0.5 46.3 15.4 
 
  1.4 2.7 6.9 7.3 0.2 16.4 5.5 
 
  
       
sham+IL-6 4136 10 12 11 24 0 57 27 
sham+IL-6 4137 4 9 30 11 3 57 18 
 229 
 
sham+IL-6 337 0 8 20 14 1 43 18 
sham+IL-6 338 0 4 6 11 0 21 10 
sham+IL-6 4045 0 0 0 0 0 0 0 
sham+IL-6 822 3 3 5 2 1 14 9 
sham+IL-6 823 5 5 13 2 2 27 14 
sham+IL-6 4135 2 0 2 0 1 5 4 
 
  3.0 5.1 10.9 8.0 1.0 28.0 12.5 
 
  3.2 4.0 9.4 8.0 1.0 20.8 8.1 
 
  1.1 1.4 3.3 2.8 0.4 7.4 2.9 
 
  
       
OVX+vector 4054 0 0 0 0 0 0 0 
OVX+vector 4042 0 0 0 1 0 1 1 
OVX+vector 4043 5 2 1 0 0 8 5 
OVX+vector 3855 1 0 1 3 0 5 3 
OVX+vector 3878 4 4 2 12 0 22 10 
 
  2.0 1.2 0.8 3.2 0.0 7.2 3.8 
 
  2.1 1.6 0.7 4.5 0.0 7.9 3.5 
 
  0.7 0.6 0.3 1.6 0.0 2.8 1.3 
 
  
       
OVX+IL-6 4159 7 0 16 10 1 34 14 
OVX+IL-6 4148 2 11 2 3 0 18 9 
OVX+IL-6 3886 2 4 1 2 0 9 4 
OVX+IL-6 3892 2 4 2 0 0 8 4 
 
  3.3 4.8 5.3 3.8 0.3 17.3 7.8 
 
  2.2 4.0 6.2 3.8 0.4 10.4 4.1 
 
  0.8 1.4 2.2 1.3 0.2 3.7 1.5 
 
COX ACTIVITY 
min OVX -4.1 
 
B6 0 
 
min 
OVX -3.2 
 
min 
intact -2.7 
 
3877 Time  Abs 3606 Time  Abs F2 Time  Abs 3392 Time Abs 
 
0 0.176 
 
0 
0.20
1 
 
0 0.209 
 
0 0.163 
 
10 0.17 
 
10 
0.17
4 
 
10 0.202 
 
10 0.158 
 
20 0.165 
 
20 
0.17
3 
 
20 0.2 
 
20 0.156 
 
30 0.158 
 
30 
0.16
5 
 
30 0.188 
 
30 0.157 
 
40 0.154 
 
40 
0.16
5 
 
40 0.184 
 
40 0.151 
 
50 0.154 
 
50 
0.16
3 
 
50 0.179 
 
50 0.148 
 
Abs/min 0.033 
 
Abs/mi
n 
0.08
4 
 
Abs/mi
n 0.042 
 
Abs/mi
n 0.021 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 230 
 
 
vol sample 0.005 
 
vol 
sample 
0.01
2 
 
vol 
sample 0.006 
 
vol 
sample 0.0054 
 
U/g/min 
6.648
4 
 
U/g/mi
n 
7.35
8 
 
U/g/mi
n 
7.0512
8 
 
U/g/mi
n 
3.9173
8 
B6 -1.02 
 
B6 -4.21 
 
min 
OVX -7.4 
 
min 
intact -14.1 
 
3464 Time  Abs 3467 Time  Abs F3 Time  Abs 3435 Time  Abs 
 
0 0.183 
 
0 
0.17
9 
 
0 0.184 
 
0 0.191 
 
10 0.169 
 
10 
0.17
3 
 
10 0.173 
 
10 0.185 
 
20 0.157 
 
20 
0.16
3 
 
20 0.163 
 
20 0.182 
 
30 0.147 
 
30 
0.16
7 
 
30 0.168 
 
30 0.171 
 
40 0.145 
 
40 
0.16
7 
 
40 0.153 
 
40 0.17 
 
50 0.138 
 
50 
0.15
6 
 
50 0.149 
 
50 0.166 
 
Abs/min 0.078 
 
Abs/mi
n 
0.04
8 
 
Abs/mi
n 0.063 
 
Abs/mi
n 0.036 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.011
1 
 
vol 
sample 
0.00
8 
 
vol 
sample 0.019 
 
vol 
sample 0.0094 
 
U/g/min 
7.078
5 
 
U/g/mi
n 
6.04
4 
 
U/g/mi
n 
3.3400
8 
 
U/g/mi
n 
3.8578
4 
min 
intact  -9.28 
 
min 
OVX -9.7 
 
min 
intact -6.1 
 
min 
intact -9.2 
 
3510 Time  Abs F5 Time  Abs 3428 Time  Abs 3434 Time Abs 
 
0 0.213 
 
0 
0.22
2 
 
0 0.193 
 
0 0.161 
 
10 0.208 
 
10 
0.21
9 
 
10 0.188 
 
10 0.156 
 
20 0.2 
 
20 
0.20
3 
 
20 0.185 
 
20 0.157 
 
30 0.178 
 
30 0.19 
 
30 0.17 
 
30 0.149 
 
40 0.178 
 
40 
0.18
5 
 
40 0.168 
 
40 0.151 
 
50 0.174 
 
50 
0.18
6 
 
50 0.159 
 
50 0.15 
 
Abs/min 0.039 
 
Abs/mi
n 
0.05
7 
 
Abs/mi
n 0.024 
 
Abs/mi
n 0.012 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.009
1 
 
vol 
sample 
0.00
8 
 
vol 
sample 0.0065 
 
vol 
sample 0.0083 
 
U/g/min 
4.317
1 
 
U/g/mi
n 
7.17
7 
 
U/g/mi
n 
3.7193
6 
 
U/g/mi
n 
1.4563
7 
min 
intact -12.2 
 
min 
OVX -8.4 
 
B6 0 
 
min 
OVX -5.7 
 
3429 Time  Abs F1 Time  Abs 3607 Time  Abs 3713 Time  Abs 
 
0 0.194 
 
0 
0.17
5 
 
0 0.246 
 
0 0.153 
 
10 0.188 
 
10 
0.16
8 
 
10 0.24 
 
10 0.148 
 
20 0.182 
 
20 0.16 
 
20 0.229 
 
20 0.143 
 
30 0.174 
 
30 
0.15
5 
 
30 0.225 
 
30 0.139 
 
40 0.167 
 
40 
0.14
6 
 
40 0.22 
 
40 0.14 
 
50 0.164 
 
50 
0.14
2 
 
50 0.22 
 
50 0.136 
 
Abs/min 0.036 
 
Abs/mi 0.04
 
Abs/mi 0.051 
 
Abs/mi 0.03 
 231 
 
n 5 n n 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.007
5 
 
vol 
sample 
0.00
9 
 
vol 
sample 0.0118 
 
vol 
sample 0.0047 
 
U/g/min 
4.835
2 
 
U/g/mi
n 
5.03
7 
 
U/g/mi
n 4.3537 
 
U/g/mi
n 
6.4297
4 
min 
intact -1 
 
B6 0 
 
min 
OVX 0 
 
B6 OVX 0 
 
3346 Time ABS 3596 Time Abs 3954 Time ABS 3716 Time ABS 
 
0 0.26 
 
0 
0.19
2 
 
0 0.222 
 
0 0.259 
 
10 0.26 
 
10 
0.17
5 
 
10 0.22 
 
10 0.248 
 
20 0.245 
 
20 
0.15
2 
 
20 0.209 
 
20 0.24 
 
30 0.24 
 
30 
0.14
8 
 
30 0.213 
 
30 0.243 
 
40 0.24 
 
40 
0.14
7 
 
40 0.208 
 
40 0.24 
 
50 0.238 
 
50 
0.14
4 
 
50 0.203 
 
50 0.23 
 
Abs/min 0.045 
 
Abs/mi
n 0.12 
 
Abs/mi
n 0.039 
 
Abs/mi
n 0.057 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.009
6 
 
vol 
sample 
0.01
3 
 
vol 
sample 0.0058 
 
vol 
sample 0.0073 
 
U/g/min 
4.721
8 
 
U/g/mi
n 
9.15
8 
 
U/g/mi
n 6.7734 
 
U/g/mi
n 
7.8654
2 
min 
intact 0 
 
min 
intac
t 0 
 
min 
OVX 0 
 
min 
intact -2.6 
 
3427 Time Abs 3518 Time ABS 3962 Time ABS 3345 Time ABS 
 
0 0.146 
 
0 
0.27
2 
 
0 0.239 
 
0 0.288 
 
10 0.139 
 
10 
0.25
5 
 
10 0.231 
 
10 0.279 
 
20 0.136 
 
20 
0.25
4 
 
20 0.228 
 
20 0.27 
 
30 0.137 
 
30 
0.25
4 
 
30 0.224 
 
30 0.26 
 
40 0.137 
 
40 0.25 
 
40 0.22 
 
40 0.248 
 
50 0.135 
 
50 0.25 
 
50 0.211 
 
50 0.242 
 
Abs/min 0.03 
 
Abs/mi
n 
0.05
4 
 
Abs/mi
n 0.033 
 
Abs/mi
n 0.054 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.005
4 
 
vol 
sample 
0.00
5 
 
vol 
sample 0.005 
 
vol 
sample 0.0085 
 
U/g/min 
5.596
3 
 
U/g/mi
n 
11.3
3 
 
U/g/mi
n 
6.6483
5 
 
U/g/mi
n 
6.3994
8 
B6 OVX -5.5 
 
min 
intac
t 0 
 
min 
OVX  -2.5 
 
min 
intact -3.5 
 
3964 Time ABS 3509 Time ABS 3960 Time ABS 3344 Time ABS 
 
0 0.187 
 
0 
0.19
2 
 
0 0.144 
 
0 0.234 
 
10 0.184 
 
10 
0.18
9 
 
10 0.131 
 
10 0.227 
 
20 0.168 
 
20 
0.17
5 
 
20 0.118 
 
20 0.222 
 
30 0.16 
 
30 
0.17
8 
 
30 0.12 
 
30 0.226 
 232 
 
 
40 0.158 
 
40 
0.17
5 
 
40 0.11 
 
40 0.22 
 
50 0.152 
 
50 
0.17
5 
 
50 0.102 
 
50 0.22 
 
Abs/min 0.057 
 
Abs/mi
n 
0.05
1 
 
Abs/mi
n 0.078 
 
Abs/mi
n 0.036 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.006
4 
 
vol 
sample 
0.01
6 
 
vol 
sample 0.0192 
 
vol 
sample 0.0137 
 
U/g/min 
8.971
5 
 
U/g/mi
n 
3.25
1 
 
U/g/mi
n 
4.0922
6 
 
U/g/mi
n 
2.6469
9 
min 
intact -0.5 
 
min 
intac
t -0.9 
 
min 
OVX 0 
 
min 
intact -1.5 
 
3519 Time ABS 3352 Time ABS 3955 Time ABS 3587 Time ABS 
 
0 0.324 
 
0 
0.28
8 
 
0 0.282 
 
0 0.315 
 
10 0.311 
 
10 0.26 
 
10 0.258 
 
10 0.293 
 
20 0.303 
 
20 
0.25
6 
 
20 0.254 
 
20 0.273 
 
30 0.304 
 
30 
0.21
3 
 
30 0.255 
 
30 0.263 
 
40 0.298 
 
40 
0.19
1 
 
40 0.25 
 
40 0.267 
 
50 0.3 
 
50 0.19 
 
50 0.25 
 
50 0.249 
 
Abs/min 0.063 
 
Abs/mi
n 
0.09
6 
 
Abs/mi
n 0.084 
 
Abs/mi
n 0.126 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.019
9 
 
vol 
sample 
0.00
5 
 
vol 
sample 0.0181 
 
vol 
sample 0.0144 
 
U/g/min 3.189 
 
U/g/mi
n 
20.1
5 
 
U/g/mi
n 
4.6748
8 
 
U/g/mi
n 8.8141 
B6 OVX -5.5 
 
min 
intac
t -6.7 
 
B6 OVX -1.8 
 
min 
intact -1.5 
 
3879 Time ABS 3511 Time ABS 3963 Time ABS 3151 Time ABS 
 
0 0.278 
 
0 0.32 
 
0 0.256 
 
0 0.31 
 
10 0.248 
 
10 
0.30
1 
 
10 0.257   10 0.308 
 
20 0.248 
 
20 0.3 
 
20 0.238 
 
20 0.3 
 
30 0.224 
 
30 
0.28
5 
 
30 0.222 
 
30 0.304 
 
40 0.212 
 
40 
0.28
4 
 
40 0.22 
 
40 0.301 
 
50 0.222 
 
50 0.27 
 
50 0.214 
 
50 0.297 
 
Abs/min 0.09 
 
Abs/mi
n 0.06 
 
Abs/mi
n 0.054 
 
Abs/mi
n 0.03 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
dilution 20 
 
vol sample 
0.003
2 
 
vol 
sample 
0.01
4 
 
vol 
sample 0.0081 
 
vol 
sample 0.0127 
 
U/g/min 
28.33
1 
 
U/g/mi
n 
4.31
7 
 
U/g/mi
n 
6.7155
1 
 
U/g/mi
n 
2.3795
1 
B6 OVX -1.7 
          
3961 Time ABS 
         
 
0 0.309 
         
 
10 0.293 
         
 
20 0.29 
         
 233 
 
 
30 0.288 
         
 
40 0.279 
         
 
50 0.279 
         
 
Abs/min 0.057 
         
 
dilution 20 
         
 
vol sample 
0.005
7 
         
 
U/g/min 
10.07
3 
          
RT-PCR 15 WEEK 
 
 
  
IL-6 18s 
    
mouse Treatment Ct Ct Dct DDct 
fold 
change Normalized 
787   35.46 15.50667 19.95333 0.937 0.522 0.482 
789   34.295 15.393 18.902 -0.114 1.082 0.999 
813   33.65 15.11 18.54 -0.476 1.391 1.284 
814   33.705 15.413 18.292 -0.724 1.652 1.524 
3826   34.815 15.423 19.392 0.376 0.770 0.711 
150   33.26 15.30 17.967 -1.049 2.069 1.910 
337   29.503 15.983 13.52 -5.496 45.125 41.651 
338   32.49 15.513 16.977 -2.039 4.109 3.793 
822   34.886 15.616 19.27 0.254 0.838 0.774 
823   34.426 15.406 19.02 0.004 0.997 0.920 
3747   32.65 15.323 17.327 -1.689 3.224 2.976 
4045   33.363 15.27 18.093 -0.923 1.896 1.750 
4135   35.21 15.563 19.647 0.631 0.646 0.596 
4136   33.986 15.44667 18.53933 -0.477 1.391 1.284 
4137   33.0066 15.336 17.6706 -1.345 2.541 2.345 
159   33.31 15.296 18.014 -1.002 2.003 1.848 
161   32.893 15.21 17.683 -1.333 2.519 2.325 
162   34.023 15.373 18.65 -0.366 1.289 1.189 
3854   34.436 15.483 18.953 -0.063 1.045 0.964 
3855   31.675 15.216 16.459 -2.557 5.884 5.431 
3878   31.43 15.23 16.20 -2.812 7.022 6.481 
4042   34.87 15.45 19.42 0.403 0.756 0.698 
4043   34.31 15.39 18.92 -0.093 1.066 0.984 
4054   34.51 15.25 19.26 0.243 0.845 0.780 
 234 
 
160   33.41 15.20 18.21 -0.809 1.752                        
168   33.45 15.31 18.13 -0.883 1.844 1.702 
176   26.29 15.60 10.68 -8.334 322.659 297.814 
3657   34.65 15.37 19.28 0.264 0.833 0.769 
3886   36.15 15.34 20.81 1.793 0.289 0.266 
3892   33.84 15.36 18.48 -0.532 1.446 1.334 
4148   28.97 16.68 12.29 -6.726 105.849 97.699 
4159   35.32 15.32 20.00 0.984 0.506 0.467 
 
 
 
 
  
IL-6r GAPDH 
    
mouse Treatment Ct Ct Dct DDct 
fold 
change Normalized 
787   28.14 24.12 4.02 0.614 0.653 0.477 
789   30.215 24.775 5.44 2.034 0.244 0.178 
813   28.115 24.515 3.6 0.194 0.874 0.638 
814   28.06 25.4 2.66 -0.746 1.677 1.224 
3826   28.025 25.3 2.725 -0.681 1.604 1.170 
3847   28.235 24.31 3.925 0.519 0.698 0.509 
3950   26.76 25.47 1.29 -2.116 4.336 3.163 
3979   28.235 24.645 3.59 0.184 0.880 0.642 
3980   23.27 28.13 -4.86 -8.266 307.885 224.590 
150   28.22 23.67 4.55 1.144 0.453 0.330 
337   22.815 25.83 -3.015 -6.421 85.702 62.516 
338   24.695 24.475 0.22 -3.186 9.102 6.640 
822   26.125 25.005 1.12 -2.286 4.878 3.558 
823   26.065 23.8 2.265 -1.141 2.206 1.609 
3747   22.16 26.025 -3.865 -7.271 154.477 112.685 
4045   25.945 24.875 1.07 -2.336 5.050 3.684 
4135   27.12 24.135 2.985 -0.421 1.339 0.977 
4136   25.96 24.23 1.73 -1.676 3.196 2.331 
4137   24.74 24.36 0.38 -3.026 8.147 5.943 
159   28.71 23.505 5.205 1.799 0.287 0.210 
161   28.51 24.015 4.495 1.089 0.470 0.343 
162   26.545 24.52 2.025 -1.381 2.605 1.900 
3854   27.61 23.085 4.525 1.119 0.460 0.336 
 235 
 
3855   26.315 23.895 2.42 -0.986 1.981 1.445 
3878   26.54 24.39 2.15 -1.261 2.397 1.749 
4042   25.29 25.52 -0.23 -3.631 12.391 9.039 
4043   26.04 25.60 0.44 -2.966 7.815 5.701 
4054   24.55 24.22 0.33 -3.076 8.434 6.152 
160   27.77 24.16 3.61 0.204 0.868 0.633 
168   27.71 24.25 3.46 0.054 0.963 0.703 
176   24.48 24.09 0.39 -3.021 8.119 5.922 
3657   26.19 23.51 2.68 -0.731 1.660 1.211 
3886   27.02 24.52 2.50 -0.906 1.874 1.367 
3892   25.84 23.84 2.00 -1.411 2.660 1.940 
4148   24.56 25.40 -0.84 -4.251 19.044 13.892 
4159   28.35 24.16 4.19 0.784 0.581 0.424 
 
  
TGFb 18s 
    
mouse Treatment Ct Ct Dct DDct 
fold 
change Normalized 
787   29.42 15.183 14.237 0.434 0.740 0.688 
789   29.81 15.18 14.63 0.827 0.564 0.524 
813   29.315 15.136 14.179 0.376 0.770 0.716 
814   29.605 15.483 14.122 0.319 0.801 0.745 
3826   28.21 15.34 12.87 -0.933 1.909 1.775 
3847   28.556 15.523 13.033 -0.770 1.705 1.585 
3950   29.663 16.09 13.573 -0.230 1.172 1.090 
3979   29.036 15.25 13.786 -0.017 1.012 0.941 
3980   29.343 15.55 13.793 -0.010 1.007 0.936 
150   30.16 15.37 14.785 0.982 0.506 0.471 
337   28.653 15.86 12.793 -1.010 2.013 1.872 
338   29.756 15.47 14.286 0.483 0.715 0.665 
822   29.345 15.533 13.812 0.009 0.993 0.924 
823   29.315 15.396 13.919 0.116 0.922 0.858 
3747   29.38 15.323 14.057 0.254 0.838 0.779 
4045   29.745 15.355 14.39 0.587 0.666 0.619 
4135   29.753 15.62 14.133 0.330 0.795 0.739 
4136   29.296 15.433 13.863 0.060 0.959 0.892 
4137   27.533 15.326 12.207 -1.596 3.022 2.810 
159   29.14 15.405 13.735 -0.068 1.048 0.974 
161   29.31 15.463 13.847 0.044 0.970 0.902 
162   28.75 15.635 13.115 -0.688 1.611 1.498 
3854   30.03 15.296 14.734 0.931 0.524 0.488 
 236 
 
3855   28.506 15.34 13.166 -0.637 1.555 1.446 
3878   28.32 15.45 12.87 -0.929 1.903 1.770 
4042   29.42 15.53 13.89 0.091 0.939 0.873 
4043   30.03 15.65 14.38 0.572 0.672 0.625 
4054   28.61 15.40 13.21 -0.593 1.508 1.402 
160   28.19 15.27 12.91 -0.890 1.853 1.723 
168   28.82 15.28 13.54 -0.259 1.196 1.112 
176   28.62 15.46 13.17 -0.636 1.554 1.445 
3657   29.32 15.37 13.95 0.142 0.906 0.842 
3886   28.96 15.30 13.66 -0.143 1.104 1.026 
3892   28.16 15.30 12.86 -0.939 1.917 1.782 
4148   28.44 16.76 11.68 -2.123 4.355 4.049 
4159   30.16 15.65 14.52 0.712 0.610 0.567 
 
  
TLR4 GAPDH 
    
mouse Treatment Ct Ct Dct DDct 
fold 
change Normalized 
787   26.14 23.24 2.9 0.507 0.704 0.549 
789   27.76 23.315 4.445 2.052 0.241 0.188 
813   25.695 23.97 1.725 -0.668 1.589 1.240 
814   26.125 24.52 1.605 -0.788 1.727 1.347 
3826   25.86 24.57 1.29 -1.103 2.148 1.676 
150   29.02 23.83 5.19 2.797 0.144 0.112 
337   25.975 26.14 -0.165 -2.558 5.889 4.595 
338   25.945 24.64 1.305 -1.088 2.126 1.659 
822   27.035 24.99 2.045 -0.348 1.273 0.993 
823   26.745 23.89 2.855 0.462 0.726 0.566 
3747   26.08 26.03 0.05 -2.343 5.074 3.959 
4045   27.135 25.07 2.065 -0.328 1.255 0.979 
4135   28.805 24.505 4.3 1.907 0.267 0.208 
4136   26.285 24.235 2.05 -0.343 1.268 0.990 
4137   24.875 24.05 0.825 -1.568 2.965 2.313 
159   27.525 23.635 3.89 1.497 0.354 0.276 
161   27.205 24.325 2.88 0.487 0.714 0.557 
162   26.57 24.825 1.745 -0.648 1.567 1.223 
3854   27.75 23.5 4.25 1.857 0.276 0.215 
3855   26.47 24.085 2.385 -0.008 1.006 0.785 
3878   26.81 24.39 2.42 0.022 0.985 0.768 
4042   31.66 25.12 6.54 4.147 0.056 0.044 
4043   27.09 25.35 1.75 -0.648 1.567 1.223 
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4054   25.69 24.06 1.63 -0.763 1.697 1.324 
160   26.85 24.19 2.66 0.262 0.834 0.651 
168   26.57 24.25 2.32 -0.073 1.052 0.821 
176   26.05 24.09 1.96 -0.433 1.350 1.053 
3657   27.67 23.51 4.16 1.762 0.295 0.230 
3892   26.46 23.84 2.62 0.227 0.854 0.667 
4148   25.91 25.40 0.51 -1.883 3.688 2.878 
4159   28.08 24.16 3.92 1.527 0.347 0.271 
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